Last updated: Apr 14, 2020 - 02:00 BST

Title Indication Intervention Actions PatientSelection Sponsor Collaborator Country StartDate EndDate Identifiers Phase Recruitment Status Sites Trial Duration Enrollment Count Contacts LastChanged
Interferon beta 1b in COVID-19 Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , interferon beta 1 b , lopinavir + ritonavir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mazandaran University of Medical Sciences Iran 2020-03-25 IR.MAZUMS.REC.1399.005, IRCT20190804044429N1 Phase 2/Phase 3 Clinical Recruiting 0 70 Majid Saeedi, Monireh Ghazaeian 2020-04-13
Evaluation and comparison of the effectiveness of standard treatment with standard treatment plus Vitamin A in treatment in covid19 patients Coronavirus disease 19 infection standard national treatment alone, vitamin A alone Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Saveh University of Medical Sciences Iran 2020-04-07 IR.SAVEHUMS.REC.1399.003, IRCT20180520039738N2 Phase 3 Clinical No longer recruiting 0 140 Dr, Mohammad Ghorbanli, Dr., Hamidreza Koohestani, Hasan Mozaffar, Mahmood Karimy, Mohamadreza Rohani, Mohammadreza Rouhani 2020-04-13
Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease Coronavirus disease 19 infection Convalescent Plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Semnan University of Medical Sciences Iran 2020-04-20 IR.SEMUMS.REC.1399.004, IRCT20151228025732N53 Phase 3 Clinical Not yet recruiting 0 12 Maral Hemati, Parviz Kokhaei 2020-04-13
CRR: COVID-19 Research Response (ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial) Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fiona Stanley Hospital, South Metropolitan Health Service Australia 2020-04-07 ACTRN12620000444987, ANZCTR12620000444987, CRR Phase Not Applicable Not yet recruiting 1 100000 Ms Giuliana Daulerio, Prof Toby Richards 2020-04-13
A Phase II Study to Assess The Effect of Ifenprodil in Patients with COVID-19 Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc US Phase 2 Clinical Planned 0 2020-04-13
A Study to Assess The Effect of Ifenprodil in Patients with COVID-19 Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc Australia Phase Not Applicable Planned 1 2020-04-13
A Study to Assess The Effect of Ifenprodil in Patients with COVID-19 Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc South Korea Phase Not Applicable Planned 1 2020-04-13
Home rehabilitation for people with COVID-19: Implementing telehealth approaches to care Coronavirus disease 19 infection exercises alone, telerehabilitation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Flinders Medical Centre Flinders University of South Australia Australia 2020-05-01 ACTRN12620000443998p, ANZCTR12620000443998 Phase Not Applicable Not yet recruiting 1 58 A/Prof Kate Laver, Prof Maria Crotty 2020-04-13
A Phase II Study to Assess The Effect of Ifenprodil in Patients with Severe COVID-19 Infection Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc Canada Phase 2 Clinical Planned 0 2020-04-13
COVID-19: A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load in COVID-19 Patients Coronavirus disease 19 infection, Viral infection hydrogen peroxide alone, povidone-iodine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Aga khan University University Of Karachi Pakistan 2020-07-01 2021-03-31 2020-SUR-ERC-20, COVID-19, NCT04341688 Phase Not Applicable Not yet recruiting 0 9 Months 5 Farhan R Khan, MS, FCPS, Syed MR Kazmi, FCPS 2020-04-13
An international, randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care Coronavirus disease 19 infection chloroquine alone, hydroxychloroquine sulfate alone, interferon beta-1a alone, local standard of care alone, lopinavir + ritonavir alone, remdesivir alone HIV protease inhibitor, RNA polymerase modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) FIB-HCSC, World Health Organization Spain 2020-03-27 2020-001366-11, Solidarity Phase 4 Clinical Recruiting 1 100000 SCREN-UICEC, UICEC 2020-04-13
MEFLOCOVID-19: Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19) Coronavirus disease 19 infection mefloquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universidad Miguel Hernandez de Elche Foundation for Health Research and Biomedical Valencia Spain 2020-03-30 2020-001194-69, MEFLOCOVID-19, MEFLOCOVID-19 Phase 3 Clinical Recruiting 1 200 Unidad de Enfermedades Infecciosas 2020-04-13
COV-HCQ: Hydroxychloroquine for COVID-19 Coronavirus disease 19 infection Hydroxychloroquine Sulfate alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Tubingen Bernhard-Nocht-Institute for Tropical Medicine, Robert Bosch Medical Center, Universitätsklinikum Hamburg-Eppendorf Germany 2020-03-29 2022-02-28 2020-001224-33, COV-HCQ, COV-HCQ, NCT04342221 Phase 3 Clinical Recruiting 1 23 Months 220 Benjamin Mordmüller, Prof., Diane Egger-Adam, Dr., Thirulamaisamy Velavan, Prof., Thirumalaisamy Velavan, Prof. 2020-04-13
PanCOVID19: Efficacy of different treatments in patients infected with COVID-19 Coronavirus disease 19 infection, Viral pneumonia Dolquine (Products and Technology SL) alone, azithromycin cinfa (Laboratorios Cinfa, SA) alone, lopinavir + ritonavir alone HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz Servicio de Farmacología Clínica, Unidad de Ensayos Clínicos (UCICEC) Spain 2020-03-27 2020-001156-18, PanCOVID19, PanCOVID19 Phase 3 Clinical Recruiting 1 1000 Alberto Borobia 2020-04-13
Acquiring Convalescent Specimens for COVID-19 Antibodies Coronavirus disease 19 infection Blood draw alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Columbia University US 2020-04-30 2021-03-31 AAAS9517, NCT04342195 Phase Not Applicable Not yet recruiting 0 11 Months 12 Brett Gray, David Ho, M.D,, Yang Luo, PhD 2020-04-13
Tocilizumab in COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) AryoGen Pharmed Co Iran 2020-03-15 IR.NIMAD.REC.1398.414, IRCT20150303021315N17 Phase 3 Clinical Recruiting 10 500 Dr. Ali Javad Mousavi, Dr. Behzad Mohsenpour, Dr. Davood Attaran, Dr. Ehsan Sharifipour, Dr. Mohammad Reza Salehi, Dr. Nafiseh Abdollahi, Dr. Payam Tabarsi, Farzin Khorvash, Nassim Anjidani, Payam Tabarsi, Roya Ghasemian, Rozita Khodashahi 2020-04-13
SCOPE: Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia sirolimus alone mTOR inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Cincinnati US 2020-04-30 2020-09-30 2020-0337, NCT04341675, SCOPE Phase 2 Clinical Not yet recruiting 0 5 Months 30 Nishant Gupta, MD 2020-04-13
Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus Kaletra in hospitalized patients with COVID-19 Coronavirus disease 19 infection Hydroxychloroquine (Iran daroo Co, Iran) plus favipiravir (Nafas farmed Co, Iran) Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ardabil University of Medical Sciences Iran 2020-04-29 IR.ARUMS.REC.1399.012, IRCT20150808023559N20 Phase 1/Phase 2 Clinical Not yet recruiting 1 100 Somaieh Matin 2020-04-13
The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients Coronavirus disease 19 infection Standard of care alone, Sovodak plus ribavirin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mazandaran University of Medical Sciences Iran 2020-03-05 IR.MAZUMS.REC.1399.019, IRCT20200328046886N1 Phase 3 Clinical No longer recruiting 1 48 Hamideh Abbaspour Kasgari 2020-04-13
ASC COVID-19: ASC Therapy for Patients With Severe Respiratory COVID-19 Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome, Viral pneumonia allogeneic adipose-derived mesenchymal stromal cell alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rigshospitalet, Denmark Denmark 2020-04-20 2021-04-30 2020-001330-36, ASC COVID-19, NCT04341610 Phase 1/Phase 2 Clinical Not yet recruiting 2 12 Months 40 Abbas Ali Qayuum, MD PhD, JKastrup, Jens Kastrup, Professor MD 2020-04-13
CONCOVID: Convalescent Plasma Therapy From Recovered Patients to Treat Severe SARS-CoV-2 Disease Coronavirus disease 19 infection, SARS coronavirus infection Convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Erasmus University Rotterdam Maasstad Hospital Netherlands 2020-04-01 2020-07-01 CONCOVID, NCT04342182, NL73489.078.20 Phase 2/Phase 3 Clinical Recruiting 2 3 Months 426 Arvind Gharbharan, MD, Bart Rijnders, MD, PhD, Casper Rokx, MD, PhD, Jan Den Hollander, MD, PhD 2020-04-13
NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure Coronavirus disease 19 infection, Respiratory failure aggravation monitoring alone, continuous positive airway pressure (CPAP) alone, non-invasive ventilation (NIV) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Morales Meseguer (Murcia, Spain) Spain 2020-04-01 2020-07-01 08-04-2020, NCT04342104 Phase Not Applicable Recruiting 1 3 Months 100 Antonio Esquinas, Miguel Filipe Martins de Matos Navarro Guia, Miguel Guia 2020-04-13
A clinical study of silmitasertib in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection silmitasertib alone Casein kinase II inhibitor Senhwa Biosciences Inc National Institute of Allergy and Infectious Diseases Phase Not Applicable Planned 0 2020-04-13
Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults Coronavirus disease 19 infection, SARS coronavirus infection University Hospital of Cologne Center for Molecular Medicine Cologne Germany 2020-04-30 2020-10-31 KICC19, NCT04341168 Phase Not Applicable Not yet recruiting 1 6 Months 160 Centina Kuiper-Makris, Christoph Hünseler, PD Dr., Esther Mahabir-Brenner, Prof. Dr., Florian Klein, PD Dr., Jan Rybniker, PD Dr. Dr., Julia Fischer, Dr., Katja Höpker, PD Dr., Lutz Weber, Prof. Dr., Miguel A Alejandre Alcazar, Prof. Dr. Dr., Robert W Koerner, Dr., Robert W Körner, Dr., Rolf Kaiser, Dr., Saleta Sierra - Aragón, PD Dr., Tom Schildberg, Dr. 2020-04-13
The Impact of Family-Based Empowerment Model on Stress, Anxiety and Satisfaction Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection empowerment training sessions alone Torbate-Heidaria University of Medical Sciences Iran 2020-03-20 IR.THUMS.REC.1398.060, IRCT20180429039463N2 Phase Not Applicable Recruiting 1 30 mohammad namazi nia, محمد نمازی نیا 2020-04-13
WHIP COVID-19: Will Hydroxychloroquine Impede or Prevent COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Henry Ford Health System US 2020-04-07 2021-04-30 1410401, NCT04341441, WHIP COVID-19 Phase 3 Clinical Not yet recruiting 0 12 Months 3000 Dee Dee Wang, MD, John McKinnon, MD, Laurie Nightengale, MD, William W O'Neill, MD 2020-04-13
BURDENCOV: Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers Coronavirus disease 19 infection, Influenza virus infection, Post traumatic stress disorder, Viral pneumonia burnout alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-09 2021-12-31 APHP200389, BURDENCOV, NCT04341519 Phase Not Applicable Not yet recruiting 1 20 Months 1464 Elie AZOULAY, MD PhD, Matthieu RESCHE-RIGON, MD PhD, Nancy KENTISH-BARNES, MD PHD, Nancy KENTISH-BARNES, PhD, matthieu resche-rigon, MD-PhD 2020-04-13
Evaluation the effects of Favipiravir in COVID-19 patients Coronavirus disease 19 infection favipiravir (Toliddaru-Sobhan Oncology company, Iran) alone, standard and supportive care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-04-05 IR.SBMU.RETECH.REC.1399.011, IRCT20151227025726N14 Phase 3 Clinical Recruiting 1 84 Afshin Zarghi, Ali Saffaei, Farzaneh Dastan, Hossein Vahidi, Payam Tabarsi 2020-04-13
Evaluation the efficacy of hot foot-bath on COVID-19 Coronavirus disease 19 infection hot foot bath alone Shaheed Beheshti Medical University Iran 2020-04-15 IR.SBMU.RETECH.REC.1399.029, IRCT20180923041093N5 Phase 3 Clinical Not yet recruiting 1 60 Afshin Zarghi, Fatemeh sadat Hasheminasab, Roshanak Mokaberinejad 2020-04-13
BIOCOVU: Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-08-31 2020-A00906-33, 2020_33, BIOCOVU, NCT04341792 Phase Not Applicable Not yet recruiting 1 4 Months 1000 Delphine Garrigue, MD 2020-04-13
A first in human trial to evaluate spike protein receptor-binding domain specific mAbs (SARS-CoV-2), Tsinghua/3rd People’s Hospital of Shenzhen/Brii Biosciences for the treatment of COVID-19 patients Coronavirus disease 19 infection spike protein receptor-binding domain specific mAbs (SARS-CoV-2), Tsinghua/3rd People’s Hospital of Shenzhen/Brii Biosciences alone Coronavirus spike glycoprotein inhibitor Brii Biosciences, The Third People’s Hospital of Shenzhen, Tsinghua University 2020-09-30 Phase 1 Clinical Planned 0 2020-04-13
Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic Coronavirus disease 19 infection telephone consultation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universite Pierre et Marie Curie France 2020-03-16 2020-06-15 GREEN GRC01, NCT04341714 Phase Not Applicable Recruiting 1 3 Months 400 Camille Chesnel, MD, Gérard Amarenco, PhD 2020-04-13
CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With COVID-19 Infection, Nested In The CORIMUNO-19 Cohort Coronavirus disease 19 infection, Viral pneumonia anakinra alone Type I IL-1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris 2020-04-30 2020-12-31 APHP200375-5, CORIMUNO-ANA, NCT04341584 Phase 2 Clinical Not yet recruiting 0 8 Months 240 Matthieu Resche-Rigon, MD, PhD, Xavier Mariette, MD, PhD 2020-04-13
NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 Coronavirus disease 19 infection nitric oxide (NO) alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Nu-Med Plus, Xijing Hospital US 2020-03-21 2022-04-01 COVID19 NOGAS MILD, NCT04290858, NCT04305457, NOGAS MILDCOVID-19, NoCovid Phase 2 Clinical Recruiting 0 24 Months 240 Lei Chong, Lorenzo Berra, Lorenzo Berra, MD 2020-04-13
University of Utah COVID-19 Hydrochloroquine Trial Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Utah US 2020-04-14 2023-04-30 IRB_00131893, NCT04342169 Phase 2 Clinical Not yet recruiting 0 36 Months 400 Adam Spivak, MD, Christina Pacchia, PhD 2020-04-13
COVID-SER: Assessment of Serological Techniques for Screening Patients Regarding COVID-19 Coronavirus disease 19 infection serological tests alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospices Civils De Lyon 2020-04-09 2020-09-09 69HCL20-0329, COVID-SER, NCT04341142 Phase Not Applicable Not yet recruiting 0 5 Months 400 Jean-Baptiste Mr FASSIER, Dr 2020-04-13
Hydroxychloroquine Versus Nitazoxanide in Patients With COVID-19 Coronavirus disease 19 infection hydroxychloroquine plus nitazoxanide Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Materno-Perinatal Hospital of the State of Mexico Mexico 2020-04-06 2020-12-30 2020-03-681, NCT04341493 Phase 4 Clinical Recruiting 1 8 Months 86 Acela Marle Santamaria Benhumea, PhD., Hugo Mendieta Zeron, Hugo Mendieta Zeron, PhD, Hugo Mendieta Zeron, PhD., José Meneses Calderon, MD 2020-04-13
COVIDeHPAD: Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease Coronavirus disease 19 infection telehealth applications alone Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Limoges 2020-04-30 2020-09-30 87RI20_0013, COVIDeHPAD, NCT04337788 Phase Not Applicable Not yet recruiting 0 5 Months 200 Achille TCHALLA, MD 2020-04-13
Video-Based Exercises and Well-Being During Social Isolation Coronavirus disease 19 infection, Influenza virus infection Video based aerobic exercise alone Healthy volunteers accepted, Young Adults (18-44 yrs) Biruni Üniversitesi Istanbul University-Cerrahpasa Turkey 2020-04-06 2020-06-30 NCT04335851, PHYSICAL ACTIVITY PROJECT Phase Not Applicable Not yet recruiting 2 2 Months 30 Ayse Zengin Alpozgen, Assistant Professor, PhD, Ayşe Zengin Alpözgen, Assistant Professor, PhD, Begum Kara Kaya, MSc, Esma Nur Kolbaşı, MSc, Eylül Pınar Kısa, MSc, Gamze Polen Şimşek, MSc, Pelin Tiryaki, MSc 2020-04-13
SHARP COVID-19: Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-risk Population (SHARP): a Cluster-randomized, Controlled Trial Coronavirus disease 19 infection hydroxychloroquine sulfate alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tan Tock Seng Hospital Duke-NUS Graduate Medical School, Dutch Ministry of Health, Welfare and Sport, National Center for Infectious Diseases, Saw Swee Hock School of Public Health, Singapore Clinical Research Institute, Singapore Eye Research Institute Singapore 2020-04-30 2020-10-31 2020/00402, NCT04342156, SHARP COVID-19 Phase 3 Clinical Not yet recruiting 1 6 Months 3000 Rupesh Agrawal, MD 2020-04-13
Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19 Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia Ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Intercommunal Creteil France 2020-03-31 2020-09-30 COVID-ECHO, NCT04341766 Phase Not Applicable Recruiting 7 6 Months 200 Antoine Luchez, MD, Ayman KHEIR, MD, Gilles MANGIAPAN, MD, Gilles Mangiapan, MD, Marie Coudurier, MD, Sophie Laroumagne, MD, Thomas Flament, MD, Yannick Simonneau, MD 2020-04-13
CORIMUNO-VIRO: Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO Coronavirus disease 19 infection, Lung disease, Viral pneumonia standard of care alone, Variable regimens including azithromycin , hydroxychloroquine , sarilumab IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris 2020-04-30 2020-07-31 APHP200375-3, CORIMUNO-VIRO, NCT04341870 Phase 2/Phase 3 Clinical Not yet recruiting 0 3 Months 60 David Saadoun, MD PhD, Matthieu Resche-Rigon, MD PhD 2020-04-13
A clinical trial to assess MN-166 in the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients Coronavirus disease 19 infection, Respiratory distress syndrome ibudilast (oral, neuropathic pain/opiate dependence/neurodegeneration/TBI/drug dependence), MediciNova alone IL-6 receptor antagonist, Interleukin-1 beta ligand inhibitor, Macrophage migration inhibitory factor inhibitor, PDE 10 inhibitor, PDE 4 inhibitor, TLR-4 antagonist, TNF alpha ligand inhibitor Yale School of Medicine US Phase Not Applicable Planned 0 Dr. Geoffrey Chupp, Dr. Insoo Kang, r. Maor Sauler 2020-04-13
Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS Coronavirus disease 19 infection, Respiratory distress syndrome plasma alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-13 IR.MUMS.REC.1399.055, IRCT20200409047007N1 Phase 2 Clinical Recruiting 1 32 Dr Abolghasem Allahyari, Dr Mohsen Seddigh Shamsi 2020-04-13
Effect of minocycline on COVID-19 Coronavirus disease 19 infection minocycline alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.053, IRCT20081019001369N4 Phase 2 Clinical Not yet recruiting 1 40 Hossein Hosseinzadeh, Javad Dehghan Nayyeri 2020-04-13
MultiCov: Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia Combined use of a respiratory broad panel multiplex PCR and procalcitonin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris bioMerieux SA France 2020-04-30 2020-08-31 2020-001324-33, APHP200392, MultiCov, NCT04334850 Phase Not Applicable Not yet recruiting 1 4 Months 194 Guillaume VOIRIOT, MD, Muriel FARTOUKH, PU-PH MD PHD 2020-04-13
Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19) Coronavirus disease 19 infection telerehabilitation exercise alone Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istanbul University-Cerrahpasa 2020-04-01 2020-07-31 002, NCT04334434 Phase Not Applicable Not yet recruiting 0 4 Months 30 Kubra Koce, MSc PT 2020-04-13
Al-COVE: AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience Coronavirus disease 19 infection, Sepsis, Transplant rejection AlloSure dd-cf DNA test alone CareDx Inc 2020-04-01 2021-03-01 AL-COVE, Al-COVE, NCT04341103 Phase Not Applicable Not yet recruiting 0 11 Months 500 Alana Burns 2020-04-13
COVA: A phase II/III study to assess the efficacy and the safety of Sarconeos (BIO-101) in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome 20‐hydroxyecdysone (oral, sarcopenia/sarcopenic obesity/Duchenne muscular dystrophy), BIOPHYTIS alone Proto-oncogene Mas agonist BIOPHYTIS France, US, Belgium COVA Phase 2/Phase 3 Clinical Planned 2 2020-04-13
The effect of elderberry syrup against COVID-19 symptoms Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Lymphocytopenia, Myalgia elderberry extract syrup alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.045, IRCT20200406046965N1 Phase 2 Clinical Not yet recruiting 0 40 Mohammad Javad Dehghan Nayyeri, Seyed Ahmad Emami 2020-04-13
Non-contact ECG Sensor System for COVID-19 Coronavirus disease 19 infection non-contact ECG alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Northwestern Medicine US 2020-04-15 2020-09-15 20-0407, NCT04341506 Phase Not Applicable Not yet recruiting 0 5 Months 100 Andrew Gostine, Andrew Gostine, MD 2020-04-13
Remdesivir in treatment of COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection Variable regimens including atazanavir , chloroquine phosphate , hydroxychloroquine sulfate , lopinavir + ritonavir , remdesivir , ribavirin HIV GAG POL polyprotein inhibitor, HIV GAG protein inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, RNA polymerase modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-03-20 IR.TUMS.VCR.REC.1398.1076, IRCT20171122037571N2 Phase 2/Phase 3 Clinical Recruiting 0 120 Aydin PoorKazemi, Azar Haddadi, Farhang BabaMahmoudi, Farzin Khorvash, Hamed Hosseini, Ilad Alavi Darazam, Mansooreh Momen-Heravi, Mehrdad Hasibi, Mohammad Reza Salehi, Mostafa Ghanei, Payam Tabarsi, Rozita Khodashahi, Saeed Kalantari 2020-04-13
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19 Cancer, Coronavirus disease 19 infection chemotherapy alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tongji Hospital China 2020-04-10 2020-07-10 2020-TJ-COVID-19, NCT04341480 Phase Not Applicable Not yet recruiting 1 3 Months 207 Qinglei Gao, Qinglei Gao, Dr. 2020-04-13
The effect of SOVODAK in the treatment of COVID-19 patients Coronavirus disease 19 infection training alone, Variable regimens including Sovodak (sofosbuvir + daclatasvir) , azithromycin , hydroxychloroquine , naproxen , pantoprazole H+ K+ ATPase inhibitor Mazandaran University of Medical Sciences Iran 2020-04-08 IR.MAZUMS.REC.1399.017, IRCT20200403046926N1 Phase 3 Clinical Recruiting 1 60 Fatemeh Roozbeh 2020-04-13
SIC: Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia methylprednisolone (Pfizer) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Ramón y Cajal Spain 2020-04-01 2020-001307-16, SIC, SIC Phase 3 Clinical Recruiting 1 104 Anabel Sánchez 2020-04-13
DEFACOVID: Defibrotide as prevention and treatment of respiratory distress and cytokine release syndrome of COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome defibrotide (iv, veno-occlusive disease), Gentium alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) Instituto de Salud Carlos III Spain 2020-04-01 2020-001409-21, DEFACOVID, IMIB-DFC-2020-02 Phase 2b Clinical Recruiting 1 120 LOLA SERNA GUIRAO 2020-04-13
Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Asociación Instituto de Investigación Sanitaria BioCruces Spain 2020-04-07 2020-001606-33, HIACO-19 Phase 3 Clinical Recruiting 1 132 Epidemiologist 2020-04-13
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases Coronavirus disease 19 infection, Liver cirrhosis Breath Analysis Test alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mayo Clinic FLORIDA US 2019-09-10 2021-12-31 19-001971, NCT04341012 Phase Not Applicable Recruiting 0 27 Months 120 Joanna Roopkumar, Robert Brannock, Tushar Patel, Tushar Patel, MBChB 2020-04-13
The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury Coronavirus disease 19 infection, Heart injury, Hemophagocytic lymphohistiocytosis, Respiratory distress syndrome immunophenotyping alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Barts and The London NHS Trust Queen Mary University of London UK 2020-04-10 2020-06-10 282289, NCT04340921 Phase Not Applicable Not yet recruiting 1 2 Months 140 Daniel E Harding, BM BCh, Federica Marelli-Berg, PhD, Sam (Saidi) Mohiddin, MD 2020-04-13
HOME-CoV: Hospitalization or Outpatient Management of Patients With a SARS-CoV-2 Infection Coronavirus disease 19 infection HOME-CoV rule implementation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France, Monaco, Belgium 2020-04-13 2020-06-01 2020-A00831-38, HOME-CoV, NCT04338841 Phase Not Applicable Not yet recruiting 29 1 Month 4000 Delphine DOUILLET 2020-04-13
REPLACECOVID: Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 Cardiovascular disease, Coronavirus disease 19 infection, Hypertension, Renal injury, Respiratory disease Angiotensin Converting Enzyme Inhibitors alone, Angiotensin Receptor Blockers alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Pennsylvania 2020-03-31 2020-12-31 842810, NCT04338009, REPLACECOVID Phase Not Applicable Not yet recruiting 0 9 Months 152 James Brian Byrd, MD, Jordana B. Cohen, MD, MSCE, Julio A Chirinos, Roberto Viau Colindres, Thomas C. Hanff, MD, MPH, Vicente Corrales-Medina, MD, PhD 2020-04-13
AspiFlu: Aspergillosis in patients with severe influenza or coronavirus Coronavirus disease 19 infection, Influenza virus infection, SARS coronavirus infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) St George's University Hospitals NHS Foundation Trust Gilead Sciences Inc UK 2019-07-06 2021-08-05 AspiFlu, CPMS 43440, IRAS 271269, ISRCTN51287266 Phase Not Applicable Recruiting 4 25 Months Dr Tihana Bicanic, Dr Youngs 2020-04-13
Multicenter, randomized, controlled, parallel study to study the effectiveness and safety of hydroxychloroquine (ZAO Biocom, Russia) in patients with a new coronavirus infection COVID-19 Coronavirus disease 19 infection hydroxychloroquine, Biocom alone JSC Biocom Russian Federation 2020-04-09 2021-03-30 ST-23032020-HQBIO Phase 3 Clinical Status not specified 1 11 Months 120 2020-04-12
Utilizing lung ultrasound in COVID-19 patients in ICU – comparison of management strategies on survival and time on ventilation Coronavirus disease 19 infection lung ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Griffith University, Royal Brisbane & Women's Hospital Australia 2020-04-20 ACTRN12620000438954 Phase Not Applicable Not yet recruiting 4 60 A/Prof Jennifer Paratz 2020-04-13
C4: Chloroquine Chemorophylaxis Countermeasure against COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection chloroquine phosphate alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Australian Defence Force Malaria and Infectious Disease Institute Defence Materiel Technology Centre (DMTC) Australia 2020-03-30 2020-05-11 ACTRN12620000417987, C4 Phase 4 Clinical Not yet recruiting 1 1 Month 680 Dr Scott Hahn, Prof Dennis Shanks 2020-04-13
VOICE: Online-Survey on distress and mental resources of medical health care workers during Covid-19-pandemic Anxiety disorder, Coronavirus disease 19 infection, Depression Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitätsklinikum Erlangen Psychosomatische und Psychotherapeutische Abteilung Universitatsklinikum Erlangen, Universitätsklinikum Bonn Klinik für Psychosomatische Medizin und Psychotherapie, Universitätsklinikum Ulm Psychosomatik Germany 2020-04-20 133_20 B, DRKS00021268, VOICE Phase Not Applicable Not yet recruiting 5 2000 Andrea Borho, Eva Morawa 2020-04-13
Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers Coronavirus disease 19 infection, Psychiatric disorder Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The National Institute of Mental Health National Institutes of Health Clinical Center US 2020-04-15 2022-04-01 20-M-N085, 999920085, NCT04339790 Phase Not Applicable Recruiting 0 23 Months 5000 Alison Gibbons, Joyce Y Chung, M.D. 2020-04-13
HCQINRLGII: Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals Coronavirus disease 19 infection Bisolvon plus Plaquenil Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto Nacional de Rehabilitacion Mexico 2020-04-10 2020-07-10 20/20, HCQINRLGII, NCT04340349 Phase 0 Clinical Not yet recruiting 1 3 Months 100 Julio Granados Montiel 2020-04-10
NODS-Cov2: Nosocomial Dissemination Risk of SARS-Cov2 Coronavirus disease 19 infection Assistance Publique Hopitaux de Paris France 2020-04-13 2020-06-15 APHP200417, NCT04339881, NODS-Cov2 Phase Not Applicable Not yet recruiting 1 2 Months 100 Bich-Tram Huynh, Didier Guillemot, Didier Guillemot, Pr 2020-04-10
COVID-19 Risk Stratification Coronavirus disease 19 infection risk score validation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Brigham & Women's Hospital US 2020-03-01 2020-04-15 2020P000944, NCT04339387 Phase Not Applicable Recruiting 0 1 Month 1500 David Levine, David Levine, MD, David M Levine, MD MPH MA 2020-04-13
FRENCH CORONA: French, Multicenter, Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Nimes France 2020-04-03 2021-04-30 2020-A00797-32, FRENCH CORONA, NCT04340466 Phase Not Applicable Recruiting 1 12 Months 220 Anissa MEGZARI, CLAIRE ROGER, CLAIRE ROGER, MD, PhD, Claire Roger, MD, PhD 2020-04-13
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection Coronavirus disease 19 infection atovaquone plus azithromycin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HonorHealth Research Institute US 2020-04-30 2021-04-30 HRI-COVID-19-ANTI-MALARIAL-001, NCT04339426 Phase 2 Clinical Not yet recruiting 0 12 Months 25 Heather Lane, Karen Lewandowski, RN, Michael Gordon, MD 2020-04-13
Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt (COVID-19) Coronavirus disease 19 infection Assiut University Egypt 2020-05-01 2020-07-30 COVID-19 IN EGYPT, NCT04339322 Phase Not Applicable Not yet recruiting 2 2 Months 200 Haidi Karam 2020-04-13
POWER-COVID_CT: Multicentric, Retrospective, Observational Study of Thoracic Scanner Performance in COVID Screening Coronavirus disease 19 infection, Lung injury thoracic CT scan alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation 2020-04-30 2020-11-30 NCT04339686, POWER-COVID_CT, POWER-COVID_CT Phase Not Applicable Not yet recruiting 0 7 Months 56000 Guillaume HERPE 2020-04-13
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection Acute lung injury, Coronavirus disease 19 infection, Hypoxia, Respiratory failure losartan alone, standard of care alone Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sharp HealthCare US 2020-03-27 2020-12-31 2003902, COVID-ARB, NCT04340557 Phase 4 Clinical Recruiting 0 9 Months 200 Adriana Valdez-Hernandez, RN, Cary Murphy, RN, George Sakoulas, MD, Katie Miller, Matthew Geriak, Matthew Geriak, PharmD 2020-04-10
Evaluation of the efficacy of Oral 25-hydroxyvitamin D3 on COVID-19 Coronavirus disease 19 infection 25-hydroxyvitamin D3, Dishmen alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tehran University of Medical Sciences Iran 2020-04-15 IR.TUMS.VCR.REC.1399.061, IRCT20200401046909N1 Phase 3 Clinical Not yet recruiting 1 260 Arash Shirvani, Mohammadali Sahraian, Mohammadali Sahraian, Research Deputy, Zhila Maghbooli 2020-04-10
COVID-19 Convalescent Plasma Coronavirus disease 19 infection COVID-19 convalescent plasma therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chicago US 2020-04-30 2021-12-31 IRB20-0523, NCT04340050 Phase 0 Clinical Not yet recruiting 0 20 Months 10 Maria Lucia Madariaga, Maria Lucia Madariaga, MD 2020-04-10
Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia CVVH machine alone, Low flow ECMO driving alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Peking Union Medical College Hospital China 2020-03-03 2020-10-15 LOW FLOW-ECMO BY CVVH IN NCP, NCT04340414 Phase Not Applicable Recruiting 2 7 Months 10 Huaiwu He, MD, Wei Cheng, MD, Xiang Zhou, MD, Yun Long, Yun Long, MD 2020-04-13
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy Coronavirus disease 19 infection Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabula Rasa HealthCare Inc US 2020-04-07 2021-04-06 COVID-PACE-2020-001, NCT04339634 Phase Not Applicable No longer recruiting 0 12 Months 12123 Jacques Turgeon, PhD, Malavika Deodhar, PhD, Sweilem B Al Rihani, PharmD, PhD, Veronique Michaud, PhD 2020-04-13
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS) Coronavirus disease 19 infection point-of-care ultrasonography alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Minnesota US 2020-04-15 2020-10-31 NCT04339998, STUDY00009429 Phase Not Applicable Not yet recruiting 0 6 Months 500 Jon Kirsch, MD, Matthew Yocum, MD 2020-04-13
Eating Habits of Adults During the Quarantine Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Eastern Mediterranean University Cyprus Science University Cyprus 2020-04-10 2020-05-31 NCT04339842, NUTR2020 Phase Not Applicable Not yet recruiting 1 1 Month 400 Eliz Arter, Eliz Arter, MSc, Zalihe Yarkiner, PhD 2020-04-13
Max COVID19 Study Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry Max Healthcare Institute Ltd, India India 2020-04-02 2020-06-30 COVID-19/MHC/2020, NCT04339608 Phase Not Applicable Recruiting 1 2 Months 10000 Samreen Siddiqui, PhD, Sandeep Budhiraja, MRCP (U.K), MD, Sujeet Jha, MRCP (U.K) 2020-04-13
ONCOVID: Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic Anxiety disorder, Cancer, Coronavirus disease 19 infection, Mood disorder Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitair Ziekenhuis Gent Belgium 2020-03-30 2020-09-30 BC-07505-LGE, NCT04340219, ONCOVID Phase Not Applicable Recruiting 1 6 Months 180 Emiel De Jaeghere, MD, Hannelore Denys, Hannelore Denys, MD, PhD, Heini Kanervo, RN 2020-04-13
AZIQUINE-ICU: Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomized, Controlled Trial Coronavirus disease 19 infection, Respiratory failure azithromycin plus hydrochloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Charles University Faculty Hospital Olomouc, General University Hospital, Prague, Masaryk Hospital Usti nad Labem, St. Anne's University Hospital Brno, Czech Republic, The Faculty Hospital Na Bulovce, University Hospital Motol, University Hospital Pilsen Czech Republic 2020-04-20 2022-06-30 2020-001456-18, AZIQUINE-ICU, AZIQUINE-ICU-25032020, NCT04339816 Phase 3 Clinical Not yet recruiting 1 26 Months 240 Frantisek Duska 2020-04-13
Evaluation of Serum Zinc Levels Response to Treatment of Covid-19 Positive Patients Coronavirus disease 19 infection Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-03-20 2020-05-03 NCT04339556, ZINCCOVID19 Phase Not Applicable No longer recruiting 1 1 Month 25 Pınar Yalcin bahat 2020-04-13
A Study on Melatonin and Vitamin C and Zinc Efficacy in Patients With COVID-19 Coronavirus disease 19 infection Variable regimens including ascorbic acid , melatonin , zinc sulfate Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Semnan University of Medical Sciences Iran 2020-04-07 IR.SEMUMS.REC.1399.005, IRCT20151228025732N52 Phase 3 Clinical Recruiting 1 10 Fatemeh Ehsani, Mahboubeh Darban 2020-04-13
The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation Coronavirus disease 19 infection, Injury FAST+ examination alone, computed tomography alone, lung ultrasound alone Healthy volunteers accepted University of Colorado, Denver, US US 2020-05-01 2021-05-01 20-0751, NCT04340479 Phase Not Applicable Not yet recruiting 0 12 Months 20 Jose L Diaz-Miron, MD 2020-04-13
Evaluating the effect of marshmallow and licorice on COVID 19 patients Coronavirus disease 19 infection marshmallow and licorice mixed herbal drink intake alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ahvaz University of Medical Sciences Iran 2020-04-09 IR.AJUMS.REC.1399.012, IRCT20200404046937N1 Phase 3 Clinical Recruiting 3 60 Mehran Varnaseri Ghandali, Mohammad Badavi, Niloofar Mohammad Rezaee Esferjani 2020-04-13
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia conventional treatment alone, human umbilical cord-derived MSCs alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Puren Hospital Affiliated to Wuhan University of Science and Technology Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Qingdao Co-orient Watson Biotechnology group co. LTD, Shanghai University China 2020-02-01 2020-06-30 NCT04339660, PR20200402 Phase 1/Phase 2 Clinical Recruiting 1 5 Months 30 Yan Liu, MD, Yue Zhu 2020-04-13
Physical Activity During Social Isolation Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul University Turkey 2020-04-30 2020-06-30 30042020-1, NCT04339491 Phase Not Applicable Not yet recruiting 1 2 Months 500 Ayse Zengin Alpozgen, PhD, Saliha Gurdal Karakelle, Saliha Gurdal Karakelle, MSc 2020-04-10
COMIHY: Hydroxychloroquine for the Treatment of Mild COVID-19 Disease Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Tubingen Bernhard-Nocht-Institute for Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf Germany 2020-04-10 2022-09-30 COMIHY, COMIHY, NCT04340544 Phase 3 Clinical Not yet recruiting 1 29 Months 2700 Diane Egger-Adam, Dr., Peter Kremsner, Prof. 2020-04-13
Safety and Efficacy of Baricitinib for COVID-19 Coronavirus disease 19 infection, Viral pneumonia baricitinib alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Colorado, Denver, US US 2020-04-30 2020-10-31 20-0738, NCT04340232 Phase 2/Phase 3 Clinical Not yet recruiting 0 6 Months 80 Angela Rachubinski, PhD, Joaquin Espinosa, PhD 2020-04-13
Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences Coronavirus disease 19 infection medications alone, Fenugreek syrup plus Viroherb capsule Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-04-05 IR.TUMS.VCR.REC.1399.099, IRCT20200402046923N1 Phase 3 Clinical Recruiting 3 110 Ali Asadollahi-Amin, Dr. Mohammad Ali Sahraeian, Hadise Hosami Roodsari, Roja Rahimi, Saeed Reza Jamali Moghaddam 2020-04-13
TCOutpatient: TXA and Coronavirus 2019 (COVID-19) in Outpatients Coronavirus disease 19 infection enoxaparin sodium plus tranexamic acid Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Alabama at Birmingham US 2020-04-15 2020-10-30 NCT04338074, TCOutpatient, TXACOVID1 Phase 2 Clinical Not yet recruiting 0 6 Months 100 Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD 2020-04-13
A first-in-human, phase I study of CORVax12 for the prevention of COVID-19 infection Coronavirus disease 19 infection APOLLO electroporation device alone, DNA vaccine targeting SARS-CoV-2 spike protein + tavokinogene telseplasmid (APOLLO electroporation, COVID-19), OncoSec Medical alone IL12 gene stimulator Healthy volunteers accepted Providence Cancer Institute at Providence Hospital OncoSec Medical Inc US Phase 1 Clinical Planned 0 Rom Leidner, MD 2020-04-09
CLOCC: Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 Coronavirus disease 19 infection camostat mesylate plus hydroxychloroquine Serine protease inhibitor, Trypsin inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Heinrich Heine Universitat Dusseldorf Hospital Schwabing Munich, Germany, Klinikum St Georg, Missioklinik, Wuerzburg, Germany, University Hospital Frankfurt, Universitätsklinikum Hamburg-Eppendorf Germany 2020-06-01 2021-12-31 CLOCC, CLOCC-2020, NCT04338906 Phase 4 Clinical Not yet recruiting 1 19 Months 334 2020-04-10
TCInpatient: Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients Coronavirus disease 19 infection enoxaparin sodium plus tranexamic acid Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Alabama at Birmingham US 2020-04-15 2020-12-15 NCT04338126, TCInpatient, TXACOVID2 Phase 2 Clinical Not yet recruiting 0 8 Months 60 Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD 2020-04-13
Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection Cconventional medication alone, umbilical cord derived mesenchymal stem cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Huangshi Hospital of Traditional Chinese Medicine China 2020-02-01 2020-12-02 ChiCTR2000031494 Phase 1 Clinical Recruiting 1 10 Months 36 Feng Ganzhu, Leng Nannan 2020-04-10
Efficacy of Kelofan syrup on COVID-19 Coronavirus disease 19 infection Kelofan syrup alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ardabil University of Medical Sciences Iran 2020-04-09 IR.ARUMS.REC.1399.009, IRCT20200405046960N1 Phase 1/Phase 2 Clinical Recruiting 2 15 Dr.Shahab Bohlooli, Ramin Nasimi Doost Azgomi 2020-04-10
CAP-1002 in Severe COVID-19 Disease Coronavirus disease 19 infection CAP-1002 alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Capricor Inc US CAP-1002-COVID-19, NCT04338347 Phase Not Applicable Recruiting 0 Khaled Alsabaawi, Mitch Gheoghiu, MD, Paula Williams, MS, Raj Makkar, MD, Siegfried Rogy, PhD 2020-04-10
Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-19 Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia nintedanib alone CSF-1 antagonist, FGF receptor antagonist, FGF1 receptor antagonist, FGF2 receptor antagonist, FGF3 receptor antagonist, Flt3 tyrosine kinase inhibitor, Lck tyrosine kinase inhibitor, Lyn tyrosine kinase inhibitor, PDGF receptor alpha antagonist, PDGF receptor antagonist, PDGF receptor beta antagonist, Src tyrosine kinase inhibitor, VEGF receptor antagonist, VEGF-1 receptor antagonist, VEGF-2 receptor antagonist, VEGF-3 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tongji Hospital China 2020-04-02 2020-08-01 HUILANZ ZHANG, NCT04338802 Phase 2 Clinical Not yet recruiting 1 4 Months 96 Huilan Zhang, Huilan Zhang, PD, Xianglin Yuan, PD 2020-04-10
ASCOT: To compare the effectiveness of two drugs (hydroxychloroquine and lopinavir/ritonavir alone or combined in treating hospitalized patients with confirmed COVID-19 compared to standard of care Coronavirus disease 19 infection hydroxychloroquine alone, lopinavir + ritonavir alone, hydroxychloroquine plus lopinavir + ritonavir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Melbourne Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Royal Brisbane & Womens Hospital Research Foundation, The Pratt Foundation, University of Queensland Australia, New Zealand 2020-04-10 ACTRN12620000445976, ANZCTR12620000445976, ASCOT Phase 3 Clinical Not yet recruiting 65 2500 A/Prof Steven Tong 2020-04-13
Effect of methylprednisolone in treatment of COVID-19 patients Coronavirus disease 19 infection methylprednisolone alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shiraz University of Medical Sciences Iran 2020-04-14 IR.SUMS.REC.1399.014, IRCT20200204046369N1 Phase 2/Phase 3 Clinical Not yet recruiting 2 48 Dr. Mohsen Moghadami, Mohammad-Javad Fallahi, Mohsen Moghadami 2020-04-13
Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Royal Brisbane & Women's Hospital Australia 2020-03-31 ACTRN12620000447954, ANZCTR12620000447954 Phase 2 Clinical Recruiting 1 150 Prof Kevin B Laupland 2020-04-10
COVID-19 and Deep Venous Thrombosis Coronavirus disease 19 infection, Deep vein thrombosis Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jessa Hospital Belgium 2020-04-17 2020-12-30 JESSAH-COVID19-DVT, NCT04338932 Phase Not Applicable Not yet recruiting 1 8 Months 12 Bjorn Stessel, Dr, Ina Callebaut, dr, Stessel Björn, Dr 2020-04-10
Evaluation of Safety and efficacy of anti-inflammatory regimens in COVID-19 Coronavirus disease 19 infection Variable regimens including azithromycin , hydroxychloroquine , naproxen , pantoprazole , prednisolone H+ K+ ATPase inhibitor Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bagheiat-allah University of Medical Sciences, Iran University of Medical Sciences Iran 2020-04-10 IR.BMSU.REC.1399.019, IRCT20200318046812N2 Phase 3 Clinical Recruiting 4 906 Ali Qazvini, Dr Abolfazl Mozafari, Dr Mahtab Niroomand, Dr Mariam Qaraati, Dr Seyed Abbas Motevalian, Mostafa Ghanei, Seyed Hassan Saadat, ََAli Qazvini 2020-04-11
NOCOVID: Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection Coronavirus disease 19 infection Nitric oxide releasing solution (SaNOtize) alone, standard precautions alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) SaNOtize Research and Development Corp The Emmes Company, LLC Canada 2020-04-06 2020-09-30 COVID-CTP-01, NCT04337918, NOCOVID Phase 2 Clinical Not yet recruiting 1 5 Months 200 Chris Miller, Ph.D., Gilly Regev, Ph.D., Jeremy Road, MD 2020-04-11
Effect of IMFLUNA herbal compound on covid-19 pneumonia symptoms Coronavirus disease 19 infection, Viral pneumonia IMFLUNA herbal compound, HomaPharmed Pharmaceutical Company alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Institute of Medicinal Plants Iran 2020-03-30 IR.BMSU.REC.1399.036, IRCT20080901001157N16 Phase 1/Phase 2 Clinical Recruiting 1 60 Fallah Huseini Hasan, Mohammadreza Gholibeikian, Morteza Khairabadi, Reza Mohtashami 2020-04-11
PROTECT: Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: an RCT Coronavirus disease 19 infection azithromycin alone, oseltamivir alone, Variable regimens including azithromycin , hydroxychloroquine phosphate , hydroxychloroquine sulfate , oseltamivir Exo-alpha sialidase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Health Sciences Lahore Federal Task Force on Science & Technology Pakistan 2020-04-07 2020-11-30 12(06)/2016-COORD, NCT04338698, PROTECT Phase 3 Clinical Not yet recruiting 1 7 Months 500 Javed Akram, FRCP, Shehnoor Azhar, Shehnoor Azhar, MPH 2020-04-11
Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19) Coronavirus disease 19 infection Algomed alone, herbal tea intake alone, treatment protocol alone Semnan University of Medical Sciences Iran 2020-03-18 IR.SEMUMS.REC.1398.325, IRCT20151228025732N51 Phase Not Applicable Recruiting 1 60 Parviz Kokhaie, Rahimeh Eskandarian 2020-04-10
Evaluation the Effect of Teicoplanin in Patients With Coronavirus Disease Coronavirus disease 19 infection Variable regimens including atazanavir + ritonavir , hydroxychloroquine , lopinavir + ritonavir , teicoplanin HIV protease inhibitor Iran University of Medical Sciences Iran 2020-03-30 IR.IUMS.REC.1399.058, IRCT20161204031229N3 Phase 3 Clinical Recruiting 1 40 Azadeh Eshraghi, Azadeh Eshraghi، Saeed Kalantari, Dr.Motevalian, Saeed Kalantari 2020-04-10
NO COV-ED: Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED Coronavirus disease 19 infection nitric oxide alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital US 2020-04-30 2022-04-30 2019P00XXXX, NCT04338828, NO COV-ED Phase 2 Clinical Not yet recruiting 0 24 Months 260 N. Stuart Harris MD MFA, N. Stuart Harris, MD, MFA 2020-04-10
SCOUT: Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study Coronavirus disease 19 infection, Viral pneumonia lung ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universiteit Hasselt Ziekenhuis Oost-Limburg Belgium 2020-04-13 2020-04-30 CTU2020032, NCT04338568, SCOUT Phase Not Applicable Not yet recruiting 1 50 David Ruttens, MD, PhD, Inge Thijs, PhD, Marc Daenen, MD, Michiel J Thomeer, MD, PhD, Michiel J Thomeer, MD,PhD, Michiel Thomeer, MD, PhD, Michiel Thomeer, MD,PhD, Prof. dr. Michiel Thomeer 2020-04-13
Evaluation of the Effects of Ozone Therapy on Covid-19 Positive Patients Coronavirus disease 19 infection ozone therapy group (covid positive alone, azithromycin plus hydroxychloroquine Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-01 2020-05-30 NCT04337866, OZONECOVID19 Phase Not Applicable No longer recruiting 2 1 Month 50 Pınar Yalcin bahat 2020-04-10
TRODVID-19: Dynamic Evaluation of COVID-19 Diagnostic Tests Coronavirus disease 19 infection antigenic rapid diagnostic orientation test (RODT) alone, polymerase chain reaction (PCR) alone, serological TROD alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier de Tourcoing France 2020-04-30 2020-10-31 NCT04337996, RIPH_2020_6, TRODVID-19 Phase Not Applicable Not yet recruiting 1 6 Months 176 Barthelemy LAFONDESMURS, MD, Pierre PATOZ, PharmD, Solange TREHOUX, PhD 2020-04-10
HOPEC: Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis Coronavirus disease 19 infection hydroxychloroquine (Amin Pharmaceutical company, Isfahan) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shahid Beheshti University of Medical Sciences Iran 2020-04-07 HOPEC, IR.SBMU.RETECH.REC.1399.026, IRCT20130917014693N10 Phase 3 Clinical Recruiting 1 100 Afshin Zarghi, Ali Saffaei, Minoosh Shabani, Omidvar Rezaiemirghaed, Zahra Sahraei 2020-04-13
Sleep COVID-19: Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic Coronavirus disease 19 infection, Insomnia online self-help leaflet alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Northumbria UK 2020-03-25 2022-04-06 ISRCTN43900695, Sleep COVID-19 Phase Not Applicable Recruiting 2 24 Months 75 Dr Elder 2020-04-10
JUPITER: Beat COVID-19 - Observational Trial Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Beat COVID LLC US 2020-04-06 2021-07-31 20200835, JUPITER, NCT04337762 Phase Not Applicable Recruiting 0 15 Months 100000 Hollis Ledbetter, Rama Jager, M.D. 2020-04-10
A phase I study of PittCoVacc for the potential prevention of COVID-19 infection Coronavirus disease 19 infection PittCoVacc alone University of Pittsburgh School of Medicine Phase 1 Clinical Planned 0 2020-04-09
Effect of berberine on COVID-19 Coronavirus disease 19 infection berberine hydrochloride (Mashhad University School of Pharmacy) alone, standard coronavirus treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.030, IRCT20081019001369N2 Phase 2 Clinical Not yet recruiting 1 40 Hossein Hosseinzadeh, Javad Dehghan Nayyeri, Mohsen Tafaghdi 2020-04-10
RuxCoFlam: Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation Coronavirus disease 19 infection, Hypoxia, Inflammatory disease, Respiratory disease, Viral pneumonia ruxolitinib alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Jena Germany 2020-05-01 2021-08-31 NCT04338958, RUXCOFLAM, RuxCoFlam Phase 2 Clinical Not yet recruiting 1 16 Months 200 Andreas Hochhaus, Prof. Dr., Christian Fabisch, Dr. 2020-04-13
The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sheba Medical Center Israel 2020-04-05 2022-04-01 NCT04338672, SMC-20-7078-YZ-CTIL Phase Not Applicable Not yet recruiting 1 23 Months 1000000 Roi Anteby, MD 2020-04-09
A clinical trial to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection Coronavirus disease 19 infection allogeneic natural killer cells alone Green Cross LabCell South Korea Phase Not Applicable Planned 1 2020-04-09
Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy Coronavirus disease 19 infection COVID-surgRES questionaire alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) IRCCS AOU San Martino – IST Italy 2020-03-15 2020-05-01 COVID-ItaliansurgRES-SPIGC, COVID-SURGRES-ITALY, NCT04338945 Phase Not Applicable Recruiting 7 1 Month 1200 Fabio Barra 2020-04-13
A clinical study to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection Coronavirus disease 19 infection allogeneic natural killer cells alone Green Cross LabCell US Phase Not Applicable Planned 0 2020-04-09
POCUSCO: Point Of Care Ultrasonography for Risk-stratification of COVID-19 Patients Coronavirus disease 19 infection lung ultrasonography alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France 2020-04-06 2021-01-29 2020-A00782-37, NCT04338100, POCUSCO Phase Not Applicable Not yet recruiting 6 9 Months 300 Francis COUTURAUD, Dr, François MORIN, Dr, Karim TAZAROURTE, Pr, Laure BAUDIN, Dr, Louis SOULAT, Pr, Luc-Marie JOLY, Pr, Nicolas MARJANOVIC, Dr, Philippe LE CONTE, Pr, Pierre-Marie ROY, Pr, Thomas DELOMAS, Dr, Thomas FLAMENT, Dr 2020-04-10
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 Coronavirus disease 19 infection COVID-19 convalescent plasma therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mayo Clinic Foundation US 20-003312, NCT04338360 Phase Not Applicable Recruiting 0 Michael Joyner, MD 2020-04-11
A Phase II efficacy Study of INO-4800 in COVID-19 infection Coronavirus disease 19 infection INO-4800 alone Inovio Pharmaceuticals Inc Phase 2 Clinical Planned 0 2020-04-13
LEOSS: Lean, European, Open Survey on SARS-CoV-2 (COVID-19) Coronavirus disease 19 infection rapid tests alone Deutsches Zentrum für Infektionsforschung Willy Robert Pitzer Stiftung Bosnia and Herzegovina, Austria, France, Switzerland, UK, Germany, Belgium, Italy, Portugal, Ireland, Spain, Iceland 2020-03-16 20-600, DRKS00021145, LEOSS Phase Not Applicable Recruiting 51 20000 Jorg Janne Vehreschild 2020-04-10
PiCCOVID: Hemodynamic Characteristics of Patients With SARS-CoV-2 Coronavirus disease 19 infection echocardiography alone, transpulmonary thermodilution alone, transpulmonary thermodilution system alone Hopital de Bicetre France 2020-04-15 2021-04-30 2020-A00793-36, NCT04337983, PiCCOVID Phase Not Applicable Not yet recruiting 1 12 Months 200 Xavier Monnet, Xavier Monnet, MD.PhD 2020-04-10
A clinical trial of anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin for the treatment of COVID-19 infection Coronavirus disease 19 infection anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin alone Octapharma AG Bio Products Laboratory Ltd, Biotest AG, CSL Ltd, LFB SA, Takeda Pharmaceutical Co Ltd Phase Not Applicable Planned 0 2020-04-09
Study of the effect of Chloroquine in addition to standard therapy in COVID-19 patients Coronavirus disease 19 infection chloroquine phosphate alone, standard therapy alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Command Hospital India 2020-04-13 CTRI/2020/04/024479 Phase 2 Clinical Not yet recruiting 1 32 SALIL GUPTA 2020-04-10
A phase I clinical study to assess IPT-001 for the prevention and treatment of COVID-19 infection Coronavirus disease 19 infection IPT-001 alone Coronavirus spike glycoprotein inhibitor, Nucleoprotein inhibitor INTELLiSTEM Technologies Inc 2020-09-30 Phase 1 Clinical Planned 0 2020-04-09
A clinical trial of ADDomer for the potential treatment of COVID-19 Coronavirus disease 19 infection ADDomer alone Imophoron Ltd Phase Not Applicable Planned 0 2020-04-09
A clinical trial to assess the efficacy and safety of tPA for the potential treatment of COVID-19-related respiratory failure Coronavirus disease 19 infection tissue plasma activator alone Beth Israel Deaconess Medical Center 2020-04-06 Phase Not Applicable Recruiting 0 Christopher D. Barrett, MD, Gyongyi Szabo 2020-04-09
Maternal and neonatal outcomes from women infected with SARS-COV2 (COVID-19) during pregnancy Coronavirus disease 19 infection, SARS coronavirus infection questionnaire alone, standard care alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Monash University, University of Melbourne Australia 2020-04-10 2021-12-31 ACTRN12620000449932 Phase Not Applicable Not yet recruiting 15 20 Months 200 Dr Clare Whitehead, Dr Miranda Davies-Tuck 2020-04-13
ZINC COVID study: Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection? Coronavirus disease 19 infection, SARS coronavirus infection Zinc Chloride alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Austin Health, University of Melbourne Australia 2020-04-09 ACTRN12620000454976, DT 62996/2020, ZINC COVID study Phase 1/Phase 2 Clinical Not yet recruiting 1 160 A/Prof Joseph Ischia A/Prof Joseph Ischia 2020-04-13
HOPE Study: Hydroxychloroquine for the Community-Based Treatment of COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Medical Research Institute of New Zealand Health Research Council of New Zealand New Zealand 2020-04-14 ACTRN12620000457943p, HOPE Study, MRINZ/20/01 Phase 2 Clinical Not yet recruiting 1 70 Dr Alex Semprini 2020-04-13
WriteForIBD: Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression evidenced-based 4-day writing program alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Crohn's & Colitis Australia, Deakin University Barwon Health Australia 2020-01-16 ACTRN12620000448943p, ANZCTR12620000457943, WriteForIBD Phase Not Applicable Not yet recruiting 4 154 A/Prof Antonina Mikocka-Walus 2020-04-10
A largest Chinese study on epidemiologic characteristics of Coronavirus Disease 2019 (COVID-19) Outbreak in China Coronavirus disease 19 infection The Chinese Centre for Disease Control and Prevention Phase Not Applicable Status not specified 0 44672 2020-04-09
SRA-COV: Renin Angiotesnin System - CoronaVirus Coronavirus disease 19 infection, Respiratory distress syndrome blood draw alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux De Marseille France 2020-04-03 2020-07-31 2020-16, 2020-A00795-34, NCT04337008, SRA-COV Phase Not Applicable Recruiting 1 3 Months 50 Emilie Garrido-Pradalie, Francois Silhol, MD, François Silhol, MD 2020-04-10
CoV-Mortality: CoV-Mortality Coronavirus disease 19 infection National Institutes of Health Malaysia Malaysia 2020-04-15 2020-10-31 54609, CoV-Mortality, NMRR-20-691-54609 Phase Not Applicable Not yet recruiting 1 6 Months Dr. Woon Yuan Liang 2020-04-10
Effects of vitamin C supplementation on patients with COVID-19 Coronavirus disease 19 infection vitamin C alone Hospital Raja Permaisuri Bainun Malaysia 2020-04-14 2020-12-31 54478, IMVC 001, NMRR-20-684-54478 Phase Not Applicable Not yet recruiting 2 8 Months Dr Leong Chee Loon, Dr. G.R. Letchuman Ramanathan, Dr. Sharon Linus Lojikip, LIM XIN JIE 2020-04-10
COVID-19 ARDS Cyto-MSC Coronavirus disease 19 infection, Respiratory distress syndrome Cyto-MSC (umbilical cord derived mesenchymal stem cells) alone Cytopeutics Sdn Bhd Malaysia 2020-04-13 2020-05-31 54521, NMRR-20-672-54521, POD0039/CP/R Phase 1 Clinical Not yet recruiting 3 1 Month 5 Dr Chin Sze Piaw, Dr Toh See Guan, Mohd Shahrizal Bin Mohd Yusoff, Prof S FADILAH ABDUL WAHID 2020-04-10
A expanded access program of opaganib to treat patients with COVID-19 infection Coronavirus disease 19 infection opaganib alone Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor Cosmo Pharmaceuticals NV US Phase Not Applicable Planned 0 2020-04-08
A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection Coronavirus disease 19 infection opaganib alone Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor Cosmo Pharmaceuticals NV Israel Phase Not Applicable Recruiting 1 2020-04-09
A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection with life-threatening clinical conditions Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection, Viral pneumonia opaganib alone Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor Cosmo Pharmaceuticals NV, RedHill Biopharma Ltd Italy Phase Not Applicable Not yet recruiting 1 140 2020-04-08
Physical Activity Level, Stress Level, Sleep Quality in Covid-19 Quarantine Coronavirus disease 19 infection social quarantine implementation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istanbul Kultur University Istanbul University-Cerrahpasa Turkey 2020-04-10 2020-06-10 FADP-2, NCT04336787 Phase Not Applicable Not yet recruiting 1 2 Months 100 Ayse Zengin Alpozgen, assistant professor, Ayşe Zengin Alpözgen, Assistant Professor, Basak Polat, PhD Student, Başak Polat, PhD Student, Cicek Duman, PhD Student, Funda Akuzum, PhD Student, Funda Aküzüm, PhD Student, Gamze Ertürk Uzunoglu, PhD Student, Gamze Ertürk Uzunoğlu, PhD Student, Halenur Evrendilek, PhD Student, Tugce Tahmaz, PhD Student, Tuğçe Tahmaz, PhD Student, Çiçek Duman, PhD Student 2020-04-10
A phase II, single-arm, non-randomized study to evaluate the safety and efficacy of autologous adipose-derived mesenchymal stem cells in patients with high risk COVID-19 infection Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hope Biosciences Inc Phase 2 Clinical Not yet recruiting 0 75 2020-04-08
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia mavrilimumab alone C-reactive protein inhibitor, Chemokine CC22 ligand inhibitor, GM-CSF receptor antagonist, Hemoglobin scavenger receptor antagonist, Metalloprotease-1 inhibitor, Metalloprotease-3 inhibitor, Small inducible cytokine A17 ligand inhibitor, VEGF gene inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Virginia Commonwealth University US 2020-04-30 2020-07-31 HM20019145, NCT04337216 Phase 2 Clinical Not yet recruiting 0 3 Months 10 Antonio Abbate, MD, PhD 2020-04-10
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia allogeneic human dental pulp stem cells (BSH BTC and Utooth BTC) alone, routine treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Renmin Hospital of Wuhan University Beijing Scitop Bio-Tech Shareholding Co.Ltd, Utooth Biological Technology Co., Ltd. Hubei China 2020-04-06 2021-03-31 2020K-G005, HDPSC-COVID-2019-02-2020, NCT04336254 Phase 1/Phase 2 Clinical Recruiting 1 11 Months 20 Chenliang Zhou, PhD, Prof. Qingsong Ye, PhD,DDS, Qingsong Ye, PhD,DDS, Ye Qingsong 2020-04-09
Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course Coronavirus disease 19 infection HELIOS Kliniken GmbH Hygiene Helios Klinik Wuppertal, Klinikum Hildesheim GmbH Germany 2020-02-15 DRKS00021161, E-01-20200319 Phase Not Applicable Recruiting 1 1000 Julius Dengler, Michael Hauptmann 2020-04-10
An expanded access clinical study of autologous adipose-tissue derived mesenchymal stem cells (AdMSCs) multiple dose infusions for the treatment in patients with COVID-19 infection Coronavirus disease 19 infection autologous mesenchymal stem cell-derived exosomes (Alzheimers disease), Celltex Therapeutics alone Celltex Therapeutics Corp US Phase Not Applicable Planned 0 Dr. Derek W. Guillory 2020-04-08
COVID-ARA2: Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 Coronavirus disease 19 infection, Respiratory failure angiotensin II type 2 receptor agonists therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France 2020-04-03 2020-12-06 COVID-ARA2, COVID-ARA2, NCT04337190 Phase Not Applicable Recruiting 2 8 Months 100 Julien Demiselle, M.D., Julien Demiselle, MD, Pierre Asfar, MD, PhD 2020-04-13
CoCo Study: Corona Contact Study - Immunoreaction After Possible SARS-CoV-2/COVID-19 Contact Coronavirus disease 19 infection immunological analysis alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hannover Medical School Deutsche Forschungsgemeinschaft (DFG), Deutsches Zentrum für Infektionsforschung, German Federal Ministry of Education and Research, Novartis Pharma GmbH Germany Germany 2020-04-05 8973_BO_K_2020, CoCo Study, DRKS00021152 Phase 1/Phase 2 Clinical Recruiting 1 1000 Georg Behrens 2020-04-08
Randomized, Comparison of Combination Azithromycin and Hydroxychloroquine versus Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 Coronavirus disease 19 infection, Viral pneumonia Plaquenil alone, Plaquenil plus azithromycin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rutgers University US 2020-04-06 2021-04-30 002011, NCT04336332, PRO2020000712 Phase 2 Clinical Not yet recruiting 0 12 Months 160 Sabiha Hussain, MD, Shobha Swaminathan, MD, Steven K. Libutti, MD, FACS 2020-04-08
A clinical trial of IVIEW-1201 for the treatment or prevention of COVD-19 infection in the eye Coronavirus disease 19 infection povidone iodine (long acting/extended-release/gel, adenoviral conjunctivitis), IVIEW therapeutics alone iVIEW Therapeutics Inc China Phase Not Applicable Planned 1 2020-04-08
A pan-india non-interventional virtual registry evaluating the prophylactic efficacy of different regimens against SARS-CoV2 infection (COVID-2019) in asymptomatic health care workers Coronavirus disease 19 infection, SARS coronavirus infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Zifo RnD Solutions India 2020-04-17 CTRI/2020/04/024482 Phase Not Applicable Not yet recruiting 1 10000 Arvind Sri Krishna Mani, Viswanathan Niranjan 2020-04-10
Knowledge, attitude and fear of COVID-19 in Bangladesh Coronavirus disease 19 infection Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre for the Rehabilitation of the Paralysed Bangladesh 2020-04-09 CTRI/2020/04/024413 Phase Not Applicable Recruiting 1 1000 K M Amran Hossain, Md Zahid Hossain, Md. Shahoriar Ahmed, Professor Md Obaidul Haque 2020-04-10
ONCOVID: Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients Advanced solid tumor, Coronavirus disease 19 infection, Hematological neoplasm Plaquenil plus azithromycin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Institut Gustave Roussy France 2020-04-03 2022-04-30 2020-001250-21, 2020/3078, NCT04341207, ONCOVID Phase 2 Clinical Recruiting 2 24 Months 1000 Lisa DEROSA, MD, Stefan MICHIELS, MD 2020-04-13
CovidSurg-Cancer Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University of Birmingham Malaysia 2020-04-08 2021-03-31 NMRR-20-693-54498 Phase Not Applicable Not yet recruiting 1 11 Months 100 Andee Dzulkarnaen Zakaria 2020-04-10
Expanded-access study of GENOSYL DS for treating COVID-19 Infection Complicating Pulmonary Hypertension Coronavirus disease 19 infection, Pulmonary hypertension nitric oxide (GeNOsyl MV-2000, inhaled, ventilator platform), GeNO alone Vero Biotech 2020-03-31 Phase Not Applicable Recruiting 0 2020-04-09
EVALUATION: Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure Coronavirus disease 19 infection, Respiratory distress syndrome PiCCO-monitoring alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ludwig-Maximilians University of Munich Technical University of Munich Germany 2020-03-11 2020-04-30 EVALUATION, ISRCTN10077335 Phase Not Applicable Recruiting 2 1 Month 25 Prof. Wolfgang Huber 2020-04-09
A phase II clinical study to assess VIR-7832 in the treatent of patients with SARS-CoV-2 infection Coronavirus disease 19 infection VIR-7832 alone Coronavirus spike glycoprotein inhibitor GlaxoSmithKline plc Vir Biotechnology Inc Phase 2 Clinical Planned 0 2020-04-08
A phase II clinical study to assess VIR-7831 in the treatent of patients with SARS-CoV-2 infection Coronavirus disease 19 infection VIR-7831 alone Coronavirus spike glycoprotein inhibitor GlaxoSmithKline plc Vir Biotechnology Inc Phase 2 Clinical Planned 0 2020-04-08
EasyCoV: Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2 Coronavirus disease 19 infection, SARS coronavirus infection sample collection alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Montpellier Skillcell, Sys2Diag France 2020-04-07 2020-04-17 EasyCoV, NCT04337424, RECHMPL20_0170 Phase Not Applicable Not yet recruiting 1 180 REYNES Jacques, PU PH 2020-04-08
Imaging Findings In Covid-19 Coronavirus disease 19 infection Hospital Tawau Malaysia 2020-04-13 2020-04-30 NMRR-20-698-54570 Phase Not Applicable Not yet recruiting 1 70 Dr Mohana A/P Letchumanan 2020-04-08
Evaluation of Blood Results of Covid 19 Positive Pregnants Coronavirus disease 19 infection Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-03-21 2020-05-22 COVID19PREGNANCIES, NCT04337294 Phase Not Applicable No longer recruiting 1 2 Months 100 Pınar Yalcin bahat 2020-04-10
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 Coronavirus disease 19 infection, Viral pneumonia favipiravir alone, supportive care alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) ASST Fatebenefratelli Sacco Italy 2020-03-25 2020-07-31 HS216C17-PHASE III, NCT04336904 Phase 3 Clinical No longer recruiting 1 4 Months 100 Giuliano Rizzardini, Md 2020-04-09
REMOTE-COVID: Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus) Coronavirus disease 19 infection SensiumVitals wearable sensor alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Imperial College London UK 2020-04-01 2021-04-01 NCT04337489, REMOTE-COVID, REMOTE-COVID Phase Not Applicable Not yet recruiting 1 12 Months 200 Ara Darzi, Prof, Fahad M Iqbal, MBChB (hons), Sadia Khan, Dr 2020-04-08
Clinical and Radiomic Model of COVID-19 Coronavirus disease 19 infection Universiteit Maastricht Wuhan Central Hospital China 2019-12-23 2020-03-03 NCT04337502, UM_2020_GY_COVID-19 Phase Not Applicable Completed 1 2 Months 300 2020-04-10
UZH COVID-19 Cohort Study: Cohort study for predicting severe disease courses in patients presenting for coronavirus testing to the University of Zurich COVID-19 Testing Center Coronavirus disease 19 infection Phone calls alone University of Zurich Switzerland 2020-03-20 2020-12-31 ISRCTN77353041, UZH COVID-19 Cohort Study Phase Not Applicable Recruiting 1 9 Months 200 Dr Dominik Menges, Prof Jan Fehr, Prof Milo A. Puhan 2020-04-09
Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns Coronavirus disease 19 infection Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-01 2020-06-20 COVID19PREGNANCYNEWBORN, NCT04337320 Phase Not Applicable No longer recruiting 1 2 Months 70 Pınar Yalcin bahat 2020-04-08
Evaluation of the Effect of High-dose Vitamin C Use in Covid 19 Positive Pregnants Coronavirus disease 19 infection vitamin C alone Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-01 2020-05-30 HIGHDOSEVITCINCOVID19, NCT04337281 Phase Not Applicable No longer recruiting 1 1 Month 50 Pınar Yalcin bahat 2020-04-09
Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Xiaotan Sanjiefang granule alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Beijing University of Chinese Medicine Chinese Ministry of Science and Technology China 2020-03-01 2020-12-31 ChiCTR2000031672, ChiMCTR2000003188 Phase 2 Clinical Not yet recruiting 1 10 Months 150 Yingshuai Li 2020-04-09
Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System Coronavirus disease 19 infection Surgical facial mask alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rigshospitalet, Denmark Denmark Technical University, HS Hvidovre Hospital, Nordsjaellands Hospital Denmark 2020-04-02 2020-07-01 2020-04-02, NCT04337541 Phase Not Applicable Recruiting 1 3 Months 6000 Christian Torp-Pedersen, Prof., DMSc, Henning Bundgaard, Prof., DMSc, Henrik Ullum, Prof., DMSc, Kasper Karmark Iversen, Prof., DMSc, Thomas Benfield, Prof., DMSc 2020-04-13
Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients Coronavirus disease 19 infection, Viral pneumonia interferon treatment alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Wenzhou Central Hospital China 2020-02-01 2021-01-31 ChiCTR2000031699 Phase 1 Clinical No longer recruiting 1 12 Months 33 Tangshaohua 2020-04-09
Evaluation of Covid 19 Anxiety in Endometriosis Patients Coronavirus disease 19 infection, Endometriosis, Generalized anxiety disorder Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-05 2020-04-25 ENDOCOVID19, NCT04337346 Phase Not Applicable No longer recruiting 1 80 Pınar Yalcin bahat 2020-04-09
COVID-CHD: Impact of Covid-19 in Congenital Heart Disease Congenital heart defect, Coronavirus disease 19 infection University Hospital, Montpellier France 2020-03-01 2020-12-30 COVID-CHD, NCT04336384, RECHMPL20_0155 Phase Not Applicable Recruiting 1 9 Months 5000 Adeline BASQUIN, MD, Alexis BLANC, MD, BERTRAND LEOBON, MD, Caroline OVAERT, MD, Céline GRUNENWALD GRONIER, MD, Daniela LAUX, MD, Jean-Benoît THAMBO, MD, PhD, Karine WARIN-FRESSE, MD, Magalie LADOUCEUR, MD, Nicolas COMBES, MD, Pascal AMEDRO, MD-PHD, Pascal AMEDRO, MD-PhD, Sébastien HASCOET, MD, Xavier IRIART, MD 2020-04-09
Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease Coronavirus disease 19 infection Ig G test alone, Questionnaire alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assiut University Egypt 2020-04-30 2020-05-31 ASSIUTU11, NCT04336657 Phase Not Applicable Recruiting 1 1 Month 100 Aliae AR Mohamed-Hussein, Aliae Mohamed-Hussein 2020-04-09
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Vienna 2020-04-30 2020-08-31 HCQ PROPHYLAXIS FOR COVID19, NCT04336748 Phase 3 Clinical Not yet recruiting 0 4 Months 440 Matthias Vossen 2020-04-09
CAPTION AI to Minimize Risk of COVID Exposure Coronavirus disease 19 infection, Viral pneumonia Caption AI alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University Caption Health Inc US 2020-04-30 2020-11-09 NCT04336774, PRO00105212 Phase Not Applicable Not yet recruiting 0 6 Months 500 Kristine Arges, BSN, Sreekanth Vemulapallli, MD 2020-04-09
INCOVPED: Prevalence of Covid-19 in Children Admitted to Pediatric Emergency Departments During the Pandemic Period in France Coronavirus disease 19 infection nasopharyngeal swab alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-12-31 2020-A00811-38, 2020_21, INCOVPED, NCT04336761 Phase Not Applicable Not yet recruiting 5 8 Months 914 Camille BREHIN, MD, Christèle LE GUEN, MD,PhD, Flora JOANNES, MD, François DUBOS, MD,PhD, François Dubos, MD,PhD, Hervé HAAS, MD, Marie Chinazzo-Vigouroux, MD 2020-04-09
A trial to assess brilacidin in the potential treatment of novel coronavirus COVID-19 treatment Coronavirus disease 19 infection brilacidin alone PDE 3 inhibitor, PDE 4 inhibitor Innovation Pharmaceuticals Inc Europe Phase Not Applicable Planned 0 2020-04-08
Rutgers COVID-19 Cohort Study Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rutgers University US 2020-03-28 2021-10-21 2020000679, NCT04336215 Phase Not Applicable Recruiting 0 18 Months 750 Jeffrey L Carson, MD, Reynold A Panettieri, MD 2020-04-09
MexCOVID-19: Outcomes of Patients With COVID-19 in the Intensive Care Unit Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto Nacional de Ciencias Medicas y Nutricion Mexico 2020-04-01 2020-05-30 MexCOVID-19, NCT04336345, TEI-3336-20-20-1 Phase Not Applicable Not yet recruiting 2 1 Month 150 Eduardo Rivero-Sigarroa, MD, Guillermo Dominguez-Cherit, MD, Silvio A. Ñamendys-Silva, MD, MSc 2020-04-09
Viral Infection and Respiratory illness Universal Study Coronavirus disease 19 infection, Viral pneumonia Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Society of Critical Care Medicine India, US, Italy, UK 2020-04-01 CTRI/2020/04/024473 Phase Not Applicable Recruiting 3 50000 Dr Mradul Kumar Daga, Dr Naresh Kumar 2020-04-09
A multicenter, phase 2/3, randomized, placebo-controlled study to assess the effect of remestemcel-L in the treatment of COVID-19 patients with acute respiratory distress syndrome Coronavirus disease 19 infection, Respiratory distress syndrome remestemcel-L alone Mesoblast Ltd, National Heart Lung and Blood Institute US Phase 2/Phase 3 Clinical Not yet recruiting 0 2020-04-13
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/very Severe COVID-19 Illness Coronavirus disease 19 infection ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Novartis AG CINC424A2001M, NCT04337359 Phase Not Applicable Recruiting 0 Novartis Pharmaceuticals, Novartis Pharmaeuticals 2020-04-09
PANDOR: Covid-19 Pediatric Observatory Coronavirus disease 19 infection real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) Centre Hospitalier Intercommunal Creteil ACTIV, France, GFRUP, GPIP (FR), Societe Francaise de Pediatrie France 2020-04-07 2021-06-30 NCT04336956, PANDOR, PANDOR Phase Not Applicable Recruiting 3 14 Months 250 Albert Faye, Camille Jung, Corinne Levy, MD, François Angoulvant, Ralph EPAUD, Xavier DURRMEYER 2020-04-13
Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent Coronavirus disease 19 infection, Viral pneumonia novel coronavirus pneumonia (COVID-19) antigen reagent alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chinese PLA General Hospital, Chongqing Infectious Disease Medical Center, Wuhan Huoshenshan Hospital Beijing Savant Biotechnology Co Ltd China 2020-04-07 2020-05-31 ChiCTR2000031700 Phase Not Applicable Not yet recruiting 3 1 Month 600 Zhang Chunyan 2020-04-09
Study for investigation of contamination by novel coronavirus pneumonia (COVID-19) in the clinical environment Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia Surface swab and air sample collection alone, Surface swab from personal protective equipment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chinese University of Hong Kong China 2020-04-01 2021-03-31 ChiCTR2000031712 Phase 1 Clinical Recruiting 1 12 Months 60 Christopher KC Lai 2020-04-09
Clinical trial of KTH-222 (alone and/or in combination with anti-viral drugs)for the treatment of cancer patients infected with the COVID-19 virus or in suspected patients with the symptoms Coronavirus disease 19 infection KTH-222 alone, anti-viral drug therapy alone MAP kinase inhibitor Kalos Therapeutics Inc, Oncology Pharma Inc Phase Not Applicable Planned 0 2020-04-09
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers Coronavirus disease 19 infection CELLECTRA 2000 alone, INO-4800 alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Inovio Pharmaceuticals Inc Coalition for Epidemic Preparedness Innovations US 2020-04-03 2020-11-30 COVID19-001, NCT04336410 Phase 1 Clinical Recruiting 0 7 Months 40 Inovio Call Center, Pablo Tebas, Program Manager Barbara Bradshaw, Program Manager Eileen Donaghy, ShuPing Yang, MD, PhD 2020-04-13
A phase III in-home, self-dosing clinical trial to assess ENU-200 in the treatment of patients with asymptomatic, mild to moderate coronavirus infections (COVID-19) utilizing their iClickCare secure clinical reporting software service to monitor the in-home trials Coronavirus disease 19 infection ENU-200 alone, iClickCare alone Coronavirus spike glycoprotein inhibitor Ennaid Therapeutics US Phase 3 Clinical Planned 0 2020-04-09
Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19 (COVID-19) Coronavirus disease 19 infection, Viral pneumonia AMS-H-03 Gas Nebulizer alone, Hydrogen-Oxygen Generator alone, conventional treatment alone, hydrogen/ oxygen inhaled therapy alone, oxygen inhaled therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shanghai Asclepius Meditec Co., Ltd First People's Hospital of Yunnan Province, Guangdong Provincial Hospital of Chinese Medicine, Henan Province People's Hospital, Shanghai First People's Hospital, Shanghai Public Health Clinical Center, Shanghai Sixth People’s Hospital, The First Affiliated Hospital of Guangzhou Medical College, The Third People’s Hospital of Shenzhen China 2020-02-15 2020-08-01 JT202002LZ, NCT04336462 Phase Not Applicable Recruiting 1 5 Months 100 Hu J Ying, master, Xin Yong Lin, master, Zhang Ze Guang, doctor, Zheng Z Guang, doctor 2020-04-09
Cardiovascular Manifestations of COVID-19 Cardiovascular disease, Coronavirus disease 19 infection echocardiography alone, serial electrocardiography alone, serial laboratory testing alone, telemetry monitoring alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Memorial Hermann Hospital US 2020-03-30 2022-03-31 HSC-MS-20-0286, NCT04335630 Phase Not Applicable Recruiting 0 24 Months 500 Efstratios Koutroumpakis, Efstratios Koutroumpakis, MD, Heinrich Taegtmeyer, MD, DPhil 2020-04-09
EPICOS: Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel Coronavirus disease 19 infection emtricitabine + tenofovir disoproxil plus hydroxychloroquine Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Effice Servicios Para la Investigacion Instituto de Salud Carlos III Spain 2020-04-01 2020-07-31 2020-001385-11, EPICOS, NCT04329520, NCT04334928, PREP COVID-19 Phase 3 Clinical No longer recruiting 1 4 Months 4000 Clinical Trials Department, Julia del Amo, PhD, Miguel Hernán, MD,PhD, Rosa Polo, MD,PhD 2020-04-13
get.calm_move.on: Tackling worries and finding strength for the crisis (COVID-19) in ten steps Coronavirus disease 19 infection get.calm and move.on online training alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Leuphana Universität Lüneburg Stiftung Öffentlichen Rechts Germany 2020-04-06 DRKS00021153, EB-Antrag_202003_12_Lehrgetcalm, get.calm_move.on Phase Not Applicable Not yet recruiting 1 352 Dirk Lehr, Hanna Heckendorf 2020-04-08
An international, multicenter, randomized, double-blind, adaptive, placebo-controlled study of the efficacy and safety of a single administration of olokizumab and RPH-104 with standard therapy in patients with severe SARS-CoV-2 virus infection (COVID-19) Coronavirus disease 19 infection RPH-104 alone, olokizumab alone IL-6 receptor antagonist, Interleukin-1 beta ligand inhibitor R-Pharm Russian Federation 2020-04-15 2021-04-30 CL04041078 Phase 2/Phase 3 Clinical Not yet recruiting 6 12 Months 250 2020-04-08
Multicenter, double-blind, placebo-controlled, adaptive, randomized, comparative study of the efficacy and safety of Polyoxidonium, lyophilisate for solution for injection and topical use, 6 mg (LLC NPO Petrovax Pharm, Russia) in patients with coronavirus infection (COVID-19) Coronavirus disease 19 infection Polyoxidonium alone NPO Petrovax Pharm LLC Russian Federation 2020-04-03 2022-04-01 PO-COV-III-20 Phase 3 Clinical Status not specified 7 23 Months 454 2020-04-13
CORSER: Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples Coronavirus disease 19 infection, SARS coronavirus infection Healthy volunteers accepted, Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Institut Pasteur France 2020-03-13 2023-02-28 2020-007, CORSER, NCT04325646 Phase Not Applicable Recruiting 12 35 Months 1000 Bruno HOEN, Pr, Christian CHIDIAC, Pr, Elisabeth BOTELHO-NEVERS, Pr, Eric SENNEVILLE, Pr, France CAZENAVE-ROBLOT, Pr, François GOEHRINGER, Jean-François FAUCHER, Pr, Jean-Marc Chapplain, Dr, Jean-Philippe LANOIX, Dr, Louis BERNARD, Pr, Marie-Noëlle UNGEHEUER, Dr, Pascal CHAVANET, Pr, Thierry PRAZUCK, Pr 2020-04-08
A clinical study of Hyperimmune globulin for the treatment of COVID-19 infection Coronavirus disease 19 infection Hyperimmune globulin alone Food and Drug Administration, National Institute of Allergy and Infectious Diseases US Phase Not Applicable Planned 0 2020-04-09
PRAETORIAN-COVID: Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease Coronavirus disease 19 infection, Respiratory distress syndrome valsartan alone Angiotensin I receptor antagonist, Angiotensin II receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Radboud University Netherlands 2020-04-30 2021-08-31 2020-001320-34, NCT04335786, NL73547.091.20, PRAETORIAN-COVID Phase 4 Clinical Not yet recruiting 1 16 Months 651 Frank Gommans, MD PhD, Niels van Royen, MD PhD, Roland RJ van Kimmenade, MD PhD 2020-04-09
An expanded access program to assess the safety and efficacy of convalescent plasma in the treatment of COVID-19 infection Coronavirus disease 19 infection convalescent plasma alone Food and Drug Administration, Mayo Clinic Foundation Biomedical Advanced Research and Development Authority (BARDA) US Phase Not Applicable Planned 0 2020-04-07
Clinical trial of therapeutic antibody (corona virus disease 19 infection), Abclon for the treatment of Coronavirus disease 19 infection Coronavirus disease 19 infection therapeutic antibody (COVID-19), Abclon alone Coronavirus spike glycoprotein inhibitor AbClon Inc Phase Not Applicable Planned 0 2020-04-08
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 Coronavirus disease 19 infection bacTRL-Spike alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Symvivo Corp Canada 2020-04-30 2021-12-31 BACTRL-SPIKE-1, NCT04334980, bacTRL-IL-Spike-1 Phase 1 Clinical Not yet recruiting 2 20 Months 84 Alexander Graves, Eric Sievers, Jill Mutch, Joanne Langley, MD, MSc, FRCPC, Karen Simmons, M. Sc., Manish Sadarangani, BM BCh DPhil, Mel Krajden, MD PhD, Michelle Jones, Muhammad Morshed, PhD, Scott Halperin, MD, Shelly McNeil, MD, FRCPC, Soren Gantt, MD PhD 2020-04-08
Investigator-Initiated Trial to Assess The Effect of AT-001, Applied Therapeutics in Patients with Acute Lung Inflammation, Cardiomyopathy and COVID-19 Coronavirus disease 19 infection, Lung inflammation, Myocardial disease AT-001, Applied Therapeutics alone Aldose reductase inhibitor Applied Therapeutics Inc US Phase Not Applicable Status not specified 0 2020-04-08
Investigator-Initiated Trial to Assess The Effect of AT-001, Applied Therapeutics in Patients with Acute Lung Inflammation, Cardiomyopathy and COVID-19 Coronavirus disease 19 infection, Lung inflammation, Myocardial disease AT-001, Applied Therapeutics alone Aldose reductase inhibitor Applied Therapeutics Inc US Phase Not Applicable Status not specified 0 2020-04-07
Investigator-Initiated Trial to Assess The Effect of AT-001, Applied Therapeutics in Patients with Acute Lung Inflammation, Cardiomyopathy and COVID-19 Coronavirus disease 19 infection, Lung inflammation, Myocardial disease AT-001, Applied Therapeutics alone Aldose reductase inhibitor Applied Therapeutics Inc US Phase Not Applicable Status not specified 0 2020-04-08
Study of Open-Label Losartan in COVID-19 Coronavirus disease 19 infection, Respiratory failure losartan alone Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Kansas Medical Center US 2020-03-25 2020-10-31 NCT04335123, STUDY00145514 Phase 1 Clinical Recruiting 0 7 Months 50 Carolina Aguiar, Charles Bengtson, MD, Lewis Satterwhite, MD, Matthias Salathe, Matthias Salathe, MD, Usman Nazir, MD 2020-04-07
A placebo-controlled prophylaxis study of chloroquine and hydroxychloroquine in preventing COVID-19 in at-risk health care workers, frontline staff, and other high-risk groups Coronavirus disease 19 infection chloroquine alone, hydroxychloroquine alone The Mahidol Oxford Tropical Medicine Research Unit Europe, Asia, UK 2020-04-30 Phase Not Applicable Not yet recruiting 1 40000 2020-04-07
LIBA: LIBA Trial in COVID-19 Coronavirus disease 19 infection ibuprofen (Flarin) alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) King's College London Guy's & St Thomas' Hospital NHS Trust UK 2020-04-06 2020-11-05 282009, LIBA, NCT04334629 Phase 4 Clinical Not yet recruiting 1 7 Months 230 Chloe Farrell, PhD, Manu Shankar-Hari, MBBS, Ndaba Mazibuko, MD 2020-04-07
A clinical study of INOmax for the treatment in patients with COVID-19 infection Coronavirus disease 19 infection nitric oxide (inhaled), Ikaria alone Hemoglobin modulator Mallinckrodt plc US Phase Not Applicable Planned 0 2020-04-07
A Study to Assess the Effect of siRNA-based SARS-CoV-2 therapies (COVID-19), Alnylam/ Vir Biotechnology in the Treatment of COVID-19 Patients Coronavirus disease 19 infection siRNA-based SARS-CoV-2 therapies (COVID-19), Alnylam/ Vir Biotechnology alone Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc Phase Not Applicable Planned 0 2020-04-07
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects Coronavirus disease 19 infection BLD-2660 alone, standard of care alone Calpain-I inhibitor, Calpain-II inhibitor, Calpain-IX inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Blade Therapeutics 2020-05-31 2020-09-30 B-2660-204, NCT04334460 Phase 2 Clinical Not yet recruiting 0 4 Months 120 2020-04-07
APN01-COVID-19: Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 Coronavirus disease 19 infection APN-01 alone Angiotensin converting enzyme 2 stimulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) APEIRON Respiratory Therapies GmbH, Apeiron Biologics GmbH Austria, Germany, Denmark 2020-04-30 2020-11-30 2020-001172-15, APN01-01-COVID19, APN01-COVID-19, NCT04335136 Phase 2 Clinical Not yet recruiting 9 7 Months 200 Alexander Zoufaly, Priv.-Doz. Dr., CRO, Christian Søborg, Christoph D. Spinner, PD DR. med., Claudia Haider, Mag., Günter Weiss, Univ.-Prof. Dr., Henning Bundgaard, Prof. Dr. med., Jan Gerstoft, Prof. Dr. med., Roman Ullrich, Prof. Dr., Sonja Höller, Dr., Stefan Schmiedel, Dr. med., Thomas L. Benfield, Prof., Troels B. Knudsen 2020-04-08
A clinical study to assess biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia Asian Ancestry The Third People’s Hospital of Shenzhen China Phase Not Applicable Status not specified 1 12 Liu et al 2020-04-08
Hydroxychloroquine for COVID-19 in moderately to severely ill hospitalized patients Coronavirus disease 19 infection, Viral pneumonia Plaquenil alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sanofi-Aventis Research and Development Denmark, Czech Republic, UK, France 2020-04-08 2020-001270-29, EFC16858, U1111-1249-6096 Phase 2/Phase 3 Clinical Recruiting 4 350 Clinical Study Unit, Direction des Opérations Cliniques, Medical Information, www.sanofi.cz 2020-04-13
Dynamics of regional lung aeration non-invasive determined by electrical impedance tomography in patients with COVID-19 Coronavirus disease 19 infection, Viral pneumonia tomography alone, ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitätsmedizin Rostock Germany 2020-04-12 A2020-0072, DRKS00021276 Phase 4 Clinical Not yet recruiting 2 24 Sven Pulletz 2020-04-07
Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019 Coronavirus disease 19 infection, Pulmonary fibrosis anluohuaxian alone, regular treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Peking University First Hospital China 2020-04-01 2020-12-01 2020 RESEARCH 110, NCT04334265 Phase 2 Clinical Not yet recruiting 9 8 Months 750 Dingyu Zhang, Guiqiang Wang, Hong Zhao, Junhua Yu, Qin Ning, Sibin Zhang, Xi Zheng, Xianxiang Chen, Yongping Chen, Zhenshun Cheng 2020-04-07
Screening for symptoms of COVID-19 Coronavirus disease 19 infection Max Super Speciality Hospital India 2020-04-08 CTRI/2020/04/024442 Phase Not Applicable Not yet recruiting 1 5000 DrSujeet Jha 2020-04-08
A compassionate use program to assess remdesivir in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection remdesivir alone RNA polymerase modulator Gilead Sciences Inc Europe Phase Not Applicable Planned 0 2020-04-09
Sensor Based Vital Signs Monitoring of COVID-19 Patients During Home Isolation Coronavirus disease 19 infection, SARS coronavirus infection biosensor (Welfare technology) alone, general recommendation alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ullevaal University Hospital Oslo University Hospital, Universidad del Pais Vasco, Universitetssykehuset Nord-Norge Hf, University of Stavanger Norway 2020-04-07 2025-12-20 127157, HSC19, NCT04335097 Phase Not Applicable Not yet recruiting 1 68 Months 214 Lars Wik, Lars Wik, MD 2020-04-07
A clinical study of gut microbiome derived therapeutics for the potential prevention of COVID-19 Coronavirus disease 19 infection gut microbiome derived therapeutics (COVID-19), Persephone Biosciences alone Persephone Biome Inc Phase Not Applicable Planned 0 2020-04-07
CORON-ACT: Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) Coronavirus disease 19 infection, Viral pneumonia tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Inselspital, Berne Roche Holding AG Switzerland 2020-04-30 2020-10-31 2020-00691, 2020DR2044, CORON-ACT, NCT04335071 Phase 2 Clinical Not yet recruiting 3 6 Months 100 Peter M. Villiger, Prof. Dr. med., Stephan Reichenbach, Prof. Dr.med. 2020-04-10
HyAzOUT: Hydroxychloroquine Versus Azithromycin for Outpatients in Utah With COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Intermountain Health Care Inc University of Utah, Utah Department of Health US 2020-04-02 2021-12-31 1051360, HyAzOUT, NCT04334382 Phase 3 Clinical Recruiting 0 20 Months 1550 Brandon Webb, MD, David P Tomer, MS, Estelle Harris, MD, Jake Krong, Valerie T Aston, MBA 2020-04-10
A clinical study of EIDD-2801 in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection EIDD-2801, Drug Innovation Ventures/Georgia State University/Emory University alone RNA polymerase inhibitor Ridgeback Biotherapeutics LP Drug Innovation Ventures at Emory LLC US 2020-04-30 Phase Not Applicable Not yet recruiting 0 2020-04-08
EPA-FFA to Treat Hospitalized Patients With SARS-CoV-2 Coronavirus disease 19 infection eicosapentaenoic acid (oral, familial adenomatous polyposis/inflammatory bowel disease/Crohns disease), SLA Pharma alone, standard of care treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) SLA Pharma AG 2020-04-13 2020-07-31 EPA-COV-001, NCT04335032 Phase 3 Clinical Not yet recruiting 0 3 Months 150 Justin Slagel 2020-04-09
HELPCOVID-19: A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , vitamin C , vitamin D , zinc Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) ProgenaBiome US 2020-04-30 2021-07-31 HELPCOVID-19, NCT04335084, PRG-042 Phase 2 Clinical Not yet recruiting 0 15 Months 600 Jordan Daniels, MS, Sabine Hazan, MD 2020-04-08
Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia Coronavirus disease 19 infection questionnaire alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jessa Hospital Belgium 2020-04-17 2023-12-20 JESSAH_COVID19_PRESCREENING, NCT04334252 Phase Not Applicable Not yet recruiting 1 44 Months 5000 Ina Callebaut, Ina Callebaut, dr, Janneke Cox, Dr 2020-04-10
eChoVid: Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 + Coronavirus disease 19 infection pulmonary ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-30 2020-05-31 2020-A00768-31, APHP200390, NCT04335019, eChoVid Phase Not Applicable Not yet recruiting 1 1 Month 300 Mehdi BENCHOUFI, MD 2020-04-08
TOSCA: Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection, Viral pneumonia tocilizumab alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universita Degli Studi Di L'Aquila 2020-04-01 2021-03-31 0064468/20, NCT04332913, TOSCA Phase Not Applicable Not yet recruiting 0 12 Months 30 Roberto Giacomelli, MD, PhD 2020-04-09
HERO-HCQ: Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University Patient Centered Outcome Research Institute US 2020-04-30 2020-07-31 HERO-HCQ, NCT04334148, PRO00105274 Phase 3 Clinical Not yet recruiting 0 3 Months 15000 Adrian Hernandez, MD, Donna Parker, Rachel Olson, RN 2020-04-08
COVID-19 REAL: A non-interventional, retrospective, database, cohort study based on anonymized and routinely collected health care data from COVID-19 patients Coronavirus disease 19 infection TFS AB IOMED Inc COVID-19 REAL Phase Not Applicable Not yet recruiting 0 2020-04-07
COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology Coronavirus disease 19 infection Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) University Hospital, Akershus Alesund Hospital, Haukeland University Hospital, Helse Fonna, Helse Stavanger HF, Levanger Hospital, Nordlandssykehuset HF, Norwegian Institute of Public Health, Oslo University Hospital, St Olavs Hospital, Sykehuset Innlandet HF, Sykehuset Ostfold, University Hospital of North Norway, University of Bristol, University of New South Wales, Vestre Viken HF Norway 2020-04-01 2030-12-31 20/03794, NCT04335773 Phase Not Applicable Not yet recruiting 1 129 Months 350 Christopher Inchley, Mr, Christopher Inchley, Phd, Lise Beier Havdal 2020-04-09
A study to assess the effect of blood plasma in the treatment of COVID-19 patients Coronavirus disease 19 infection blood plasma alone Karolinska Institutet Sweden Phase Not Applicable Not yet recruiting 2 30 Joakim Dillner 2020-04-07
A multi-site clinical trial investigating whether hydroxychloroquine can effectively prevent COVID-19 in participants already exposed to the infection Coronavirus disease 19 infection hydroxychloroquine alone University of Washington New York University School of Medicine, US US Phase Not Applicable Not yet recruiting 0 2000 2020-04-07
A compassionate use program of CAP-1002 for the treatment of ARDS pneumonia in COVID-19 patients Coronavirus disease 19 infection, Respiratory distress syndrome CAP-1002 alone Capricor Therapeutics Inc US Phase Not Applicable Recruiting 0 2020-04-07
ORCHID: Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease Coronavirus disease 19 infection, SARS coronavirus infection Hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital National Heart Lung and Blood Institute US 2020-04-02 2021-07-31 NCT04332991, ORCHID, PETAL 05 ORCHID Phase 3 Clinical Recruiting 0 15 Months 510 Boyd Taylor Thompson, MD, Katie Oldmixon, RN, Nancy Ringwood, BSN 2020-04-09
A Canadian pilot study of inhaled formulation of nitric oxide (NO) for the treatment of COVID-19 infection Coronavirus disease 19 infection Nitric Oxide Delivery Device (INODD) alone, nitric oxide (inhalant, cystic fibrosis/non-tuberculous mycobacteria infection), Novoteris alone Mallinckrodt plc, Novoteris LLC Canada Phase Not Applicable Not yet recruiting 1 2020-04-07
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases Arthritis, Coronavirus disease 19 infection, Psoriatic arthritis, Rheumatoid arthritis, Spondylarthritis, Systemic lupus erythematosus blood sampling alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Region Nordjylland Aalborg Sygehus Denmark 2020-04-08 2021-09-01 20200401, NCT04335747 Phase Not Applicable Not yet recruiting 1 16 Months 333 Line Uhrenholt, MD, Salome Kristensen, MD, PhD 2020-04-13
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers Coronavirus disease 19 infection Hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Baylor Research Institute US 2020-04-03 2020-07-30 020-132, NCT04333225 Phase 2 Clinical Recruiting 0 3 Months 360 Peter A McCullough, MD, MPH 2020-04-13
ATCO: Angiotensin-(1,7) Treatment in COVID-19 Coronavirus disease 19 infection, Respiratory failure, Respiratory insufficiency, Viral pneumonia angiotensin 1-7 alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Erasme Hospital Fonds Erasme Belgium 2020-03-31 2020-06-15 ATCO, NCT04332666, P2020/201 Phase 2/Phase 3 Clinical Not yet recruiting 1 2 Months 60 Fabio S Taccone, PD,PhD, Filippo Annoni, MD, Robson AS Santos, MD,PhD 2020-04-08
Study Testing Convalescent Plasma versus Best Supportive Care Coronavirus disease 19 infection, Pneumonia, SARS coronavirus infection high-titer anti-Sars-CoV-2 plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Baylor Research Institute 2020-04-01 2022-12-31 020-123, NCT04333251 Phase 1 Clinical Not yet recruiting 0 33 Months 115 2020-04-09
COVID-19 Registry Rhineland-Palatinate (Germany) Coronavirus disease 19 infection IHF GmbH - Institut für Herzinfarktforschung Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz Germany 2020-04-06 2021-09-30 COVID-19 REGISTRY, NCT04335188 Phase Not Applicable Recruiting 1 17 Months 4000 Anselm Gitt, MD, Sebastian Diebold, PhD 2020-04-09
Recovery-RS: Respiratory support: respiratory strategies in patients with coronavirus COVID-19 - CPAP, high-flow nasal oxygen and standard care Coronavirus disease 19 infection continuous positive airway pressure therapy alone, high flow nasal oxygen therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Warwick University UK 2020-03-30 2021-05-05 IRAS 282338, ISRCTN16912075, Recovery-RS, SPONSOR: 26/19-20 Phase Not Applicable Recruiting 1 13 Months 4002 Dr Keith Couper 2020-04-08
DEFI-VID19: Defibrotide in COVID-19 Pneumonia Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia defibrotide alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) IRCCS San Raffaele Italy 2020-04-06 2020-12-31 DEFI-VID19, DEFI-VID19, NCT04335201 Phase 2 Clinical Not yet recruiting 1 8 Months 50 Ciceri Fabio,, Fabio Ciceri, MD, Stefania Trinca 2020-04-08
A Case Study on Treating COVID-19 in a Patient with Multiple Myeloma Coronavirus disease 19 infection, Viral pneumonia tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Male, Asian Ancestry Anhui Provincial Hospital China Phase Not Applicable Status not specified 1 1 Changcheng Zheng, MD 2020-04-09
CP-COVID-19: Convalescent Plasma for Patients With COVID-19: a Randomized, Open-label, Parallel, Controlled Clinical Study Coronavirus disease 19 infection, Viral pneumonia Variable regimens including azithromycin , convalescent plasma , hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Del Rosario University CES University, Fundación Universitaria de Ciencias de la Salud, Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud Colombia 2020-04-01 2020-12-31 ABN011-2, CP-COVID-19, NCT04332835 Phase 2/Phase 3 Clinical Not yet recruiting 1 9 Months 80 Adriana Rojas Villarraga, MD, Anha M Robledo Moreno, Bernardo Camacho Rodríguez, MD, MSc, Carlos E Perez, MD, Cristian A Ricaurte Perez, MSc, Diana M Monsalve Carmona, PhD, Gustavo A Salguero López, MD, PhD, Gustavo Quintero, MD, MSc, Heily C Ramírez Santana, MSc, PhD, Isaura P Torres Gómez, MSc, PhD, Jeser S Grass Guaqueta, MSc, Juan C Diaz Coronado, MD, MSc, Juan E Gallo Bonilla, MSc, PhD, Juan M Anaya Cabrera, MD, PhD, Luisa P Duarte Correales, Manuel E Rojas Quintana, MD, MSc, Oscar M Gómez Guzmán, MSc, PhD, Paula A Pedroza Rodríguez, Paula Gaviria, MSc, Ruben D Manrique Hernández, MSc, PhD, Ruben D Mantilla, MD, Sara Velez Gomez, Yeny Y Acosta Ampudia, PhD, Yhojan A Rodríguez Velandia, MD 2020-04-08
HAZCpaC: A Study of Quintuple Therapy to Treat COVID-19 Infection Coronavirus disease 19 infection Variable regimens including Plaquenil , azithromycin , vitamin C , vitamin D , zinc Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) ProgenaBiome US 2020-04-30 2021-07-31 HAZCpaC, NCT04334512, PRG-044 Phase 2 Clinical Not yet recruiting 0 15 Months 60 Jordan Daniels, MS, Sabine Hazan, MD 2020-04-08
A Study to Assess the Effect of Repurposed Camostat in the Treatment of Coronavirus Disease 19 Infection (COVID-19) Patients Coronavirus disease 19 infection repurposed camostat (COVID-19), University of Tokyo alone Serine protease inhibitor, Trypsin inhibitor University of Tokyo 2020-04-30 Phase Not Applicable Planned 0 2020-04-07
A phase I trial to evaluate safety and immunogenicity of vaccine (coronavirus disease 19 infection), State Research Center of Virology and Biotechnology VECTOR for the treatment of patients with coronavirus disease 19 infection Coronavirus disease 19 infection vaccine (coronavirus disease 19 infection), State Research Center of Virology and Biotechnology VECTOR alone State Research Center of Virology and Biotechnology VECTOR 2020-06-29 Phase 1 Clinical Planned 0 60 2020-04-07
A phase III clinical trial to evaluate the safety and efficacy of remdesivir in the treatment of patients with moderate COVID-19 infection Coronavirus disease 19 infection remdesivir alone RNA polymerase modulator Gilead Sciences Inc UK 2020-04-02 Phase 3 Clinical Recruiting 1 2020-04-07
A Study to Assess the Effect of Nafamostat in the Treatment of Coronavirus Disease 19 Infection (COVID-19) Patients Coronavirus disease 19 infection nafamostat (Middle East respiratory syndrome), University of Tokyo alone Serine protease inhibitor University of Tokyo 2020-04-30 Phase Not Applicable Planned 0 2020-04-08
A phase III clinical trial to evaluate the safety and efficacy of remdesivir in the treatment of patients with severe COVID-19 infection Coronavirus disease 19 infection remdesivir alone RNA polymerase modulator Gilead Sciences Inc UK 2020-04-02 Phase 3 Clinical Recruiting 1 2020-04-07
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Coronavirus disease 19 infection hydroxychloroquine alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Providence Health & Services Providence Cancer Center, Earle A. Chiles Research Institute US 2020-03-30 2023-09-30 2020000186, NCT04334967 Phase 4 Clinical Recruiting 0 42 Months 1250 Brian Kendal, MD, Trista Johnson, PhD, MPH 2020-04-08
CovCardioVasc: Cardiovascular Complications and COVID-19 Cardiovascular disease, Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire De Nice France 2020-02-28 2020-08-28 20REAMEDCOVID19, CovCardioVasc, NCT04335162 Phase Not Applicable Recruiting 2 6 Months 100 Denis DOYEN, Mathieu Jozwiak 2020-04-08
COPERNICO: Checkpoint Blockade in COVID-19 Pandemic Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia pembrolizumab plus tocilizumab (intravenous), Roche/Chugai IL-6 receptor antagonist, IL-6 receptor modulator, Programmed cell death protein 1 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medica Scientia Innovation Research 2020-03-30 2020-05-15 COPERNICO, MEDOPP376, NCT04335305 Phase 2 Clinical Not yet recruiting 0 1 Month 24 Alicia García, Javier Cortés 2020-04-08
Safety in Convalescent Plasma Transfusion to COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection Convalescent Plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital San Jose Tec de Monterrey Instituto Tecnologico y de Estudios Superiores de Monterrey Mexico 2020-04-15 2021-04-30 NCT04333355, PC-TECSALUD FASE I Phase 1 Clinical Not yet recruiting 1 12 Months 20 José Fe Castilleja-Leal, MD., Servando Cardona-Huerta, MD., Ph. D., Sylvia De la Rosa, MD 2020-04-09
A clinical trial of mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of COVID-19 Coronavirus disease 19 infection mRNA-encoded neutralizing anti-SARS-CoV-2 antibodies alone Ethris GmbH, Neurimmune Holding AG 2020-12-31 Phase Not Applicable Planned 0 2020-04-07
SOVECOD: Comparative assessment of the efficacy and safety of add on treatment with 'Sofosbuvir plus Velpatasvir' to 'standard of care therapeutic regimen' in patients with COVID-19 Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , lopinavir + ritonavir , sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead HIV protease inhibitor, Hepatitis C virus NS5B polymerase inhibitor, Hepatitis C virus protein NS5A inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kermanshah University of Medical Sciences Iran 2020-04-08 IRCT20130812014333N145, Ir.kums.rec.1399.044, SOVECOD Phase 3 Clinical Recruiting 2 80 Dr. Babak Sayad, Dr. Farid Najafi, Dr. Reza Khodarahmi, Samin Sharifi 2020-04-09
Phase II Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection Coronavirus disease 19 infection, SARS coronavirus infection Standard of care alone, azithromycin alone, hydroxychloroquine alone, azithromycin plus hydroxychloroquine Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University US 2020-04-30 2020-08-01 NCT04335552, PRO00105339 Phase 2 Clinical Not yet recruiting 0 3 Months 500 Jason Stout, MD 2020-04-09
Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers (COVID-Antibody) Coronavirus disease 19 infection, SARS coronavirus infection SARS-CoV-2 IgG Antibody Testing Kit (Ray Biotech) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Indiana University US 2020-04-01 2021-01-01 2003973826, NCT04334876 Phase Not Applicable Not yet recruiting 0 9 Months 340 Courtney Rowan, MD, Kirsten Ramberg 2020-04-08
Comparison of therapies for COVID-19 Coronavirus disease 19 infection chloroquine alone, hydroxychloroquine alone, lopinavir + ritonavir alone, remdesivir alone, standard of care alone, Interferon plus lopinavir + ritonavir HIV protease inhibitor, RNA polymerase modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ministry of Health and Medical Education, IRAN Iran 2020-04-08 IR.NREC.1399.001, IRCT20200405046953N1 Phase 3 Clinical Recruiting 28 3000 Ahmad Hormati, Alireza Musavi, Alireza Soleimani, Atousa Hakami Fard, Behnam Mahmoodieh, Behnaz Khodabakhshi, Farhang Baba Mahmoodi, Fariborz Mansour Ghanaie, Farzin Khorvash, Hadiseh Hosami, HamidReza Najjari, Hassan Mozaffar, Hossein Poustchi, Hossein Sarmadian, Ilad Alavi Darazam, Khalil Ansarin, Kiana Shirani, Mahnaz Amini, Mehdi Mesri, Mehrdad Salahi, Minoo Mohraz, Mitra Ranjbar, Mohammad Reza Ghadir, Mohammad Reza Salehi, Mohsen Moghadami, Mostafa Ghanei, Mostafa Javanian, Payam Tabarsi, Roya Ghasemian, Saeid Hafizi Lotfabadi 2020-04-09
HOPE COVID 19: International COVID-19 Clinical Evaluation Registry Coronavirus disease 19 infection Hospital Clinico San Carlos Spain 2020-03-23 2020-05-05 20/241-E, EUPAS34399, HOPE COVID 19, NCT04334291 Phase Not Applicable Recruiting 1 1 Month 2500 IVAN J NUNEZ GIL, MD, PhD, MSc, IVAN J NUÑEZ GIL, IVAN J NUÑEZ J NUÑEZ GIL, MD 2020-04-09
IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection Advanced solid tumor, Coronavirus disease 19 infection, Hematological neoplasm, Metastasis, SARS coronavirus infection GNS-561 alone, Standard of care alone, nivolumab alone, tocilizumab alone Autophagy protein inhibitor, Programmed cell death protein 1 inhibitor, Solute carrier family inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Leon Berard France 2020-04-30 2020-08-31 2020-001373-70, ET20-076 - IMMUNONCOVID-20, IMMUNONCOVID, NCT04333914 Phase 2 Clinical Recruiting 1 4 Months 273 Julien GAUTIER, Philippe CASSIER, Philippe Cassier 2020-04-09
Investigation of the influence of the new coronavirus pandemic (COVID-19) on pain, mood and everyday life of patients with painful polyneuropathy Coronavirus disease 19 infection, Neuropathic pain, Polyneuropathy Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitatsklinikum Schleswig-Holstein Campus Kiel Germany 2020-04-05 D453/20, DRKS00021254 Phase Not Applicable Recruiting 1 50 Dilara Kersebaum 2020-04-08
STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection umbilical cord Wharton's jelly-derived mesenchymal stromal cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-01 2021-05-31 2020-001287-28, APHP200395, NCT04333368, STROMA-CoV2 Phase 1/Phase 2 Clinical Not yet recruiting 2 14 Months 60 Antoine A MONSEL, MD, PhD, Antoine MONSEL, MD, PhD, Jean-Luc DIEHL, MD, PhD, Philippe MENASCHE, MD, PhD, Philippe MENASCHÉ, MD, PhD 2020-04-08
C-19-ACS: Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomized, Controlled Trial Acute coronary syndrome, Coronavirus disease 19 infection Aspirin alone, atorvastatin alone, clopidogrel alone, omeprazole alone, rivaroxaban alone Factor Xa antagonist, H+ K+ ATPase inhibitor, HMG CoA reductase inhibitor, P2Y12 purinoceptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Imperial College London UK 2020-04-03 2021-03-30 20HH5868, C-19-ACS, NCT04333407 Phase 4 Clinical Recruiting 2 11 Months 3170 Alena Marynina, BSc, MSc, Clare Coyle, BMBCh, BA, MRCP, Prapa Kanagaratnam, FRCP, PhD 2020-04-10
PANAMO: Open-label, Randomized Study of IFX-1 in Patients with Severe COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia IFX-1 alone, best supportive care alone Complement C5a factor inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) InflaRx GmbH Netherlands 2020-03-31 2020-12-31 IFX-1-P2.9, NCT04333420, PANAMO Phase 2/Phase 3 Clinical Recruiting 1 9 Months 130 A Vlaar, MD, A. V., MD, PhD, Korinna Pilz, MD 2020-04-08
Piclidenoson for Treatment of COVID-19 Coronavirus disease 19 infection, Respiratory tract infection piclidenoson alone Adenosine A3 receptor agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Can-Fite BioPharma Ltd Rabin Medical Center Israel 2020-04-06 2020-07-06 CAN-COR-1, NCT04333472 Phase 2 Clinical Not yet recruiting 1 3 Months 40 Zivit Harpaz 2020-04-08
Application of Desferal to Treat COVID-19 Coronavirus disease 19 infection, Viral pneumonia deferoxamine mesylate alone, standard treatment regimens alone Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kermanshah University of Medical Sciences Iran 2020-04-30 2021-03-31 1398.1224, NCT04333550 Phase 1/Phase 2 Clinical Recruiting 1 11 Months 50 Alireza Ghaffarieh, MD, Amir Kiani, PhD, Yadollah Shakiba, MD, PhD 2020-04-08
Mindfulness-based 'STOP (Stop, Take a Breath, Observe, Proceed) Touching Your Face' Intervention Coronavirus disease 19 infection Mindfulness-based 'STOP touching your face' practice alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shao Yifu Hospital China 2020-04-02 2020-04-30 2020S001, NCT04330352 Phase Not Applicable Recruiting 1 1000 Yanhui Liao, Yanhui Liao, MD 2020-04-10
FingoCov: Effect of Fingolimod for treatment of COVID-19-induced cytokine storm Coronavirus disease 19 infection, Viral pneumonia fingolimod alone, standard regimen alone Cannabinoid receptor antagonist, Sphingosine-1-phosphate receptor-1 modulator, Sphingosine-1-phosphate receptor-3 modulator, Sphingosine-1-phosphate receptor-4 modulator, Sphingosine-1-phosphate receptor-5 modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-04-08 FingoCov, IR.TBZMED.REC.1399.001, IRCT20200317046797N2 Phase 3 Clinical Recruiting 1 40 Dr Khalil Ansarin, Dr Mohammad Samiei, Mohammadreza Ardalan, Sepideh Zununi Vahed 2020-04-09
TOCI-RE: EEfficacy of Tocilizumab - COVID-19 Effectiveness of Tocilizumab - COVID-19 Coronavirus disease 19 infection, Viral pneumonia tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azienda Unita Sanitaria Locale di Reggio Emilia Italy 2020-03-27 2020-001386-37, RCT-TCZ-COVID-19, TOCI-RE Phase 2 Clinical Recruiting 1 398 Trial Information Support Line-TISL 2020-04-09
EPI-COVID-19: Household Transmission Investigation Study for COVID-19 in French Guiana Coronavirus disease 19 infection, SARS coronavirus infection Blood sample alone, Nasopharyngeal swab alone Healthy volunteers accepted Institut Pasteur Centre Hospitalier de Cayenne, Institut Pasteur de Guyane French Guiana 2020-03-23 2022-03-23 2020-009, EPI-COVID-19, NCT04328129 Phase Not Applicable Recruiting 2 24 Months 450 Claude Flamand, PhD, Claude Flamand, Phd, Dominique Rousset, MD 2020-04-07
Evaluation of the effect of traditional Iranian medicine product on improvement of clinical manifestation of COVID-19 Coronavirus disease 19 infection Traditional Medicine (Astragalus gossypinus with food spice) alone Kerman University of Medical Sciences Iran 2020-03-24 IR.KMU.REC.1399.003, IRCT20101219005416N2 Phase 3 Clinical Recruiting 1 80 Haleh Tajadini 2020-04-07
Umifenovir effectiveness in the treatment of COVID-19 Coronavirus disease 19 infection Variable regimens including Arbidol (Pharmstandard) , atazanavir + ritonavir , hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Center for Progress and Development of Iran Iran 2020-03-28 2020-04-20 IR.TUMS.VCR.REC.1398.1037, IRCT20200322046833N1 Phase 3 Clinical Recruiting 1 100 Azar Haddadi, Behnam Bayatani, Bita Shahrami, Farhad Najmeddin, Morteza Pirali 2020-04-08
Hemoperfusion in patients with COVID-19 Coronavirus disease 19 infection HA230 hemoperfusion filter (Jafron Company) alone, HA280 hemoperfusion filter (Jafron Company) alone, hemoperfusion alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Babol University of Medical Sciences Iran 2020-03-24 IR.MUBABOL.HRI.REC.1399.038, IRCT20150704023055N2 Phase 2 Clinical No longer recruiting 1 10 Masoumeh Asgharpour, Reza Ghadimi, Simin Mouodi 2020-04-08
Comparison of efficacy of oral levamisole and formoterol + budesonide inhaler with standard treatment of Corona infection Coronavirus disease 19 infection Variable regimens including budesonide + formoterol fumarate, AstraZeneca , hydroxychloroquine sulfate , levamisole (Poursina pharmaceutical Company) , lopinavir + ritonavir Beta 2 adrenoceptor agonist, HIV protease inhibitor Fasa University of Medical Sciences Iran 2020-04-01 IR.FUMS.REC.1399.002, IRCT20200324046852N1 Phase 2/Phase 3 Clinical Recruiting 1 30 Dr. Jalal Karimi, Dr. Mojtaba Farjaam, Dr. Siamack Afazeli, Dr.Siamack Afazeli 2020-04-07
Supplementation in COVID-19 Coronavirus disease 19 infection Soluvit (Fresenius Kabi New Zealand) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Tehran University of Medical Sciences Iran 2020-04-02 IR.TUMS.VCR.REC.1399.090, IRCT20200319046819N1 Phase 3 Clinical Recruiting 1 60 Dr. Mohammad Ali Sahraian, Sama Bitarafan 2020-04-07
A clinical study to assess KL4 surfactant for treatment of lung injury resulting from severe COVID-19 infection Coronavirus disease 19 infection, Lung injury lucinactant (aerosol), Windtree Therapeutics/ Esteve/ Lee's Pharmaceutical alone BMP10 gene inhibitor, BMP15 gene inhibitor Windtree Therapeutics Inc Phase Not Applicable Planned 0 2020-04-06
The effect of dental pulp mesenchymal stem cells in treatment of corona virus disease Coronavirus disease 19 infection, Viral pneumonia dental pulp mesenchymal stem cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Kerman University of Medical Sciences Iran 2020-04-04 IR.KMU.REC.1399.018, IRCT20140911019125N6 Phase 2 Clinical Recruiting 2 10 Abbas Pardakhty, Alireza Farsinejad, Mehrdad Farrokhnia 2020-04-07
TOVID-49: Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19 Coronavirus disease 19 infection Telephony alone, Videophony alone Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France 2020-03-27 2020-09-30 2020/29, NCT04333849, TOVID-49 Phase Not Applicable Recruiting 1 6 Months 100 Cedric ANNWEILER, MD, PhD 2020-04-09
HOPE: Chroloquine Phosphate Against Infection by the Novel Coronavirus Coronavirus disease 19 infection, Viral pneumonia chroloquine phosphate, Uni-Pharma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories Sa Greece 2020-04-02 2020-001345-38, HOPE, UNIKINON-01/HOPE Phase 2 Clinical No longer recruiting 1 60 Regulatory Affairs department 2020-04-09
COVID-19 in Patients With HIV Coronavirus disease 19 infection, SARS coronavirus infection University of Missouri US 2020-04-01 2020-10-01 262095, NCT04333953 Phase Not Applicable Recruiting 0 6 Months 500 Dima Dandachi, Dima Dandachi, MD 2020-04-09
Efficacy and safety of sofosbuvir in the treatment of SARS-CoV-2: an open-label, phase II trial Coronavirus disease 19 infection, SARS coronavirus infection sofosbuvir alone, standard of care treatment alone Hepatitis C virus NS5B polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-04-04 IR.SBMU.RETECH.REC.1399.001, IRCT20200328046882N1 Phase 2 Clinical Recruiting 1 60 Afshin Zarghi, Mostafa Alavi-Moghaddam 2020-04-08
COVITD-19: Vitamin D on Prevention and Treatment of COVID-19 Coronavirus disease 19 infection ACE2 inhibitor therapy alone, Angiotensin II Receptor Blockers therapy alone, NSAIDs therapy alone, Vitamin D alone, thiazolidinediones therapy alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) University of Granada Spain 2020-04-10 2020-06-30 COVITD-19, COVITD-19, NCT04334005 Phase Not Applicable Not yet recruiting 2 2 Months 200 Manuel J Castillo, MD, PhD, Manuel J. Castillo Garzón, Proffesor Amaro Gahete, PhD student 2020-04-09
Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia Coronavirus disease 19 infection, Viral pneumonia camostat mesylate alone, standard regimen alone Serine protease inhibitor, Trypsin inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-04-08 IR.TBZMED.REC.1398.1312, IRCT20200317046797N1 Phase 3 Clinical Recruiting 1 40 Dr Khalil Ansarin, Mohammad Reza Ardalan, Sepideh Zununi Vahed 2020-04-09
ReciGen for treatment of Covid-19 Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Hypoxia standard treatment alone, chloroquine plus interferon beta-1a follow-on biologic (subcutaneous), CinnaGen Interferon beta ligand Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-03-27 IR.TUMS.VCR.REC.1399.026, IRCT20150914024017N1 Phase 3 Clinical Recruiting 1 40 Pooya Payandemehr 2020-04-08
Escape: Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction Coronavirus disease 19 infection, Multiple organ failure anakinra alone, tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator, Type I IL-1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hellenic Institute for the Study of Sepsis Greece 2020-04-01 2022-04-01 2020-001039-29, ESCAPE, Escape, NCT04339712 Phase 2 Clinical Not yet recruiting 16 24 Months 20 Antigoni Kotsaki, MD, PhD, Apostolos Armaganidis, MD, PhD, Evangelos Giamarellos-Bourboulis, MD, PhD 2020-04-13
CROWN CORONA: CROWN CORONATION: Chloroquine Repurposing to healthworkers for Novel CORONAvirus mitigation Coronavirus disease 19 infection chloroquine alone, hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Washington University School of Medicine, US Canada, Australia, South Africa, US, Ireland, UK 2020-04-30 2021-02-28 202004XXX, CROWN CORONA, NCT04333732 Phase 2 Clinical Not yet recruiting 6 10 Months 55000 Catherine Martin, MBBCh MSc, David Mazer, MD, David Story, MD, Dermot McGuckin, MD, Ellen O'Sullivan, MD, FRCA,FCAI, Eric Dubberke, MD, Gemma Jones, MsC, Gloria Maimela, MBBCh MBA, Hakim-Moulay Dehbi, PhD, Helen Rees, MD, Jessica Spence, MD, FRCPC, Laurence Lovat, MD, PhD, Linda Yun, BS, Mary Politi, MD, Michael S. Avidan, MBBCh, Michael S. Avidan, MBBCh, FCASA, Michelle Moorhouse, MBChB, Nick Freemantle, PhD, Ramani Moonesinghe, MD, Saiqa Mullick, MBBCh PhD, Sherry McKinnon, Sherry McKinnon, BS, Sinead Delany-Moretlwe, MBChB, PhD, DTM&H 2020-04-08
Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy Coronavirus disease 19 infection desynchronization strategy alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Inselspital, Berne Switzerland 2020-03-19 2021-12-31 2020-00563, NCT04333862 Phase Not Applicable Recruiting 1 21 Months 500 Guido Beldi, Guido Beldi, Prof. Dr. 2020-04-08
Effect of febuxostat against coronavirus Coronavirus disease 19 infection, Lung injury acetaminophen plus febuxostat Xanthine oxidase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mazandaran University of Medical Sciences Iran 2020-03-16 2020-04-09 IR.MAZUMS.REC.1398.1452, IRCT20190727044343N1 Phase 3 Clinical No longer recruiting 1 60 Lotfollah Davoodi, Majid Saeedi 2020-04-07
Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Gastrointestinal disease, Viral pneumonia chloroquine plus rabeprazole H+ K+ ATPase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Fifth Affiliated Hospital, Sun Yat-Sen University China 2020-02-12 2021-07-31 ChiCTR2000031454 Phase 0 Clinical Recruiting 1 17 Months 56 Xiao Fei 2020-04-09
Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial Coronavirus disease 19 infection, Viral pneumonia 2019-nCov IgG test alone, PCR Nucleic acid detection alone First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) Taizhou Zecheng Biotechnology Co. Ltd. China 2020-03-25 2021-03-31 ChiCTR2000031465 Phase 0 Clinical Not yet recruiting 1 12 Months 200 Pang Jifeng, Xiang Changgang 2020-04-07
Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study Coronavirus disease 19 infection, Viral pneumonia earplugs alone, eye patch alone Shanghai East Hospital China 2020-02-10 2020-02-25 ChiCTR2000031499 Phase Not Applicable Completed 1 55 Li Chen, Ma Shaolin 2020-04-07
ARMS-I COVID: A randomized, placebo-controlled, crossover study to evaluate whether the ARMS-I helps prevent airborne transmission of coronavirus COVID-19 and whether it reduces the symptoms of healthcare providers who have tested positive for the virus Coronavirus disease 19 infection, Upper respiratory tract infection ARMS-I alone Viral envelope glycoprotein inhibitor University Hospitals Of Cleveland ARMS Pharmaceutical LLC, Case Western Reserve University US 2020-04-30 ARMS-I COVID Phase Not Applicable Planned 0 Robert Salata 2020-04-07
Effect of hydroxychloroquine on prevention of Covid-19 virus Coronavirus disease 19 infection, Viral infection hydroxychloroquine, Amin Pharmaceutical alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Tehran University of Medical Sciences Iran 2020-03-29 IR.TUMS.VCR.REC.1399.001, IRCT20120826010664N6 Phase 2 Clinical Recruiting 1 310 Mohammad Ali Sahraian, Reihaneh Pirjani, Reihaneh Pirjani MD. 2020-04-07
A multicenter, randomized Phase II clinical trial of plitidepsin for the treatment of patients with COVID-19 pneumonia Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia plitidepsin alone Elongation factor 1 alpha 2 modulator, VEGF-1 receptor modulator PharmaMar SA Spain Phase 2 Clinical Planned 1 160 2020-04-06
The Effect of Tanacetum parthenium (L) sch Syrup on Clinical Manifestations of Patients with COVID-19 Coronavirus disease 19 infection, Respiratory tract infection Trachyspermum copticum syrup (Barij Essence and Shahid Beheshti Pharmaceutical Group) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Ghoum University of Medical Sciences Qom University of Medical Science Iran 2020-04-07 IR.MUQ.REC.1399.012, IRCT20180610040049N4 Phase 3 Clinical Recruiting 1 60 Ehsan Sharifipour, Mohammad KamaliNejad, Mohsen Bahrami, Reza Shirvani 2020-04-13
Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia cold outdoor environment alone, temperature measuring distance alone Young Adults (18-44 yrs) Peking University First Hospital China 2020-03-07 2020-04-12 ChiCTR2000031500 Phase 0 Clinical No longer recruiting 1 1 Month 58 LI HANG, PENG RUI 2020-04-07
Study of the effect of vitamin C in patients with COVID-19 Coronavirus disease 19 infection Variable regimens including chloroquine phosphate (Pars) , hydroxychloroquine sulfate (Tehran) , lopinavir + ritonavir , vitamin C HIV protease inhibitor Abadan School of Medical Sciences Iran 2020-04-19 IR.ABADANUMS.REC.1398.119, IRCT20200324046850N5 Phase 2 Clinical Not yet recruiting 1 40 Sara Mobarak, سارا مبارک 2020-04-07
The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study Coronavirus disease 19 infection, Viral pneumonia convalescent plasma alone, routine treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Nanjing General Hospital of Nanjing Military Command, PLA China 2020-03-17 2020-07-17 ChiCTR2000031501 Phase 0 Clinical Not yet recruiting 1 4 Months 20 Lu Ke, Weiqin Li 2020-04-07
Clinical trial to assess Vicromax in the treatment of patients with Coronavirus disease 19 infection (COVID-19) Coronavirus disease 19 infection merimepodib alone Inosine monophosphate dehydrogenase inhibitor Biosig Technologies Inc US Phase Not Applicable Planned 0 2020-04-07
Effects of nano curcumin supplementation on the reduction of inflammation and mortality in patients with coronavirus 2019 admitted to ICU ward of Imam Reza hospital in Tabriz Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia Variable regimens including hydroxychloroquine , lopinavir , nano curcumin, Exir Sina , oseltamivir , ribavirin Exo-alpha sialidase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-03-29 IR.TBZMED.REC.1398.1314, IRCT20200324046851N1 Phase 2/Phase 3 Clinical Recruiting 1 86 Hamed Valizadeh, Hassan soleimanpor, Majid Ahmadi, Ramin Pourakbari 2020-04-07
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive Coronavirus disease 19 infection favipiravir alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Peking University First Hospital China 2020-04-01 2020-09-15 2020 RESEARCH 112, NCT04333589 Phase 2 Clinical Not yet recruiting 8 5 Months 210 Dingyu Zhang, Guiqiang Wang, Hong Zhao, Junhua Yu, Sibin Zhang, Xianfeng Han, Xianxiang Chen, Xinghuan Wang, Xinsheng Chen, Yongping Chen 2020-04-13
A phase IIb/III clinical study to assess leronlimab in the treatment of severe and critically ill patients with COVID-19 infection Coronavirus disease 19 infection leronlimab alone CCR5 chemokine antagonist CytoDyn Inc US 2020-04-07 Phase 2/Phase 3 Clinical Recruiting 0 390 2020-04-13
A pilot feasibility study of INTERCEPT coronavirus convalescent plasma (CCP)system for the treatment of severe COVID-19 Coronavirus disease 19 infection INTERCEPT system alone, coronavirus convalescent plasma alone Cerus Corp, University Hospital Basel Switzerland 2020-04-02 Phase Not Applicable Recruiting 1 2020-04-07
Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 Coronavirus disease 19 infection chloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HaEmek Medical Center Israel 2020-04-30 2021-12-31 EMC 0045-20, NCT04333628 Phase 2/Phase 3 Clinical Not yet recruiting 1 20 Months 210 Lee Goldstein, MD, gilat ron avraham 2020-04-08
Hydroxychloroquine in Outpatient Adults With COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sanofi SA US 2020-03-31 2020-05-31 2020-001269-35, EFC16855, NCT04333654, U1111-1249-6168 Phase 1b Clinical Recruiting 0 2 Months 210 Clinical Sciences & Operations 2020-04-08
Covid-VAS: Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study Coronavirus disease 19 infection vascular surgery alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sociedad Espanola de Angiologia y Cirugia Vascular Spain 2020-04-01 2020-11-01 Covid-VAS, NCT04333693, RIV-2020-1 Phase Not Applicable Not yet recruiting 1 7 Months 50 Alvaro Torres, MD, PhD, Carlos Vaquero, MD, PhD, Prof, Enrique M San Norberto, MD, PhD, MsC, Investigator Council, Joaquin de Haro, MD, PhD, Jorge Cuenca, MD, PhD, Jorge Fernández-Noya, MD, PdD, Luis Riera, MD, PhD, Raul Lara, MD, PhD, Sergi Bellmunt, MD, PhD 2020-04-07
Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune Coronavirus disease 19 infection, Viral pneumonia isolate blood monocyte therapy alone Healthy volunteers accepted, Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) 2nd People's Hospital of Fuyang City, Institute of Blood Transfusion, Chinese Academy of Medical Sciences China 2020-04-20 2021-04-20 ChiCTR2000031627 Phase 0 Clinical Not yet recruiting 2 12 Months 60 Shasha Li, Xiuyong Li 2020-04-09
Treatment of SARS Caused by COVID-19 With Ruxolitinib Coronavirus disease 19 infection, Dyspnea, SARS coronavirus infection, Viral pneumonia chest CT-scan alone, ruxolitinib alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cooperative Group of Malignant Hemopathies Mexico 2020-04-01 2020-06-01 HAL 345/2020, NCT04334044 Phase 1/Phase 2 Clinical Not yet recruiting 1 2 Months 20 2020-04-08
Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia celecoxib alone Cyclooxygenase 2 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Guangzhou 8th People's Hospital China 2020-02-17 2020-06-17 ChiCTR2000031630 Phase 0 Clinical Recruiting 1 4 Months 60 Hong wenxin 2020-04-07
Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia non-invasive multi-channel cardiopulmonary monitor alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shanghai Sixth People’s Hospital China 2020-04-01 2022-10-31 ChiCTR2000031503 Phase Not Applicable Not yet recruiting 1 31 Months 100 Chen Yu, Shen Chengxing 2020-04-07
A phase II clinical study to assess ifenprodil in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection ifenprodil (long-acting, oral, COVID-19/acute lung injury), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals Novotech (Australia) Pty Ltd Australia Phase 2 Clinical Planned 1 2020-04-06
An investigator-initiated feasible phase II clinical study to assess ifenprodil in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection ifenprodil (long-acting, oral, COVID-19/acute lung injury), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Asian Ancestry Algernon Pharmaceuticals Novotech (Australia) Pty Ltd South Korea Phase 2 Clinical Planned 1 2020-04-06
A multicenter telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tongji Hospital, Huazhong University of Science and Technology China 2020-04-01 2021-03-31 ChiCTR2000031504 Phase Not Applicable Not yet recruiting 1 12 Months 2000 Ji-Xin Zhong, Lingli Dong 2020-04-08
Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia nintedanib alone CSF-1 antagonist, FGF receptor antagonist, FGF1 receptor antagonist, FGF2 receptor antagonist, FGF3 receptor antagonist, Flt3 tyrosine kinase inhibitor, Lck tyrosine kinase inhibitor, Lyn tyrosine kinase inhibitor, PDGF receptor alpha antagonist, PDGF receptor antagonist, PDGF receptor beta antagonist, Src tyrosine kinase inhibitor, VEGF receptor antagonist, VEGF-1 receptor antagonist, VEGF-2 receptor antagonist, VEGF-3 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tongji Hospital, Huazhong University of Science and Technology China 2020-04-02 2020-08-01 ChiCTR2000031453 Phase 4 Clinical Not yet recruiting 1 4 Months 80 Huilan Zhang, Xianglin Yuan 2020-04-08
A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Wuhan medical care center for women and children China 2019-03-15 2020-06-30 ChiCTR2000031539 Phase Not Applicable Not yet recruiting 3 15 Months 180 Zhang Hua-nian 2020-04-07
A multicenter, national, follow-up study to evaluate the effectiveness of convalescent serum therapy against the COVID-19 virus infection Coronavirus disease 19 infection convalescent serum therapy alone Houston Methodist US Phase Not Applicable Planned 0 2020-04-06
Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia rehabilitation Nursing Program alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Zunyi Medical University China 2020-02-05 2020-12-05 ChiCTR2000031540 Phase 1 Clinical Recruiting 1 10 Months 100 Huang Di, Jiang ZhiXia 2020-04-07
A paired clinical study for novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Huazhong University of Science and Technology China 2020-01-27 2022-12-31 ChiCTR2000031587 Phase 0 Clinical Recruiting 1 35 Months 2000 Xiaomei Guo 2020-04-08
CORA: Survey of the Anxiety Associated With the SARS-CoV-2 Pandemic Anxiety disorder, Coronavirus disease 19 infection online questionnaire alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Charite University Germany 2020-03-27 2021-09-30 CORA, EA1/071/20, NCT04331106 Phase Not Applicable Recruiting 1 18 Months 5000 Andreas Ströhle, Prof.Dr., Antonia Bendau, M.Sc.Psych. 2020-04-08
COVID-19 Symptom Tracker Coronavirus disease 19 infection COVID-19 symptom tracker app alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) King's College London Harvard TH Chan School of Public Health, Massachusetts General Hospital, Stanford University, Zoe Global Ltd UK, US 2020-03-23 2022-03-23 COVID-19 SYMPTOM TRACKER, NCT04331509 Phase Not Applicable Recruiting 1 24 Months 10000000 Andrew Chan, Andrew T. Chan, MD, David A Drew, PhD, Tim D Spector, Victoria Vazquez 2020-04-08
QUARANTINE2020: Chloroquine as Antiviral Treatment in Coronavirus Infection 2020 Coronavirus disease 19 infection, SARS coronavirus infection chloroquine phosphate alone, standard of care alone, telemedical supervision alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Wroclaw Medical University 2020-04-06 2020-12-31 NCT04331600, QUARANTINE2020, QUARANTINE2020 Phase 4 Clinical Not yet recruiting 0 8 Months 400 Marta Duda-Sikula, MBA 2020-04-06
COVIPRIM: Accompanying monitoring of primary care in GP practices during the COVID-19 pandemic Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Graz, Paracelsus Medical University J.W. Goethe University Hospital Austria, Germany 2020-04-03 20-619, COVIPRIM, DRKS00021231 Phase Not Applicable Not yet recruiting 2 2000 Ms. Dr. Dagmar Schaffler 2020-04-06
PrEP_COVID: Pre-exposure Prophylaxis With Hydroxychloroquine for High-risk Healthcare Workers During the COVID-19 Pandemic Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Barcelona Institute for Global Health Hospital Clinic of Barcelona, Laboratorios Rubio SA Spain 2020-04-03 2020-10-30 2020-001565-37, NCT04331834, PREP_COVID, PrEP_COVID Phase 3 Clinical Recruiting 1 6 Months 440 Jose F Muñoz Gutiérrez, MD, PhD, Jose Munoz Gutierrez, MD, PhD, Jose Muñoz Gutiérrez, Marc Fernández Pardos, MSc 2020-04-13
Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last computed tomography (CT) criteria Scores From Sequential Chest CT Coronavirus disease 19 infection, Viral pneumonia computed tomography (CT) scoring criteria alone American Roentgen Ray Society China Phase Not Applicable Status not specified 1 25 Erpeng Cai, Guangbin Wang, Guoquan Huang, Jianwen Wang, Liangjie Lin, Shirong Li, Tao Gong, Xiaohu Li, Xinfu Guo, Yongqiang Yu 2020-04-06
DIIC19: Efficacy of dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 Coronavirus disease 19 infection standard treatment alone, Variable regimens including dexamethasone , hydroxychloroquine , interferon beta , intravenous immunoglobulin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Gorgan University of Medical Sciences Iran 2020-04-18 2020-06-19 DIIC19, IR.GOUMS.REC.1399.004, IRCT20120225009124N4 Phase 2 Clinical Not yet recruiting 1 2 Months 105 Dr Nafiseh Abdolahi, Gholamreza Roshandel, Mohammadreza Honarvar 2020-04-06
The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak Coronavirus disease 19 infection, Viral pneumonia mindfulness exercise alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Asian Ancestry China European International Business School (CEIBS) China 2020-02-20 2020-03-02 ChiCTR2000031272 Phase Not Applicable Completed 1 110 Zheng Xue 2020-04-07
ACTION: Azithromycin for COVID-19 Treatment in Outpatients Nationwide Coronavirus disease 19 infection, SARS coronavirus infection azithromycin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of California San Francisco US 2020-04-01 2021-07-30 20-30504, ACTION, NCT04332107 Phase 3 Clinical Not yet recruiting 0 15 Months 2271 Catherine Cook, MPH, Catherine Oldenburg, ScD, MPH, Jessica M Brogdon, MPH, Thuy Doan, MD, PhD 2020-04-09
Hyperbaric Oxygen for COVID-19 Patients Coronavirus disease 19 infection, Respiratory distress syndrome hyperbaric oxygen alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) NYU Langone Health US 2020-04-06 2020-07-31 NCT04332081, S20-00399 Phase 2 Clinical Recruiting 0 3 Months 40 David Lee, David Lee, MD, Scott Gorenstein 2020-04-10
C19REG: COVID-19 Public Image Registry Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) RAD-AID International BioClinica Inc, Google Inc US 2020-03-30 2025-03-30 C19REG, C19REG, NCT04331860 Phase Not Applicable Recruiting 0 60 Months 500000 Dan Gebow, PhD, Daniel Mollura, MD, TBD TBD 2020-04-06
CP-COVID-19: Convalescent Plasma for Patients With COVID-19: A Pilot Study Coronavirus disease 19 infection, Viral pneumonia convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Del Rosario University CES University, Fundación Universitaria de Ciencias de la Salud, Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud Colombia 2020-04-01 2020-12-31 ABN011-1, CP-COVID-19, NCT04332380 Phase 2 Clinical Not yet recruiting 1 9 Months 10 Adriana Rojas Villarraga, MD, Anha M Robledo Moreno, Bernardo Camacho Rodríguez, MD, MSc, Carlos E Perez, MD, Cristian A Ricaurte Perez, MSc, Diana M Monsalve Carmona, PhD, Gustavo A Salguero López, MD, PhD, Gustavo Quintero, MD, MSc, Heily C Ramírez Santana, MSc, PhD, Isaura P Torres Gómez, MSc, PhD, Jeser S Grass Guaqueta, MSc, Juan C Diaz Coronado, MD, MSc, Juan E Gallo Bonilla, MSc, PhD, Juan M Anaya Cabrera, MD, PhD, Luisa P Duarte Correales, Manuel E Rojas Quintana, MD, MSc, Oscar M Gómez Guzmán, MSc, PhD, Paula A Pedroza Rodríguez, Paula Gaviria, MSc, Ruben D Manrique Hernández, MSc, PhD, Ruben D Mantilla, MD, Sara Velez Gomez, Yeny Y Acosta Ampudia, PhD, Yhojan A Rodríguez Velandia, MD 2020-04-06
An adaptive, multicenter, randomized controlled clinical study to evaluate the safety and efficacy of IFX-1 in patients with severe COVID-19 pneumonia Coronavirus disease 19 infection, Viral pneumonia IFX-1 alone Complement C5a factor inhibitor InflaRx GmbH Netherlands Phase Not Applicable Recruiting 1 2020-04-03
A Study to Assess The Effect Of AP-1189 in the Treatment of Coronavirus Disease 19 Infection (COVID-19) Patients Coronavirus disease 19 infection AP-1189 alone Melanocortin MC1 receptor agonist, Melanocortin MC3 receptor agonist SynAct Pharma ApS Phase Not Applicable Planned 0 2020-04-03
COVID-Lambda: Mild COVID-19 Peginterferon Lambda Coronavirus disease 19 infection, SARS coronavirus infection peginterferon lambda-1a, Eiger BioPharmaceuticals alone, standard of care treatment alone Interferon receptor modulator, Interleukin-29 ligand Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Stanford University US 2020-04-15 2022-05-31 55619, COVID-Lambda, NCT04331899 Phase 2 Clinical Not yet recruiting 0 25 Months 120 Julie Parsonnet, Upinder Singh 2020-04-13
A clinical trial of Veyonda in patients at risk of developing COVID-19 associated acute respiratory distress syndrome (ARDS) and multi-organ failure Coronavirus disease 19 infection, Multiple organ failure, Respiratory distress syndrome idronoxil (suppository, cancer), Noxopharm alone CASP8-FADD-like regulator inhibitor, Ecto NOX disulfide thiol exchanger 2 inhibitor, Sphingosine kinase inhibitor, Sphingosine-1-phosphate receptor-1 antagonist, Stimulator of interferon genes protein stimulator, Topoisomerase inhibitor, X-linked inhibitor of apoptosis protein inhibitor Noxopharm Ltd Phase Not Applicable Planned 0 2020-04-06
CORIMUNO-TOC: CORIMUNO-19 - Tocilizumab Trial - TOCI Coronavirus disease 19 infection, Viral pneumonia tocilizumab alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris 2020-03-31 2021-12-31 APHP200375-1, CORIMUNO-TOC, NCT04331808 Phase 2 Clinical Not yet recruiting 0 21 Months 240 Matthieu RESCHE-RIGON, MD PhD, Olivier HERMINE, MD-PhD 2020-04-09
Evaluation of Efficacy of Levamisole and Formoterol + Budesonide in Treatment of COVID-19 Coronavirus disease 19 infection Variable regimens including budesonide + formoterol , hydoxychloroquine , levamisole , lopinavir + ritonavir HIV protease inhibitor Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fasa University of Medical Sciences Iran 2020-03-31 2020-05-20 97548, NCT04331470 Phase 2/Phase 3 Clinical Not yet recruiting 1 1 Month 30 Mojtaba Farjaam, MD, Siamack Afazeli, Siamack Afazeli, Pharm.D 2020-04-06
TOCOVID: Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 Coronavirus disease 19 infection Variable regimens including azithromycin , hydroxychloroquine , tocilizumab Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU Instituto de Salud Carlos III Spain 2020-04-02 2020-10-31 2020-001442-19, IIBSP-COV-2020-23, NCT04332094, TOCOVID Phase 2 Clinical Recruiting 1 6 Months 276 Pere Domingo, MD, PhD, UICEC Sant Pau 2020-04-13
GO2 PEEP: Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19 Coronavirus disease 19 infection GO2 PEEP Mouthpiece alone, PEEP therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Emory University US 2020-04-30 2020-04-30 GO2 PEEP, NCT04331366, STUDY00000381 Phase Not Applicable Not yet recruiting 0 5 Jeffrey Miller, MD 2020-04-06
Tofacitinib in SARS-CoV2 Pneumonia Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia tofacitinib alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Universita Politecnica delle Marche Italy 2020-04-10 2020-07-10 NCT04332042, TOFACOV Phase 2 Clinical Not yet recruiting 1 3 Months 50 Armando Gabrielli, Armando Gabrielli, Prof, Giovanni Pomponio, Dr 2020-04-06
COVID CALL 15: Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patient's Triage Coronavirus disease 19 infection Moovcare alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Weprom Assistance Publique Hopitaux de Paris, DOCAPOSTE, Direction generale de l'offre de soins, Institut Pasteur France 2020-03-17 2020-07-31 COVID CALL 15, NCT04331171, WP-2020-02 Phase Not Applicable Recruiting 1 4 Months 3000000 Fabrice DENIS, MD 2020-04-07
An Observational Study of Patients With Coronavirus Disease 2019 (COVID-19) Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) TARGET PharmaSolutions, Inc US 2020-04-30 2021-03-31 NCT04331886, TARGET-COVID-19 Phase Not Applicable Not yet recruiting 0 11 Months 5000 Chuck Moser 2020-04-10
COVIDOSE: Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis Coronavirus disease 19 infection, Viral pneumonia tocilizumab alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chicago US 2020-04-04 2020-12-31 COVIDOSE, IRB20-0515, NCT04331795 Phase 2 Clinical Recruiting 0 8 Months 50 Pankti Reid, MD, MPH 2020-04-10
INHASCO: Protective Role of Inhaled Steroids for Covid-19 Infection Coronavirus disease 19 infection Usual practice alone, budesonide + formoterol fumarate, AstraZeneca alone Beta 2 adrenoceptor agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Assistance Publique Hopitaux de Paris France 2020-04-30 2020-07-31 2020-001306-35, INHASCO, NCT04331054, P 200394 Phase 3 Clinical Not yet recruiting 1 3 Months 436 Bruno CRESTANI, MD, PhD, Camille TAILLE, MD, PhD 2020-04-06
Study on home pharmaceutical care for chronic patients over the novel coronavirus pneumonia (COVID-19) epidemic Coronavirus disease 19 infection, Viral pneumonia Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) People's hospital of Zhengzhou University China 2020-03-12 2021-03-11 ChiCTR2000031176 Phase Not Applicable Recruiting 1 12 Months 100 Zhang Yi 2020-04-07
The efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 who have not responded to standard three-drug protocol Coronavirus disease 19 infection intravenous immunoglobulin alone, heparin plus intravenous immunoglobulin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-04 IR.MUMS.REC.1399.013, IRCT20200325046859N1 Phase 2 Clinical Recruiting 1 50 Dr Mohsen Tafaghodi, Rozita Khodashahi 2020-04-06
Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS Coronavirus disease 19 infection, Respiratory distress syndrome human embryonic stem cells derived M cells (CAStem) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Asian Ancestry Chinese Academy of Sciences Beijing YouAn Hospital China 2020-01-27 2020-12-31 CHINESEASZQ-006, NCT04331613 Phase 1/Phase 2 Clinical Recruiting 1 11 Months 9 Hao Jie, Doctor, Wang Liu, Doctor, Zhou Qi, Doctor 2020-04-07
A Phase I, First in Human trial to Assess The Effect of OpenCorona, Karolinska Institutet In Treatment of Coronavirus disease 19 infection (COVID-19) Patient Coronavirus disease 19 infection SARS-CoV-2 vaccine (coronavirus COVID-19 infection), Karolinska Institutet alone Cobra Biologics Holding AB, The European Union Sweden Phase 1 Clinical Planned 1 2020-04-07
Nosocomial infection of coronavirus disease 2019 in the hospital without negative pressure chamber Coronavirus disease 19 infection, Infectious disease Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Oita San-ai Medical Center Japan 2020-04-02 UMIN000040033 Phase Not Applicable Recruiting 1 300 Ryota Sagami 2020-04-06
A clinical study of trans sodium crocetinate in patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 infection Coronavirus disease 19 infection, Respiratory distress syndrome trans sodium crocetinate (intravenous), Diffusion Pharmaceuticals alone Diffusion Pharmaceuticals LLC, University of Virginia US Phase Not Applicable Planned 0 Dr. Andrew Southerland 2020-04-03
COLCOV19-BX: COVID-19 Biological Samples Collection Coronavirus disease 19 infection, SARS coronavirus infection biological sampling alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Bordeaux France 2020-04-02 2023-03-31 CHUBX 2020/11, COLCOV19-BX, NCT04332016 Phase Not Applicable Recruiting 1 35 Months 2000 Aurelie POUZET, Aurélie POUZET, Isabelle PELLEGRIN 2020-04-07
A proof-of-concept clinical trial to assess rhu-pGSN in the treatment of patients suffering from severe lung injury due to COVID-19 pneumonia Coronavirus disease 19 infection, Lung injury, Viral pneumonia gelsolin, BioAegis Therapeutics alone Actin antagonist BioAegis Therapeutics Inc US Phase Not Applicable Planned 0 2020-04-06
SARS-RAS: Renin-angiotensin System Inhibitors and COVID-19 Coronavirus disease 19 infection, Hypertension, SARS coronavirus infection RAS inhibitor therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Societa Italiana dell'Ipertensione Arteriosa Italy 2020-03-10 2020-04-30 NCT04331574, SARS-RAS, SARS-RAS Phase 4 Clinical Recruiting 1 1 Month 2000 Claudio Borghi, MD, Claudio Ferri, MD, Guido Grassi, MD, Guido Iaccarino, MD, Guido Iaccarino, MD, PhD, Leonardo Sechi, MASSIMO VOLPE, MD, MariaLorenza Muiesan, MD, Marialorenza Muiesan 2020-04-06
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia Standard of Care (SoC) alone, ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Incyte Corp, Novartis AG, The University Health Network Canada 2020-04-06 2021-01-31 20-5315, NCT04331665, U-DEPLOY: RUX-COVID Phase 3 Clinical Not yet recruiting 1 9 Months 64 Steven Chan, M.D., Vikas Gupta, M.D. 2020-04-08
A clinical study to assess anti-androgen therapy in patients with COVID-19 infection Coronavirus disease 19 infection anti-androgen therapy alone Applied Biology Inc US Phase Not Applicable Planned 0 Andy Goren, MD 2020-04-04
A clinical study to assess safety and efficacy of Lambda in the treatment of patients with COVID-19 Coronavirus disease 19 infection peginterferon lambda-1a, Eiger BioPharmaceuticals alone Interferon receptor modulator, Interleukin-29 ligand Eiger BioPharmaceuticals Inc US Phase Not Applicable Planned 0 2020-04-03
Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients Coronavirus disease 19 infection convalescent plasma alone, plasma-derived immunoglobulin-enriched solution alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Ahvaz University of Medical Sciences Iran 2020-03-24 IR.AJUMS.REC.1399.003, IRCT20200310046736N1 Phase 2/Phase 3 Clinical Not yet recruiting 1 45 Mandana Puladzadeh, Mehdi Safdarian, Mohammad Badavi 2020-04-06
Treatment of patients with Coronavirus infection Coronavirus disease 19 infection, Respiratory distress syndrome Septimeb alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tehran University of Medical Sciences Iran 2020-03-28 IR.TUMS.VCR.REC.1399.041, IRCT20200324046847N1 Phase 2 Clinical Recruiting 1 30 Dr. Mohammad Ali Sahraian, Hamidreza Khorram Khorshid, Minoo Mohraz 2020-04-06
COV-AID: Treatment of COVID-19 Patients With Anti-interleukin Drugs Coronavirus disease 19 infection, Hypoxia, Respiratory failure anakinra alone, siltuximab alone, tocilizumab (intravenous), Roche/Chugai alone, Variable regimens including anakinra , siltuximab , tocilizumab (intravenous), Roche/Chugai Heat shock protein inhibitor, IL-6 receptor antagonist, IL-6 receptor modulator, Type I IL-1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitair Ziekenhuis Gent Belgium Health Care Knowledge Centre Belgium 2020-04-30 2020-12-31 2020-001500-41, COV-AID, COV-AID, NCT04330638 Phase 3 Clinical Recruiting 9 8 Months 342 Anja Delporte, Bart Lambrecht, MD PhD, Bart Lambrecht, MD, PhD, CyrJean Yombi, MD PhD, Elisabeth Dewaele, HIRUZ CTU, Manu Malbrain, MD PhD, Maya Hites, MD PhD, Mesotten Dieter, MD PhD, Necsoi Coca, MD, Olivier Malaise, Sebastien Anguille, MD, Stefaan Vandecasteele, MD 2020-04-09
Comparison of the safety and efficacy of favipiravir and Kaletra in COVID-19 Coronavirus disease 19 infection routine care alone, favipiravir plus hydroxychloroquine RNA polymerase inhibitor Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bagheiat-allah University of Medical Sciences Iran 2020-04-01 IR.BMSU.REC.1399.017, IR.IUMS.REC.1399.065, IRCT20200318046812N1 Phase 3 Clinical Recruiting 14 324 Dr Abolfazl Mozafari, Dr Akram Asghari, Dr Behzad Einollahi, Dr Farhad Zamani, Dr Farzaneh Dastan, Dr Hossein Khalili, Dr Javad Khodadadi, Dr Mansooreh Momen Heravi, Dr Mariam Qaraati, Dr Mohamad Memarian, Dr Mostafa Ghanee, Dr Ramin Sami, Dr Roya Qasemian, Dr Saeid Kalantari, Dr Shadi Ziaei, Dr. Mostafa Ghanei, Hossein Biganeh 2020-04-13
Effect of Licorice in COVID-19 Coronavirus disease 19 infection licorice extract syrup alone, standard treatment alone Artesh University of Medical Sciences Iran 2020-03-23 IR.AJAUMS.REC.1398.267, IRCT20160316027081N1, LCT-19 Phase 3 Clinical Recruiting 4 374 Dr. Ali Asgari, Dr. Amir Ezzati, Dr. Saeed Soleiman Meigooni, Dr. Saeed Soleiman-Meigooni, Dr.Mohammad Aminianfar, Dr.Saeed Soleiman-Meigooni, Ramin Hamidi Farahani 2020-04-07
Investigating the effectiveness of psychological interventions on mental health Coronavirus disease 19 infection, Psychiatric disorder Skype alone, WhatsApp alone, psychological counseling program alone Kerman University of Medical Sciences Iran 2020-03-30 IR.KMU.REC.1398.737, IRCT20170611034452N11 Phase Not Applicable No longer recruiting 1 60 Atefeh Ahmadi, Firoozeh Mirzaee, Masoome Ghazanfarpur 2020-04-10
A Trial of Ciclesonide in Adults With Mild COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca alone Glucocorticoid receptor agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Korea University Guro Hospital South Korea 2020-04-01 2020-09-30 KUMC-COVID-19, NCT04330586 Phase 2 Clinical Not yet recruiting 1 6 Months 141 Joon Young Song, MD, PhD, Woo Joo Kim, Professor 2020-04-06
A clinical study of first plasma therapy for the treatment of COVID-19 infection Coronavirus disease 19 infection convalescent serum therapy alone Houston Methodist US Phase Not Applicable Recruiting 0 Eric Salazar, M.D., Ph.D 2020-04-06
CORONACION: Coronavirus ACEi/ARB Investigation Coronavirus disease 19 infection, Hypertension, SARS coronavirus infection amlodipine alone, bendroflumethiazide alone, chlorothiazide alone, chlorthalidone alone, diltiazem alone, felodipine alone, hydrochlorothiazide alone, indapamide alone, metolazone alone, nicardipine alone, nifedipine alone, nimodipine alone, nitrendipine alone, verapamil alone Calcium channel inhibitor, Calcium channel inhibitor L-type Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National University of Ireland Galway Ireland 2020-03-30 2021-03-01 C.A. 2348, C.A. 2628, CORONACION, NCT04330300 Phase 4 Clinical Recruiting 1 11 Months 2414 Chee Hwui Liew, MSc, Darren Mylotte, MBBCh PhD, Faisal Sharif, MBBS PhD, John William McEvoy, MBBCh MHS 2020-04-03
A small field study to detect SARS-CoV-2 in unselected patient samples Coronavirus disease 19 infection pool testing of SARS-CoV-02 samples alone infektiologikum frankfurt Phase Not Applicable Status not specified 0 50 2020-04-02
A validation study to test the efficacy of at-home COVID-19 test for the diagnosis of COVID19 infection Coronavirus disease 19 infection at-home COVID-19 test alone Care Access Research US Phase Not Applicable Status not specified 0 500 2020-04-03
A study of INOpulse inhaled nitric oxide system (iNO) in a patient with novel coronavirus disease (COVID-19) Coronavirus disease 19 infection nitric oxide (inhaled, INOpulse), Bellerophon alone Bellerophon Therapeutics LLC US 2020-03-31 Phase Not Applicable Recruiting 0 2020-04-03
HOPE: Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2 Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Gangnam Severance Hospital South Korea 2020-04-01 2022-03-30 3-2020-0036, HOPE, NCT04330144 Phase 3 Clinical Not yet recruiting 1 23 Months 2486 Yong Goo Song, Professor 2020-04-03
Evaluation of the effects of losartan in patients with Coronavirus disease 2019 Coronavirus disease 19 infection losartan alone, routine treatment protocol alone Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-03-31 IR.TBZMED.REC.1399.002, IRCT20180802040678N4 Phase 3 Clinical Recruiting 1 100 Akbar Sharifi, Armin Sadeghi, Mohammad Samiei 2020-04-06
Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and/or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Fundacion Instituto de Investigacion Marques de Valdecilla, IDIVAL 2020-04-06 2020-11-06 ENCOVID-HIDROXICLOROQUINA, NCT04330495 Phase 4 Clinical Not yet recruiting 0 7 Months 800 Javier Crespo, MDPhD 2020-04-06
Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS) Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia BreathSpec alone, breath test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) NHS Lothian 2020-03-25 2020-03-25 282014, NCT04329507 Phase Not Applicable Not yet recruiting 0 200 Michael Eddleston 2020-04-03
CATCO: Treatments for COVID-19: Canadian Arm of the Solidarity Trial Coronavirus disease 19 infection, SARS coronavirus infection lopinavir + ritonavir alone, standard of care alone HIV protease inhibitor Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sunnybrook Health Sciences Centre AbbVie Inc Canada 2020-03-18 2022-05-18 2114, CATCO, NCT04330690 Phase 2 Clinical Recruiting 2 26 Months 440 Asgar Rishu, Dominique Marcoux, Francois Lamontagne, MD, Robert Fowler, MD 2020-04-13
PERN-COVID-19: Clinical Characteristics and Outcomes of Pediatric COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) University of Calgary Canada 2020-03-18 2022-03-17 NCT04330261, PERN-COVID-19, REB18-0107-MOD9 Phase Not Applicable Recruiting 1 24 Months 12500 Anna Funk, PhD, Stephen Freedman, MD, Stephen Freedman, MDCM, MSc 2020-04-03
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia standard care alone, azithromycin plus hydroxychloroquine sulfate Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azidus Brasil Prevent Senior Private Operadora de Saúde LTDA 2020-04-03 2020-06-30 HIAPRE0320OR, NCT04329572 Phase 0 Clinical Not yet recruiting 0 2 Months 400 Alvaro Razuk Filho, Carla Morales Guerra Godoy, MD, PhD, Luciana Ferrara 2020-04-03
Alberta Hope COVID-19 for the Prevention of Severe COVID19 Disease Coronavirus disease 19 infection Plaquenil alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Calgary Canada 2020-04-15 2020-08-31 ABCOV-01, ABCOV-01 version 1.1, NCT04329611 Phase 3 Clinical Not yet recruiting 1 4 Months 1660 Carol C Kenney, RN, CCRP, Dr. L Metz, MD, Dr. M Hill, MD, Dr. Michael Hill, Luanne M Metz, MD, FRCPC, Luanne Metz, MD, Michael D Hill, MD, Michael D Hill, MD.FRCPC 2020-04-08
Hydroxychloroquine for COVID-19 PEP Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine sulfate alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Washington Bill & Melinda Gates Foundation, New York University US 2020-03-31 2020-10-31 NCT04328961, STUDY00009750 Phase 1 Clinical Not yet recruiting 0 7 Months 2000 Anna Bershteyn, PhD, Christine Johnston, MD, Helen Stankiewicz Karita, MD, Justice Quame-Amaglo, Kirsten Hauge, Meighan Krows, Ruanne V. Barnabas, MBChB, DPhil 2020-04-06
HAHPS: Hydroxychloroquine versus Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Intermountain Health Care Inc University of Utah US 2020-03-30 2021-12-31 1051355, HAHPS, NCT04329832 Phase 2 Clinical Recruiting 0 21 Months 300 David P Tomer, MS, Estelle Harris, MD, Samuel M Brown, MD MS, Valerie T Aston, MBA, Valerie T Aston, MD MS 2020-04-10
COVID-19 During Pregnancy: a Prospective, Observational, Cohort Coronavirus disease 19 infection, Pregnancy disorder, SARS coronavirus infection Máxima Medical Center Netherlands 2020-03-27 2020-12-31 N20.035, NL8485 Phase Not Applicable Recruiting 1 9 Months 20 Marion Frenken 2020-04-03
A clinical trial of ALLTest Rapid Screen Antibody Test Cassette to evaluate the presence of the IgG and IgM antibodies to COVID-19 in whole blood, serum or plasma samples of COVID-19 patients Coronavirus disease 19 infection ALLTest Rapid Screen Antibody Test Cassette alone University of North Carolina Phase Not Applicable Status not specified 0 2020-04-02
A clinical study to detect COVID-19 using SeroFlash SARS-CoV-2 IgG/IgM Antibody Detection Kit Coronavirus disease 19 infection SeroFlash SARS-CoV-2 IgG/IgM Antibody Detection Kit alone Epigentek Group Inc Phase Not Applicable Status not specified 0 267 2020-04-02
ECMOCARD: ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19) Coronavirus disease 19 infection, Hypoxia, Respiratory disease ISARIC, Monash University, The Prince Charles Hospital Extracorporeal Life Support Organization Vietnam, Thailand, Japan, Taiwan, Australia, US, Singapore, Indonesia, Hong Kong, Italy, UK, South Korea 2020-03-05 2020-07-31 ACTRN12620000421932, ANZCTR12620000421932, ECMOCARD Phase Not Applicable Recruiting 18 4 Months 400 A / Prof Gianluigi Li Bassi, Prof John Fraser 2020-04-13
Mesenchymal Stem Cell therapy in COVID-19 Coronavirus disease 19 infection, Viral pneumonia conventional treatment alone, mesenchymal stem cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Bagheiat-allah University of Medical Sciences Iran 2020-03-28 2020-04-29 IR.BMSU.REC.1399.007, IRCT20200325046860N2 Phase 1 Clinical Recruiting 1 1 Month 5 Hasan Abolghasemi, Hasan abolghasemi 2020-04-03
ACORES-2: ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic Coronavirus disease 19 infection, SARS coronavirus infection discontinuation of RAS blocker therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris Hopital Universitaire de la Pitie Salpetriere France 2020-04-30 2020-05-31 ACORES-2, APHP200409, NCT04329195 Phase 3 Clinical Not yet recruiting 1 1 Month 554 Gilles MONTALESCOT, MD, PhD, Mathieu KERNEIS, MD 2020-04-07
COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicenter, Observational Study Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hepatopancreatobiliary Surgery Institute of Gansu Province Affiliated Hospital of Jiangsu University, Ankang City Central Hospital, Dalian Sixth People's Hospital, Guangxi Zhuang Autonomous Region Guangxi, Hubei University for Nationalities, Hubei University of Medicine, LanZhou University, Lishui Central Hospital, Renmin Hospital of Wuhan University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, The Third People’s Hospital of Shenzhen, The sixth people's hospital of Shenyang, Tianjin Infectious Disease Hospital, Wuhan Union Hospital, China, XINGTAI PEOPLE HOSPITAL China 2020-03-30 2021-06-29 CHESS2002, NCT04329559 Phase Not Applicable Recruiting 15 15 Months 50 Bin Xiong, MD, Chuxiao Shao, MD, Dengxiang Liu, MD, Fengmei Wang, MD, Guo Zhang, MD, Hongguang Zhang, MD, Hongmei Yue, MD, Hua Yang, MD, Mingkai Chen, MD, Qing He, MD, Xiaodan Li, MD, Xiaolong Qi, Xiaolong Qi, MD, Yanna Liu, MD, Ye Gu, MD, Yong Zhang, MD, Zhengyan Wang, MD, Zicheng Jiang, MD 2020-04-03
SEB-COVID-19: SEB-COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Likas Malaysia 2020-04-01 2020-12-31 54437, NMRR-20-595-54437, SEB-COVID-19 Phase Not Applicable Not yet recruiting 1 9 Months Dr Cheah Phee Kheng 2020-04-03
PATCH: Prevention And Treatment of COVID-19 With Hydroxychloroquine Coronavirus disease 19 infection, Viral pneumonia Plaqeunil alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Pennsylvania US 2020-04-08 2021-12-01 842838, NCT04329923, PATCH Phase 2 Clinical Not yet recruiting 0 19 Months 400 Amelia Anderson, Ravi Amaravadi, MD 2020-04-08
A phase I trial of COVID-19 Vaccine, Ad26 SARS-CoV-2, for treatment of COVID-19 Coronavirus disease 19 infection Ad26 SARS-CoV-2 alone Johnson & Johnson Phase 1 Clinical Planned 0 2020-04-02
Impact of the Coronavirus (COVID-19) on Patients With Cancer Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Stanford University US 2020-04-30 2022-05-31 55596, NCT04330521 Phase Not Applicable Not yet recruiting 0 25 Months 50 Manali Indravadan Patel 2020-04-06
Evaluation of the performance of novel rapid diagnostics for COVID-19 at point-of-care Coronavirus disease 19 infection POC tests alone, standard PCR test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Heidelberg Germany 2020-04-05 DRKS00021220, S-180/2020 Phase Not Applicable Not yet recruiting 1 2000 Claudia Denkinger 2020-04-03
COVit: Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease Coronavirus disease 19 infection nicotinamide alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitatsklinikum Schleswig-Holstein Campus Kiel Germany 2020-04-06 A 107/20, COVit, DRKS00021214 Phase Not Applicable Not yet recruiting 1 1300 Stefan Schreiber 2020-04-03
UKOSS: Pandemic COVID-19 in pregnancy Coronavirus disease 19 infection, Pregnancy disorder Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) University of Oxford National Institute for Health Research (NIHR) UK 2020-01-24 2022-12-31 CPMS 14162, IRAS 112935, ISRCTN40092247 Phase Not Applicable Recruiting 1 35 Months 500 Prof Knight 2020-04-07
COVIDENCE: Longitudinal. Population-based, Observational Study of Coronavirus Disease in the UK Population Coronavirus disease 19 infection, Viral pneumonia Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Queen Mary University of London King's College London, London School of Hygiene and Tropical Medicine UK 2020-04-02 2025-04-01 COVIDENCE, COVIDENCE, NCT04330599 Phase Not Applicable Not yet recruiting 1 60 Months 12000 Adrian Martineau, PhD, Hayley Holt, MSc 2020-04-06
Effects of High-dose Vitamin C on COVID-19 Coronavirus disease 19 infection standard treatment alone, vitamin C alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-04-03 IR.TUMS.VCR.REC.1399.056, IRCT20190917044805N2 Phase 2/Phase 3 Clinical Recruiting 1 60 Kourosh Sadeghi, Mohammad Ali Sahraian 2020-04-07
Effect of oral multi-herbal preparation on COVID-19 Coronavirus disease 19 infection routine treatment alone, capsule (dried extract of Hyssopus officinalis L., Punica granatum L.) plus decoction (Glycyrrhiza glabra L., Althaea officinalis L., Ziziphus jujuba Mill) Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tehran University of Medical Sciences Iran 2020-03-23 IR.TUMS.VCR.REC.1399.024, IRCT20180712040449N2 Phase 3 Clinical Recruiting 3 68 Mehrdad Karimi, Mohammad Ali Sahraian, Samaneh Soleymani 2020-04-07
CORKUM: COVID-19 Registry of the LMU Hospital Munich Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinikum der Universitat Muenchen Germany 2020-04-02 20-245, CORKUM, DRKS00021225 Phase Not Applicable Not yet recruiting 1 1500 Johannes Hellmuth, Maximilian Münchhoff 2020-04-03
Efficacy and Safety of Siltuximab versus Corticosteroids in Hospitalized Patients With COVID19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia siltuximab alone Heat shock protein inhibitor, IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundacion Clinic per a la Recerca Biomédica Spain 2020-04-01 2020-05-20 NCT04329650, SILCOR-COVID-19 Phase 2 Clinical Not yet recruiting 2 1 Month 100 Alex Soriano, MD, Felipe García, MD, Judit Pich Martínez, Clinical Research Manager 2020-04-07
A Phase II Study to Assess The Effect of anti-Covid vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency in the Treatment of Coronavirus disease 19 infection (Covid 19) Patient Coronavirus disease 19 infection prototype vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency alone Federal Medical Biological Agency 2021-03-31 Phase 2 Clinical Planned 0 2020-04-03
A Phase I Study to Assess The Effect of anti-Covid vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency in the Treatment of Coronavirus disease 19 infection (Covid 19) Patient Coronavirus disease 19 infection prototype vaccine (coronavirus disease 19 infection), Federal Medical Biological Agency alone Federal Medical Biological Agency 2020-12-31 Phase 1 Clinical Planned 0 2020-04-03
Understanding COVID Coronavirus disease 19 infection, SARS coronavirus infection sampling alone Hopitaux Universitaires De Geneve University of Geneva Switzerland 2020-03-27 2022-03-31 2020-00516, NCT04329546 Phase Not Applicable Recruiting 1 24 Months 250 Angela Huttner, MD, Claire-Anne Siegrist, MD 2020-04-03
TBA: A weapon against COVID-19: (Social) media and influencers Coronavirus disease 19 infection, SARS coronavirus infection social media and influencers alone Fred Foundation, Noaber Foundation Netherlands 2020-03-16 2020-03-29 METc VUmc 2020.141, NL8483, TBA Phase Not Applicable Recruiting 1 17000 Hamza Yousuf 2020-04-06
HB-MCO-Covid19: HB-MCO-Covid19 Coronavirus disease 19 infection National Institutes of Health Malaysia Malaysia 2020-04-01 2020-05-31 54511, HB-MCO-Covid19, NMRR-20-634-54511 Phase Not Applicable Status not specified 1 2 Months Norbaidurah binti Ithnain 2020-04-06
A clinical study to assess bucillamine in the treatment of subjects with COVID-19 infection Coronavirus disease 19 infection, SARS coronavirus infection repurposed formulation of bucillamine (gout/cystinuria/Wilson disease), Revive Therapeutics alone Xanthine oxidase inhibitor Revive Therapeutics Ltd NOVOTECH ASIA KOREA CO. LTD. South Korea, Japan Phase 2 Clinical Planned 2 2020-04-13
Psychological effects of coronavirus disease 2019 (covid-19) amongst healthcare workers Coronavirus disease 19 infection, Psychiatric disorder National Institutes of Health Malaysia Malaysia 2020-04-01 2020-05-31 54488, NMRR-20-633-54488 Phase Not Applicable Status not specified 1 2 Months Mr Kamarul Zaman bin Salleh 2020-04-02
Phase III Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia Coronavirus disease 19 infection, Viral pneumonia favipiravir alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) FUJIFILM Toyama Chemical Co Ltd Japan 2020-03-31 2020-06-30 JapicCTI-205238 Phase 3 Clinical Recruiting 1 3 Months 96 2020-04-13
BCG-CORONA: Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine Coronavirus disease 19 infection, SARS coronavirus infection Bacillus Calmette-Guerin vaccine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitair Medisch Centrum Utrecht Radboud University Netherlands 2020-03-25 2020-12-25 BCG-CORONA, NCT04328441, NL73249.041.20, NL8477 Phase 3 Clinical Recruiting 8 9 Months 1500 Andreas Voss, MD, PhD, Angele Kerckhoffs, MD, PhD, Anna Roukens, MD, PhD, Bart Rijnders, MD, PhD, Jaap den Oever, MD, PhD, Karin Veerman, MD, Kees van Nieuwkoop, MD, PhD, MJM Bonten, Thijs ten Doesschate, MD, Thomas van der Vaart, MD, Wim Boersma, MD, PhD 2020-04-06
Clinical Characteristics and Prognostic Factors of Patients With COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shanghai 10th People's Hospital Chibi People's Hospital China 2020-01-30 2020-04-15 HBCBH-IEC-2020-101, NCT04328454 Phase Not Applicable Recruiting 1 2 Months 120 Ming Li, Ming Li, M.D. 2020-04-02
Prevention of COVID-19 infection in a medical institution and maintenance of medical system Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jichi Medical School Japan 2020-04-01 UMIN000039997 Phase Not Applicable Not yet recruiting 1 3700 Hironori Yamamoto 2020-04-02
A clinical study of BOLD-100 in the treatment in patients of COVID-19 infection Coronavirus disease 19 infection IT-139 alone Grp78 calcium binding protein inhibitor, Jun N terminal kinase inhibitor, Transferrin modulator, p38 MAP kinase modulator Bold Therapeutics Inc Phase Not Applicable Planned 0 2020-04-02
A study of hydroxychloroquine for the treatment of patients with COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Sandoz International GmbH, US Department of Health and Human Services US Phase Not Applicable Planned 0 2020-04-02
A phase I clinical study to assess immunogenicity of single-dose, intranasal AdCOVID in the treatment of COVID-19 Coronavirus disease 19 infection AdCOVID alone Altimmune Inc University of Alabama at Birmingham 2020-09-30 Phase 1 Clinical Planned 0 2020-04-06
CRONOS: COVID-19 related obstetric and neonatal outcome study Coronavirus disease 19 infection Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Deutschen Gesellschaft für Perinatale Medizin e.V.c/o Conventus Congressmanagement & Marketing GmbH Germany 2020-04-01 CRONOS, D 451/20, DRKS00021208 Phase Not Applicable Not yet recruiting 1 100 Ulrich Pecks 2020-04-03
A compassionate use program to assess PLX cell therapy in the treatment of patients with coronavirus infection (COVID-19) Cardiac failure, Coronavirus disease 19 infection, Inflammatory disease, Renal failure, Respiratory distress syndrome PLX stem cell therapy, Pluristem/Cha Bio & Diostech alone IL-6 receptor agonist Pluristem Therapeutics Inc Charite University Israel Phase Not Applicable Status not specified 1 7 2020-04-09
Phase II clinical trial of antroquinonol to treat Covid-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia antroquinonol alone MEK-1 protein kinase inhibitor, Ras gene inhibitor Golden Biotechnology Corp Phase 2 Clinical Planned 0 2020-04-02
COVID-19-HBO: Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome hyperbaric oxygen alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Karolinska University Hospital Blekingesjukhuset, Karlskrona, Karolinska Institutet, University of California San Diego Sweden 2020-04-25 2022-12-31 2020-001349-37, 4-1199/2020, COVID-19-HBO, K-2020-2611, NCT04327505 Phase 2/Phase 3 Clinical Not yet recruiting 1 32 Months 200 Anders Kjellberg, MD, Peter Lindholm, MD, PhD 2020-04-02
CODEX: COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III Adult respiratory distress syndrome, Coronavirus disease 19 infection dexamethasone alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sociedade Beneficiente De Senhoras Hospital Sirio Libanes Ache Laboratorios Farmaceuticos SA, Brazilian Research In Intensive Care Network, Hospital do Coracao, Sociedade Beneficente Israelita Brasileira Hospital Albert Einsten Brazil 2020-04-01 2020-08-30 CODEX, CODEX_V1.1, NCT04327401 Phase 3 Clinical Not yet recruiting 21 4 Months 290 Adrian PM Kormann, MD, Bruno M Tomazini, MD, Bruno Tomazini, M.D, Carla MG Godoy, MD, Cintia MC Grion, MD, Cristina P Amendola, MD, Eduardo LV Costa, PhD, Eraldo A Lucio, MD, Felipe Dal Pizzol, MD, Fernando C Neuenschwander, MD, Fernando G Zampieri, MD, Flavia R Machado, MD, Frederico C DallOrto, MD, Israel S Maia, MD, Jorge LR Paranhos, MD, Luciano CP Azevedo, PhD, Luciano Cesar Pontes Azevedo, Ph.D, Luiz F. L. Reis, Ph.D., Marco AV Guedes, MD, Maria SM Paiva, MD, Mauro E Hernandes, MD, Otávio Berwanger, PhD, Rodrigo C Figueiredo, MD, Rodrigo S Biondi, MD, Viviane C Veiga, MD, Wilson J Lovato, MD 2020-04-02
A medical records based study for safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy Coronavirus disease 19 infection, Viral pneumonia chloroquine plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Peking University Third Hospital China 2020-03-28 2020-05-29 ChiCTR2000031376 Phase Not Applicable Recruiting 1 2 Months 600 Chunyang Wang, Dongyang Liu 2020-04-06
A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research Coronavirus disease 19 infection, SARS coronavirus infection Foam nasal swabs alone, Polyester nasal swabs alone UnitedHealth Group Inc Bill & Melinda Gates Foundation, Mayo Clinic Foundation, PATH (US) US 2020-03-25 2020-04-10 20-002, NCT04327804 Phase Not Applicable Recruiting 0 120 Ethan Berke, Yuan Po Tu, MD, Yuan Tu 2020-04-02
The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19 Coronavirus disease 19 infection, Respiratory failure focused lung ultrasound alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Aarhus University Denmark 2020-03-14 2020-05-15 COVID-FLUS, NCT04327674 Phase Not Applicable Recruiting 2 2 Months 375 Jesper Weile, Søren H Skaarup, Søren Helbo SH Skaarup, MD 2020-04-02
Mindfulness During COVID-19 Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection Mindfulness session(s) alone Healthy volunteers accepted Wake Forest University Health Sciences, US US 2020-03-22 2020-12-31 IRB00064587, NCT04319445 Phase Not Applicable Recruiting 0 9 Months 200 Rebecca E Wells, MD, MPH, Rebecca Wells, MD 2020-04-09
COV19-PLASMA: Hyperimmune Plasma for Critical Patients With COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection hyperimmune plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fondazione IRCCS Policlinico San Matteo ASST Cremona, Carlo Poma Hospital, Lodi Hospital Italy 2020-03-17 2020-05-31 COV19-PLASMA, IRCCSSANMATTEOH, NCT04321421 Phase 2 Clinical No longer recruiting 1 2 Months 49 Cesare Perotti, MD 2020-04-02
PROACTIVE-19: Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary Coronavirus disease 19 infection, Heart arrhythmia, Respiratory distress syndrome, Shock Personalized health education alone Healthy volunteers accepted, Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Of Pécs Hungary 2020-04-01 2021-08-21 IV/2428- 2 /2020/EKU, NCT04321928, PROACTIVE-19 Phase Not Applicable Not yet recruiting 1 16 Months 7576 Bálint Erőss, MD, Péter Hegyi, MD, PhD, DSc 2020-04-02
DISPOSE: DIgital Online SuPport for COVID-19 StrEss Acute stress disorder, Coronavirus disease 19 infection, Depression, Generalized anxiety disorder Guided online support program alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) International Psychoanalytic University Selfapy GmbH Germany 2020-04-30 2021-12-31 DISPOSE, IPUB_2020_01, NCT04324190 Phase Not Applicable Not yet recruiting 1 20 Months 600 Gunther Meinlschmidt, Prof. Dr., Kati Bermbach 2020-04-13
Covid: Effectiveness of Hydroxychloroquine in Covid-19 Patients Coronavirus disease 19 infection, Viral pneumonia hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Ayub Medical College Pakistan 2020-03-28 2020-06-28 ATH/CT101/22/3, Covid, NCT04328272 Phase 3 Clinical Not yet recruiting 2 3 Months 75 Muhammad J Khan, MBBS, Prof. Dr. Umar Farooq, Dean, Umar Farooq, PhD, Umer Farooq, PhD 2020-04-06
Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study Anxiety disorder, Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-03-26 2020-04-28 NCT04327531, TURKISHCOVID19 Phase Not Applicable No longer recruiting 1 1 Month 200 Pınar Yalcin bahat 2020-04-03
COVID-19 Rapid Test Kit Use in Screening Center Coronavirus disease 19 infection COVID-19 IgG/IgM Rapid Test kit alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sabah Women and Children's Hospital Malaysia 2020-04-10 2020-09-30 NMRR-20-640-54491 Phase Not Applicable Not yet recruiting 1 5 Months Darlene Flavius Ongkili, Dr Cheah Phee Kheng 2020-04-02
CORONA: Hydroxy Chloroquine, in open-labelled, Randomized intervention for prevention of new infection and adverse outcomes following COVID-19 infection -A Tertiary Hospital based study Coronavirus disease 19 infection hydroxychloroquine sulphate alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Aster Malabar Institute of Medical Sciences India 2020-04-08 CORONA, CTRI/2020/03/024402 Phase 3 Clinical Not yet recruiting 1 500 Dr Remesh Bhasi 2020-04-02
COVIDMED: Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine sulfate alone, lopinavir + ritonavir alone, losartan alone, standard care alone Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist, HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bassett Healthcare US 2020-04-06 2021-04-01 1581969, COVIDMED, NCT04328012 Phase 2/Phase 3 Clinical Recruiting 0 11 Months 4000 Daniel Freilich, MD, Jennifer Victory, RN, Kristin Pullyblank, RN, MS, daniel Freilich, MD, daniel freilich, MD 2020-04-09
Study for the changes of the brain structure and function in healed patients of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia functional magnetic resonance imaging technology alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Union Hospital Tongji Medical School Huazhong University Of Science & Technology China 2020-04-01 2021-04-04 ChiCTR2000031356 Phase Not Applicable Not yet recruiting 1 12 Months 600 Wenliang Fan 2020-04-02
COVIDAXIS: Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine alone, lopinavir + ritonavir alone HIV protease inhibitor Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Saint Etienne Institut Pasteur France 2020-04-11 2020-11-30 2020-001188-96, 20PH061, COVIDAXIS, NCT04328285 Phase 3 Clinical Not yet recruiting 3 7 Months 1200 Amandine GAGNEUX-BRUNON, Arnauld Garcin, Bernard TARDY, Bruno Hoen, MD, PhD, Elisabeth BOTELHO-NEVERS, Elisabeth Botelho-Nevers, MD, PhD, Isabelle PELLIER, Marc-Antoine CUSTAUD, Nathalie Jolly, Sandrine ACCASSAT, Vincent DUBEE, Xavier DUVAL 2020-04-13
A phase I clinical treatment to evaluate the safety and efficacy of COVID-19 vaccine for the potential prevention of coronavirus infection COVID-19 Coronavirus disease 19 infection SARS-CoV-2 recombinant adenoviral vector vaccine (AdVac/PER.C6, COVID-19), Johnson & Johnson/Biomedical Advanced Research and Development Authority/Beth Israel Deaconess Medical Center alone Beth Israel Deaconess Medical Center, Johnson & Johnson 2020-09-30 Phase 1 Clinical Planned 0 2020-04-02
COVID-19 HOPE Trial: Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation of Pulmonary Function Coronavirus disease 19 infection N-acetylcysteine plus heparin Atossa Genetics Inc COVID-19 HOPE Trial Phase Not Applicable Not yet recruiting 0 Dr Steven Quay 2020-04-02
A clinical study of CytoSorb for the treatment of in patients infected with COVID-19 Coronavirus disease 19 infection CytoSorb alone CytoSorbents Corp Phase Not Applicable Status not specified 0 2020-04-06
Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis Coronavirus disease 19 infection, Fever, Influenza virus infection medical records based analysis alone Chinese PLA General Hospital China 2020-04-01 2020-05-31 ChiCTR2000031366 Phase Not Applicable Not yet recruiting 1 2 Months 5000 Bin Liu, Kun Xiao 2020-04-02
BRACE: BCG Vaccination to Protect Healthcare Workers Against COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia BCG vaccine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Murdoch Childrens Research Institute Royal Childrens Hospital, Melbourne Australia 2020-03-30 2022-03-30 62586, BRACE, NCT04327206 Phase 3 Clinical Recruiting 9 24 Months 4170 A/Prof Tony Korman, MBBS FRACP, Dr Laurens Manning, MBChB PhD, Dr Nicole Tan, MBBS FANZCA, Kaya Gardiner, Prof Michaela Lucas, MD PhD, Prof Nigel Curtis, Prof Nigel Curtis, MBBS PhD, Prof Peter Richmond, MBBS FRACP 2020-04-08
To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients Coronavirus disease 19 infection, Viral pneumonia LC-MS-based metabolomic analysis alone, TMT-based quantitative proteomics alone Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Westlake University China ChiCTR2000031365 Phase 0 Clinical Recruiting 1 Bo Shen, Haixiao Chen 2020-04-02
COLCOVID: The ECLA PHRI COLCOVID Trial Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia colchicine alone, local standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Estudios Clinicos Latino America Population Health and Research Institute, Trivandrum, Kerala, india 2020-03-31 2020-06-30 COLCOVID, COLCOVID VERSION1.2, NCT04328480 Phase 3 Clinical Not yet recruiting 0 3 Months 2500 Andres Orlandini, MD, Rafael Diaz, MD 2020-04-02
TPB-COVID-19 Coronavirus disease 19 infection National Institutes of Health Malaysia Ministry of Health, Malaysia Malaysia 2020-04-01 2020-06-30 54505, NMRR-20-632-54505 Phase Not Applicable Not yet recruiting 1 3 Months MUHAMMAD RIDZWAN BIN ZAKARIA 2020-04-03
VICO: The Vietnam Chloroquine Treatment on COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection chloroquine phosphate alone, standard of care therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Oxford University Clinical Research Unit, Vietnam Can Gio COVID Hospital, Cho Ray Hospital, Cu Chi COVID Hospital, Department of Health, Ho Chi Minh city, Ministry of Health and Welfare, Vietnam, National Institute for Infectious And Tropical Diseases, The Hospital for Tropical Diseases Vietnam 2020-04-01 2022-04-01 COVID, NCT04328493, VICO Phase 2 Clinical Not yet recruiting 5 24 Months 250 Dung Nguyen, PhD. MD, Guy Thwaites, PhD. MD, Hung Le Quoc, MD, Jeremy Day, PhD. MD, Manh Hung Le, Nguyen Huy Man Dinh, Dr, Phuong Thao Huynh, Phar, Thach N Pham, PhD. MD, Thach N Pham, PhD.MD, Thanh Dung Nguyen, Thanh Dung Nguyen, Dr, Thanh Phong Nguyen, Dr, Thanh Truong Nguyen, Dr, Van Vinh Chau Nguyen, Dr, Van Vinh Chau Nguyen, PhD, MD 2020-04-03
Audio Data Collection for Identification and Classification of Coughing Allergic rhinitis, Asthma, Chronic obstructive pulmonary disease, Common cold, Coronavirus disease 19 infection, Coronavirus infection, Cough, Influenza virus infection, Respiratory tract infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HealthMode Inc. US 2020-03-25 2022-09-25 HM070102, NCT04326309 Phase Not Applicable Recruiting 0 30 Months 1000 Daniel R Karlin, MD, MA 2020-04-02
COntAGIouS: In-depth Immunological Investigation of COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection Patient sampling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitaire Ziekenhuizen Leuven 2020-03-27 2020-09-30 CONTAGIOUS, COntAGIouS, NCT04327570 Phase Not Applicable Not yet recruiting 0 6 Months 100 Joost Wauters, MD PhD 2020-04-02
A randomized trial to evaluate the effectiveness and safety of COVID-19 convalescent plasma for both treatment of COVID-19 positive patients at all stages of disease progression as well as prevention of infection after high-risk exposure Coronavirus disease 19 infection COVID-19 convalescent plasma alone Healthy volunteers accepted Johns Hopkins University Albert Einstein College of Medicine, Bloomberg Philanthropies, Mayo Clinic, Minnesota, Stanford University Medical Center US Phase Not Applicable Planned 0 Arturo Casadevall 2020-04-02
A Phase I/II safety trial of ST-266 for Treatment of the Severe Inflammatory cytokine storm Response Associated with COVID-19 Coronavirus disease 19 infection ST-266 alone Noveome Biotherapeutics Inc 2020-12-31 Phase 1/Phase 2 Clinical Planned 0 2020-04-07
Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection Cardiovascular disease, Coronavirus disease 19 infection, SARS coronavirus infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitatsklinikum Essen Germany 2020-03-26 2026-03-25 20-9213-BO, NCT04327479 Phase Not Applicable Recruiting 1 72 Months 6000 Amir A Mahabadi, MD, Matthias Totzeck, MD, Tienush Rassaf, MD 2020-04-03
EDPREPA: Covid-19 preparedness among Emergency Departments: a cross-sectional study in France Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Universite Paris Est France 2020-03-24 EDPREPA, TCTR20200324001 Phase Not Applicable Not yet recruiting 1 650 Enrique Casalino 2020-04-09
Pre-exposure Prophylaxis for SARS-coronavirus-2 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Minnesota US 2020-04-06 2020-08-31 NCT04328467, RAJASINGHAM, STUDY00009414 Phase 3 Clinical Recruiting 0 4 Months 3500 Radha Rajasingham (Please Email), MD, Radha Rajasingham, MD, Sarah Lofgren 2020-04-11
Antivirals for COVID-19: Covid-19: A randomized, open-label, adaptive, proof-of-concept clinical trial of new antiviral drug candidates against SARS-CoV-2 Coronavirus disease 19 infection itraconazole alone Lanosterol-14 demethylase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) UZ Leuven-University Hospitals Belgium 2020-04-26 2020-001243-15, Antivirals for COVID-19, S63874 Phase 2 Clinical No longer recruiting 1 200 Laurens Liesenborghs 2020-04-02
N-ReCOVID 19: A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) Coronavirus disease 19 infection Plaquenil plus remdesivir RNA polymerase modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Oslo University Hospital Norway 2020-03-26 2020-000982-18, N-ReCOVID 19, WHO-NOR-COVID-19 Phase 3 Clinical No longer recruiting 1 443 Sect. Clin. Imm. & Infect. Diseases 2020-04-02
A medical records based study for novel coronavirus pneumonia (COVID-19) patients undergoing endotracheal intubation Coronavirus disease 19 infection, Viral pneumonia endotracheal intubation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tongji Hospital, Huazhong University of Science and Technology China 2020-02-04 2020-03-12 ChiCTR2000031439 Phase Not Applicable No longer recruiting 1 1 Month 59 Hongbo Zheng, Li Wan 2020-04-03
The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of Immunological, biochemical, and Metabolic Parameters: a Retrospective, Observational Study Coronavirus disease 19 infection, Viral pneumonia Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tongji Hospital, Huazhong University of Science and Technology China 2020-04-01 2021-03-31 ChiCTR2000031429 Phase Not Applicable Not yet recruiting 1 12 Months 2000 Ji-Xin Zhong, Lingli Dong 2020-04-03
Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial Coronavirus disease 19 infection First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) Taizhou Zecheng Biotechnology Co. Ltd. China 2020-03-01 2020-03-25 ChiCTR2000031427 Phase 0 Clinical Not yet recruiting 1 200 Pang Jifeng, Xiang Changgang 2020-04-02
COVID-19-FR: COVID-19 Registry Freiburg Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Heart Centre Freiburg-Bad Krozingen Germany 2020-03-26 153/20, COVID-19-FR, DRKS00021206 Phase Not Applicable Recruiting 1 400 Achim Lother, Mr. Prof. Dr. Daniel Dürschmied 2020-04-02
Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Wuhan Asia Heart Hospital China 2020-02-05 2020-10-04 ChiCTR2000031428 Phase Not Applicable No longer recruiting 1 8 Months 500 Qingkun Fan, Zejin Liu 2020-04-02
Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia Conventional treatment regimen alone, human umbilical cord mesenchymal stem cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) 302 Military Hospital of China China 2020-03-14 2021-12-31 ChiCTR2000031430 Phase 2 Clinical Recruiting 4 21 Months 200 Fu-Sheng Wang, Lei Shi 2020-04-03
A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adults Coronavirus disease 19 infection, Viral pneumonia microRNA2911 plasmid alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Nanjing Drum Tower Hospital, Nanjing University China 2020-04-01 2020-08-31 ChiCTR2000031432 Phase 1 Clinical Not yet recruiting 1 5 Months 15 Chenyu Zhang, Yanbo Wang 2020-04-06
Treating COVID-19 With a Bidirectional Oxygenation Valve Coronavirus disease 19 infection bidirectional oxygenation mouthpiece alone, non-rebreather face mask alone, oxygen alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) TMC HealthCare PEEP Medical, LLC US 2020-03-27 2020-06-01 COVID19PEEP2020, GO2 PEEP Study, NCT04326452 Phase Not Applicable Recruiting 0 2 Months 15 Ashvinder Khanna, MD, Jeffrey Miller, MD, Joseph Levitt, MD, Matthew Weiner, MD, Natalia Elias Calles, MPH, Sonya Mathewson, RN 2020-04-02
PREDICT: Prediction of Diagnosed Covid-19 Infection in IUC Patients Coronavirus disease 19 infection, Respiratory tract infection PCR alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-03-30 2021-09-30 2020-A00763-36, 2020_20, NCT04327180, PREDICT Phase Not Applicable Recruiting 1 18 Months 500 Julien Goutay, MD, Julien Poissy, MD,PhD, Martine Remy-Jardin, MD,PhD, Morgan Caplan, MD, Philippe Mathurin, MD,PhD, Sophie Susen, MD,PhD 2020-04-07
Efficacy of Tumor Necrosis Factor-Alpha Inhibitor in COVID-19 Coronavirus disease 19 infection etanercept biosimilar, AryoGen alone TNF antagonist, TNF binding agent, Type II TNF receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-03-27 IR.TUMS.VCR.REC.1399.034, IRCT20200312046749N1 Phase 2/Phase 3 Clinical Recruiting 1 80 Mohammad Ali Sahraian, Raheleh Assari, Vahid Ziaee 2020-04-13
GARM-COVID19: Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome Centricyte 1000 (Healeon Medical) alone, Microcannula Closed System (Tulip Med) alone, autologous cellular stromal vascular fraction alone, lipoaspiration alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HEALEON MEDICAL INC Robert W. Alexander, MD US 2020-03-25 2021-12-31 GARM COVID19, GARM-COVID19, NCT04326036 Phase 0 Clinical Recruiting 0 21 Months 10 Robert W Alexander, MD 2020-04-02
EC-COVID-RCT: Early CPAP in COVID Patients With Respiratory Failure Coronavirus disease 19 infection, Respiratory failure continuous positive airway pressure ventilation alone, current clinical practice alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Istituto di Ricerche Farmacologiche Mario Negri Italy 2020-04-06 2020-11-09 EC-COVID-RCT, EC-COVID-RCT-FENICE, NCT04326075 Phase Not Applicable Not yet recruiting 1 7 Months 900 Elena Garbero, M.Sc., Guido Bertolini, MD 2020-04-02
Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong Coronavirus disease 19 infection, Viral pneumonia laboratory monitoring alone, nasopharyngeal aspiration alone, sputum collection alone, swab flocking alone, tracheal aspiration alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chinese University of Hong Kong Hong Kong 2020-02-24 2021-06-17 COVID-19 STUDY 2020.076, NCT04325919 Phase Not Applicable Recruiting 1 15 Months 170 Paul CHAN, Paul KS Chan 2020-04-03
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS Coronavirus disease 19 infection, Respiratory distress syndrome Prone positioning alone, high flow nasal cannula alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rush University Medical Center Medical College of Wisconsin US 2020-04-06 2020-06-30 COVID-19-HFNC+PP, NCT04325906 Phase Not Applicable Not yet recruiting 0 2 Months 346 David Vines, PhD, Jennifer Peterson, PhD, Jie Li, PhD, Kellianne Fleming, MS, Rahul Nanchal, MD, Sara Mirza, MD, Victoria Arinta, MS 2020-04-04
Psychological distress of the COVID-19 pandemic: A comparison between cancer patients and healthy controls Anxiety disorder, Coronavirus disease 19 infection, Depression Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinik fur Psychosomatische Medizin und Psychotherapie, Univeristat Duisburg-Essen Germany 2020-03-16 19-8834-BO, DRKS00021164 Phase Not Applicable Recruiting 1 220 Venja Musche 2020-04-02
COVIDx: Evaluation of Novel Diagnostic Tests for COVID-19 Coronavirus disease 19 infection CT scan alone, SAMBA II device alone, chest X-ray alone, polymerase chain reaction alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cambridge University Hospitals NHS Foundation Trust UK 2020-04-06 2021-10-07 COVIDX, COVIDx, NCT04326387 Phase Not Applicable Recruiting 2 18 Months 200 Anne-Laure Vallier, PhD., Dami Collier, MBBS, Ravi Gupta, PhD, Ravi K Gupta, PhD, Ravindra Prof. Gupta, BMBCh, Richard D. Skells, BSc. 2020-04-13
Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19 Coronavirus disease 19 infection Power-breath device alone, Winner-flow device alone, expiratory training alone, inspiratory training alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universidad Complutense de Madrid Spain 2020-04-26 2020-10-12 COVID_ISCIII 20/265-E_BS, NCT04326114 Phase Not Applicable Not yet recruiting 1 5 Months 240 César Calvo Lobo, César Calvo Lobo, PhD 2020-03-31
GRECCO-19: The GReek Study in the Effects of Colchicine in COVID-19 complications prevention Coronavirus disease 19 infection, Myocardial infarction, SARS coronavirus infection, Viral pneumonia Colchicine alone, Standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) ELPEN Pharmaceutical Co Inc, Hellenic Society of Rhythmology, National and Kapodistrian University of Athens Greece 2020-04-06 2020-09-30 2020-001455-40, 906295542, GRECCO-19, NCT04326790 Phase 2 Clinical Recruiting 1 5 Months 180 Hellenic Society of Rhythmology, Spyridon Deftereos 2020-04-13
CoV-Ak-Test: Development of a test to measure the immune response in patients with Covid-19 Coronavirus disease 19 infection, SARS coronavirus infection SARS-CoV-2 antibody ELISA alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Institut für Virologie, Universitätsklinikum Leipzig Germany 2020-03-30 124/20-ek, CoV-Ak-Test, DRKS00021166 Phase Not Applicable Not yet recruiting 1 15 Christian Jassoy 2020-04-02
Clinical study of recombinant protein subunit vaccine (COVID-19) Coronavirus disease 19 infection recombinant protein subunit vaccine (COVID-19), SK Bioscience alone SK Bioscience 2020-09-30 Phase Not Applicable Planned 0 2020-04-02
A Phase I Study to Assess the Effect of Gimsilumab in The Treatment of COVID-19 Associated With Acute Respiratory Distress Syndrome (ARDS) Patients Coronavirus disease 19 infection, Respiratory distress syndrome gimsilumab alone GM-CSF ligand inhibitor Altasciences Company Inc, Roivant Sciences Ltd 2020-03-27 Phase 1 Clinical Completed 0 2020-03-31
Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with corona virus disease-2019 (COVID-19) referring to Sina Hospital in 2020 Coronavirus disease 19 infection, Viral pneumonia beta-blocker therapy alone, calcium channel blocker therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-04-05 IR.TUMS.VCR.REC.1399.028, IRCT20151113025025N3 Phase 4 Clinical Recruiting 1 60 Maryam Bahreini, Mohammad Ali Sahraian 2020-04-06
Convalescent Plasma therapy for COVID-19 Patients Coronavirus disease 19 infection convalescent plasma alone, current treatment alone Darman Ara, Iran Blood Transfusion Organization Iran 2020-03-15 IR.BMSU.REC.1398.434, IR.TMI.REC.1398.031, IRCT20200325046860N1 Phase 2 Clinical Recruiting 4 200 Abbas Ali Imani Fooladi, Dr Ehsan Sharifipour, Dr Hassan Abolghasemi, Dr Masoud Reza Sohrabi, Dr. Payam Tabarsi, Hassan Abolghasemi 2020-04-02
The effect of naproxen on the healing process of patients with COVID-19 Coronavirus disease 19 infection, Viral pneumonia Variable regimens including chloroquine phosphate , hydroxychloroquine sulfate , lopinavir + ritonavir , naproxen HIV protease inhibitor Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Abadan School of Medical Sciences Iran 2020-03-28 IR.ABADANUMS.REC.1398.115, IRCT20200324046850N3 Phase 3 Clinical Recruiting 1 40 Sara Mobarak 2020-04-02
Effect of Benson Relaxation on Quality of Life and job stress in nurses Acute stress disorder, Coronavirus disease 19 infection Benson relaxation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Sabzevar University of Medical Sciences Iran 2020-02-28 IR.MEDSAB.REC.1398.141, IRCT20131113015393N6 Phase Not Applicable Recruiting 1 62 Ali Taj Abadi, Narjes Heshmati Far, Narjes Heshmatifar 2020-04-02
Active Monitoring And Determinants of Incidence Infection of COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundacion Teofilo Hernando Spain 2020-03-23 2020-09-20 AMADIICH, NCT04326400 Phase Not Applicable Recruiting 1 5 Months 1000 Artuto García, Joan Soriano, MD, PhD, Marcos Maroto 2020-04-02
A single-center, open-label, randomized, and controlled trial of darunavir and cobicistat (DRV/c) in treating laboratory-confirmed COVID-19 patients Coronavirus disease 19 infection darunavir + cobicistat (fixed dose, HIV infection), Janssen R&D/ Gilead alone Cytochrome P450 3 inhibitor, HIV-1 protease inhibitor Johnson & Johnson China Phase 2 Clinical Status not specified 1 30 2020-04-07
Effect of metformin in COVID-19 mortality rate and symptom improvement Coronavirus disease 19 infection, Viral pneumonia metformin hydrochloride alone, standard regimen therapy alone AMP activated protein kinase stimulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-03-20 IR.TBZMED.REC.1398.1310, IRCT20160310026998N11 Phase 3 Clinical Recruiting 1 200 Saba Ghaffary 2020-04-06
Effect of vitamin A in patients with COVID-19 Coronavirus disease 19 infection vitamin A alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-04-03 IR.TBZMED.REC.1398.1305, IRCT20170117032004N3 Phase 2 Clinical Recruiting 1 30 Dr. Mohammad Sameiee, Zeinab Niknaiz, Zeinab Nikniaz 2020-04-06
Sarilumab COVID-19 Coronavirus disease 19 infection, Viral pneumonia sarilumab alone, supportive care alone IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sanofi SA, Sanofi-Aventis Research and Development Regeneron Pharmaceuticals Inc Italy, Russian Federation, Spain, Japan, Germany, Canada, France 2020-03-29 2021-06-30 2020-001162-12, EFC16844, JapicCTI-205253, NCT04327388, U1111-1249-6021 Phase 2/Phase 3 Clinical Recruiting 17 15 Months 300 Clinical Sciences & Operations, Clinical Studies Unit, Sanofi Co., Ltd. 2020-04-13
Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia Coronavirus disease 19 infection Variable regimens including Plaquenil , vitamin A , vitamin C , vitamin D , zinc Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istinye Universitesi Turkey 2020-03-20 2020-09-01 2020-2/1, NCT04326725 Phase Not Applicable Recruiting 1 5 Months 80 Istinye University M ozmen, Prof, Mahir M Ozmen, Professor, Mehmet Mahir Ozmen 2020-04-13
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection Coronavirus disease 19 infection, Lung injury tradipitant alone NK1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Vanda Pharmaceuticals Inc US 2020-04-01 2020-08-31 NCT04326426, ODYSSEY, ODYSSEY, VLY-686-3501 Phase 3 Clinical Not yet recruiting 0 5 Months 300 Vasilios Polymeropoulos, MD 2020-04-07
HYCOVID: Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France, Monaco 2020-04-30 2020-09-30 49RC20_0071, HYCOVID, NCT04325893 Phase 3 Clinical Recruiting 37 5 Months 1300 Alina Tone, MD, Aurélie Baldolli, MD, Aurélien Lorleac'h, MD, Bernard Louis, MD, Blandine Rammaert, MD, DRCI ANGERS, Edouard Devaud, MD, Elisabeth Bothelo-Nevers, MD, Emma D'Anglejean, MD, François Laterza, MD, Guillaume Martin-Blondel, MD, Jean-Baptiste LAINE, Jean-François Faucher, MD, Jean-Philippe Lanoix, MD, Jean-Philippe Talarmin, MD, Julia Brochard, MD, Karine Lacombe, MD, Lionel Piroth, MD, Marie Gousseff, MD, Martin Martinot, MD, Olivier Grossi, MD, Olivier Robineau, MD, Patrick Rispal, MD, Philippe Prazuck, MD, Philippe RAFFI, MD, Raphaël Lepeule, MD, Robin Dhote, MD, Rodolphe Buzele, MD, Roxane Courtois, MD, Rémi VATAN, MD, Simon Sunder, MD, Sylvain Diamantis, MD, Séverine Ansart, MD, Thomas Gey, MD, Thomas Guimard, MD, Valérie Pourcher, MD, Vincent DUBEE, Vincent Dubée, Yann-Erick Claessens, MD 2020-04-09
A trial to evaluate transplantation of ACE2-mesenchymal stem cells in patients diagnosed with COVID-19 pneumonia Coronavirus disease 19 infection, Viral pneumonia ACE2-mesenchymal stem cells alone Celltex Therapeutics Corp China Phase 2 Clinical Status not specified 1 7 2020-04-01
A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury Coronavirus disease 19 infection, Heart injury, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) China-Japan Union Hospital of Jilin University, Tongji Hospital, Huazhong University of Science and Technology Jilin Provincial Science & Technology Department China 2020-03-27 2020-04-27 ChiCTR2000031301 Phase Not Applicable Not yet recruiting 2 1 Month 100 Si Daoyuan 2020-04-01
A trial to evaluate human umbilical cord mesenchymal stem cells for the treatment of COVID-19 patients Coronavirus disease 19 infection allogenic human umbilical cord mesenchymal stem cells alone Female Chinese Academy of Sciences Phase 2 Clinical Status not specified 0 1 2020-03-31
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients Coronavirus disease 19 infection, Viral pneumonia allogeneic human dental pulp mesenchymal stem cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Renmin Hospital of Wuhan University China 2020-04-01 2020-07-31 ChiCTR2000031319 Phase 2 Clinical Not yet recruiting 1 4 Months 20 Dr. Chenliang Zhou, Prof Qingsong Ye 2020-04-01
A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Jinyebaidu granule alone, routine treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tongji Hospital, Union Hospital Tongji Medical School Huazhong University Of Science & Technology China 2020-02-12 2020-05-30 ChiCTR2000029755, ChiMCTR2000002999 Phase 4 Clinical Recruiting 1 3 Months 120 Chen Qian, Liu Dong 2020-04-01
Risk factors of death from coronavirus disease 2019 Coronavirus disease 19 infection, SARS coronavirus infection Yokohama City University Japan 2020-03-28 UMIN000039986 Phase Not Applicable Not yet recruiting 1 Nobuyuki Horita 2020-04-01
Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People Coronavirus disease 19 infection, Viral pneumonia Healthy volunteers accepted Sichuan University, West China Hospital China 2020-02-10 2022-02-10 ChiCTR2000029754 Phase Not Applicable Recruiting 1 24 Months 1500 Chen Lei, Lai Wanlin 2020-04-01
Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Shanghai Public Health Clinical Center China 2020-03-23 2020-09-30 ChiCTR2000031174 Phase Not Applicable Not yet recruiting 1 6 Months 1000 Lu Shuihua, Xia Lu 2020-04-01
Evaluation of the effectiveness of Ipecac homeopathic remedy in control of Clinical manifestations of COVID-19 Coronavirus disease 19 infection alcohol plus ipecac homeopathic remedy with C30 potency, Hellios homeopathy pharmacy Iran University of Medical Sciences Iran 2020-04-03 IR.IUMS.REC.1399.039, IRCT20140907019073N4 Phase 3 Clinical Recruiting 2 60 Ali Mazaherinezhad, Farbod Rahnama Chitsaz, Proffessor A.Motevalian, Somaye Mahroozade 2020-04-06
Persian Medicine Products in Covid-19 Coronavirus disease 19 infection Iranian medicine alone, herbal therapy alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-04-03 IR.TBZMED.REC.1398.1318, IRCT20140617018126N2 Phase 3 Clinical Recruiting 1 60 Hojjat Pourfathi Nematabad, Mohammad Samiei 2020-04-06
A medical records based retrospective study for novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Wuhan third Hospital China 2020-03-23 2020-04-30 ChiCTR2000031187 Phase Not Applicable Not yet recruiting 1 1 Month 1292 Pengcheng Luo, Yilin Yin 2020-04-01
Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients Coronavirus disease 19 infection, Viral pneumonia interferon plus lopinavir + ritonavir HIV protease inhibitor Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) 302 Military Hospital of China China 2020-01-10 2020-12-31 ChiCTR2000031196 Phase 2 Clinical Recruiting 1 11 Months 90 Zhe Xu 2020-04-01
Clinical features and prognosis of invasive mechanical ventilation patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study Coronavirus disease 19 infection, Viral pneumonia Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Renmin Hospital of Wuhan University China 2020-03-26 2020-04-06 ChiCTR2000031227 Phase Not Applicable Not yet recruiting 1 40 Qianqian Qiao, Qingta Meng 2020-04-06